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Resumo alargado 
 
Os fatores de crescimento endotelial vascular (VEGF) são importantes reguladores da 
proliferação, da migração e da permeabilidade das células endoteliais, não só durante a fase 
embrionária e vasculogénese, mas também na angiogénese fisiológica e patológica.  
A família VEGF é constituída por sete membros, os quais incluem o VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F e o factor de crescimento placentário (PlGF), cada um com uma 
expressão única, especificidade e função. Estes membros com diferentes propriedades físicas 
e biológicas específicas, atuam através de três receptores tirosina quinase, VEGFR-1, VEGFR-2 
e VEGFR-3, e dois receptores de sinalização neuropilina-1 (NRP-1) e NRP-2. 
Quase 80% do globo ocular é constituído por uma substância clara, semelhante a um gel, 
designada por humor vítreo, que preenche o centro do olho e está em contacto contínuo com 
a retina. O humor vítreo é constituído por água (~ 99%), hialócitos, ácido hialurónico, ácido 
ascórbico, sais inorgânicos, glucose e uma rede de fibrilhas de colagénio. 
No presente estudo, foram investigadas três citoquinas (VEGF-A, VEGF-B e PIGF) no humor 
vítreo e soro de doentes com patologia ocular através da quantificação por ELISA (“Enzyme-
Linked Immunosorbent Assay”). 
 
Para comparar e caracterizar os achados quantitativos destes fatores de crescimento, os 
doentes foram divididos em 2 grupos:  
1. Doentes com doenças oculares neovasculares classificados posteriormente nos seguintes 
subgrupos de doentes: degenerescência macular da idade (DMI), oclusão da veia da retina 
(OVR) e retinopatia diabética (RD); 
2. Doentes com doenças oculares não-neovasculares, ou seja, doentes com síndroma de 
tracção vitreomacular de etiologia idiopática ou doentes com descolamento retiniano 
regmatogénio. 
Além disso, os fatores de crescimento foram comparados ou correlacionados entre: 
1. Os grupos de doentes estudados (neovascular vs. não neovascular); 
2. As diferentes patologias oculares; 
3. As características clínicas de “baseline” do doente, como por exemplo, doentes naïve 
versus doentes não-naïve, tratamentos efetuados antes de serem submetidos a vitrectomia, 
presença de glaucoma e estadio de retinopatia diabética (retinopatia diabética não 
proliferativa vs. retinopatia diabética proliferativa). 
Para uma investigação mais aprofundada, os valores médios das concentrações séricas e 
vítreas de VEGF-A, VEGF-B e PIGF foram correlacionadas entre si e entre as alterações 
estruturais ocorridas nestes doentes, avaliadas por tomografia de coerência óptica (OCT) e 
medições da acuidade visual (AV). 
As principais conclusões deste estudo foram as seguintes: 
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1. Os níveis vítreos de VEGF-A, VEGF-B e PIGF encontram-se sobre-expressos em doentes com 
doença ocular neovascular em comparação com os doentes sem doença ocular neovascular; 
2. Nos doentes diabéticos, os níveis de fatores de crescimento endotelial vascular no humor 
vítreo aumentaram com a progressão da doença, sendo as concentrações obtidas de VEGF-A, 
VEGF-B e PIGF, menores em doentes com retinopatia diabética não proliferativa e maiores em 
doentes com retinopatia diabética proliferativa. Contudo, os níveis séricos de VEGF-A, VEGF-B 
e PIGF apresentaram valores maiores em doentes com retinopatia diabética não proliferativa 
em comparação com os doentes com retinopatia diabética proliferativa; 
3. Não se observaram diferenças estatisticamente significativas entre valores de concentração 
de VEGF-A, VEGF-B ou PIGF sérico entre doenças neovasculares e não neovasculares; 
4. Observou-se uma correlação positiva e forte entre VEGF-A e VEGF-B, tanto no vítreo como 
no soro analisado, sugerindo um aumento patológico em simultâneo dessas citoquinas; 
5. Não foram reportadas correlações entre os níveis séricos e os níveis vítreos para todos os 
factores de crescimento endotelial vascular: VEGF-A, VEGF-B e PIGF; 
6. Foi encontrada uma correlação positiva entre VEGF-A ou VEGF-B e volume macular; 
7. Através da análise descritiva de terapêuticas prévias administradas aos doentes com 
doença ocular neovascular, e das análises comparativas entre doentes naïve e não-naïve, 
confirmou-se a existência provável de doentes com resposta insuficiente às terapêuticas 
actualmente aprovadas, reconhecendo-se assim a necessidade de investigação de novos 
fármacos para o tratamento de doenças neovasculares. 
Em resumo, todos os resultados sugeriram uma sobre-expressão dos níveis vítreos para as três 
citoquinas estudadas; as correlações entre fatores de crescimento de VEGF-A e VEGF-B, 
confirmaram o seu aumento em simultâneo em patologias neovasculares oculares; e as 
correlações com o estadio da retinopatia diabética e características funcionais e estruturais 
das doenças neovasculares, demonstraram a ação destas citoquinas na progressão da doença. 
O enfoque na inibição de VEGF-A ou VEGF-B ou PIGF pode ter implicações benéficas e um 
grande impacto no tratamento das doenças neovasculares, não apenas em termos de melhor 
eficácia, mas também em termos de regressão da doença (no caso da diabetes). 
A identificação de biomarcadores ou outras características da doença quantificáveis e a sua 
correlação com os níveis de VEGF-A, VEGF-B e PIGF no vítreo poderá conduzir a uma 
intervenção precoce na prevenção destas doenças, através da detenção da neovascularização 
ocular antes do aparecimento de sintomas clínicos, conduzindo assim à prevenção da 
cegueira. 
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Abstract 
 
Vascular Endothelium Growth Factors (VEGFs) are important regulators of endothelium cell 
proliferation, migration, and permeability not only during embryonic vasculogenesis but also 
in physiological and pathological angiogenesis. The VEGF family comprises seven members, 
including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and Placental Growth Factor 
(PIGF); each one has a unique expression, specificity, and function. These members with 
different physical and biological properties act through three specific receptor tyrosine 
kinases, VEGFR-1, VEGFR-2, VEGFR-3, and two semaphorins receptors neuropilin-1 (NRP-1) 
and NRP-2. 
Almost 80% of the volume of the eye is made up of a clear gel-like substance called vitreous 
humor that fills the center of the eye and is in continuous contact with the retina. It consists 
of water (~99%), hyalocytes, hyaluronic acid, ascorbic acid, inorganic salts, glucose, and a 
network of collagen fibrils.  
In the present study, three cytokines (VEGF-A, VEGF-B and PIGF) were investigated in vitreous 
humor and serum of patients with ocular pathology, measured by Enzyme-linked 
immunosorbent assay (ELISA).  
To compare and characterize the quantitative results obtained by ELISA, the patients were 
categorized into two groups:  
1. Patients with neovascular ocular diseases were categorized into the following subgroups: 
age-related macular degeneration (AMD), retinal vein occlusion (RVO), and diabetic 
retinopathy (DR) patients and  
2. Patients with non-neovascular ocular diseases: vitreomacular traction syndrome patients of 
idiopathic etiology or rhegmatogenous retinal detachment patients.  
Additionally, the growth factors were compared or correlated between:  
1. The studied groups of patients;  
2. The different ocular pathologies;  
3. With patient baseline clinical characteristics such as naïve vs. non-naive patients, previous 
treatments, the presence of glaucoma, and stage of diabetic retinopathy (non-proliferative 
diabetic retinopathy vs. proliferative diabetic retinopathy). 
For further investigation, serum and vitreous concentration levels of VEGF-A, VEGF-B, and 
PIGF were correlated between each other and between changes assessed by optical 
coherence tomography (OCT) and visual acuity (VA) measurements.  
 
The major conclusions of this study were as follows: 
1. VEGF-A, VEGF-B, and PIGF vitreous levels are overexpressed in patients with neovascular 
ocular diseases in comparison with patients with non-neovascular ocular diseases; 
2. In diabetic patients the vitreous vascular endothelial growth factors levels increase with 
the progression of the disease, being lower in non-proliferative diabetic retinopathy patients 
Abstract 
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and higher in proliferative diabetic retinopathy patients. However, serum levels of VEGF-A, 
VEGF-B and PIGF were higher in non-proliferative diabetic retinopathy patients in comparison 
with proliferative diabetic retinopathy patients; 
3. There were no statistical differences between the concentration values of serum VEGF-A, 
VEGF-B or PIGF between neovascular and non-neovascular diseases; 
4. There was a positive and strong correlation between vitreous and serum VEGF-A and VEGF-
B, suggesting a simultaneous pathological increase in those cytokines; 
5. There was no correlation between serum levels and vitreous levels of all growth factors: 
VEGF-A, VEGF-B and PIGF; 
6. There was a correlation between VEGF A or VEGF-B and macular volume; 
7. Through the descriptive analysis of previous treatments as well as the comparative analysis 
between naïve and non-naïve patients, the existence of patients with insufficient response to 
the current therapies was confirmed, and therefore, there is an unmet need for the research 
of new drugs to treat neovascular ocular diseases. 
 
Taken altogether, these results suggest an overexpression of vitreous levels for the three 
studied cytokines. The correlations between VEGF-A and VEGF-B growth factors confirmed 
they may be simultaneously increased in neovascular eye pathologies. The correlations with 
diabetic retinopathy stage as well with structural and functional characteristics of studied 
neovascular disorders demonstrated the action of these cytokines in the progression of the 
disease. 
Targeting VEGF-A or VEGF-B or PIGF inhibition may have beneficial and impactful implications 
in the treatment of neovascular diseases, not only in terms of better outcomes but also in the 
regression of disease (in the case of diabetes).  
The identification of serum markers or other disease characteristics is easily measurable. 
Their correlation with vitreous levels will also lead to early intervention in disease prevention 
through the detention of ocular neovascularization before the appearance of clinical 
symptoms, subsequently leading to the prevention of blindness. 
 
 
 
Keywords 
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Thesis overview 
 
The work presented in this PhD thesis was carried out at the Universidade da Beira Interior, 
Centro de Investigação em Ciências da Saúde (CICS-UBI) between September 2013 - 2017.  
This thesis is structured in four chapters: 
1. The first chapter is divided in seven main sections and a review paper. The chapter 
consists of a literature revision related to the studied subject. On the first section it is 
highlighted the structure of the eye with emphasis on anatomy and physiology. The second 
section comprises an overview of eye diseases with focus on the posterior eye diseases. The 
third and fourth sections briefly reviewed ocular drug delivery, angiogenesis and retinal 
diseases. The fifth and six sections are appraisals of the vascular endothelial growth factor 
and correspondent VEGF receptors and neuropilins. On the seventh section it is discussed the 
actual treatment of retinal diseases. The last section of the chapter comprises a review paper 
of the existing literature concerning quantification of vitreous levels VEGF-A, VEGF-B and 
PIGF and their respective roles in eye diseases.  
2. The chapter II describes the global aims of the study. 
3. The chapter III contains the research work developed during these four years and includes 
3 original research papers:  
(1) Paper II –VEGF-B Levels in the Vitreous of Diabetic and Non-Diabetic Patients with Ocular 
Diseases and Its Correlation with Structural Parameters;  
(2) Paper III – Serum and vitreous placental growth factor in diabetic retinopathy patients: 
Relationship with disease severity and optical coherence tomographic parameters; 
(3) Paper IV – Quantitative analysis and correlation of VEGF-A and VEGF-B in serum and 
vitreous of patients with neovascular vs. non-neovascular ocular diseases; 
4. The chapter IV of this dissertation includes a general discussion. 
5. The chapter V consists of the conclusion remarks &future directions obtained with this 
work. 
6. The last chapter (chapter VI) incorporates the references used in the introduction and 
discussion of the thesis. 
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Introduction  
 
 1. Structure of the Eye: anatomy and physiology 
The human eye is a complex organ that serves as the core of our most treasured sense sight. 
The eye captures light and transmits information to the brain, and this information is 
transformed by the brain into the images that we see. The adult eye is a filled sphere about 
2.5 cm in diameter. Only the anterior one-sixth of the eye can be seen. The remaining part of 
the eye is enclosed within the eye socket, protected by a cushion of fat and the walls of the 
skeletal orbit (Marieb, 2008), (Figure 1). 
 
 
 
Figure 1: Illustrative diagram of the human eye. Horizontal section of the right eye. By RhCastilhos. 
(Public Domain). 
 
There are 3 anatomical continuous layers of the eye: 
1. The outer layer of the sclera and cornea; 
2. The inner layer of the retina; 
3. The middle layer of the choroid, ciliary body and iris, called uvea (Yorio et al., 2008). 
It is usual to divide the eye in two segments: anterior and posterior (Snell & Lemp, 1998), 
which are protected by anatomical and biological barriers (Yorio et al., 2008). 
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The anterior segment 
The main function of the anterior segment is to allow the passage of controlled quantities of 
light into the eye and refract this light so that it focuses on the retina. The cornea is a 
transparent and a vascular structure continuous with the sclera, observable as the white part 
of the eye. It is composed of five layers and joins the sclera at the limbus region. From the 
anterior to the posterior surface of the cornea these layers are surface epithelium, Bowman’s 
layer, stroma, Descemet’s membrane, and endothelium.  
The cornea and the crystalline lens are mainly responsible for the focusing of incident light 
entering the eye. Light enters the eye through the cornea. Together the cornea and sclera 
enclose and protect the internal structures of the eye in a robust, fibrous coat.  
The conjunctiva is a mucous membrane composed of non-keratinizing squamous epithelium 
that covers the external surface of the eye and inner surface of the eyelids. The majority of 
the conjunctiva is made up of specialized stratified squamous cells. Goblet cells are 
interspersed within this epithelium assisting in the production of mucin. This helps in 
nourishing the cornea and decreasing the friction and drying of the opposing palpebral and 
bulbar conjunctiva (Gray et al., 1991).  
The lens is a transparent, elastic capsule of cells that changes shape to focus near and distant 
objects in the retina by a mechanism called accommodation. It is composed of concentric 
layers of cells, which form a biconvex structure which functions to focus images on the 
retina. It is located directly behind the posterior chamber and pupil and is enclosed in a 
fibrous, elastic capsule suspended from the ciliary body by suspensory ligaments. During 
accommodation, the ciliary muscle contracts and decreases tension in the suspensory 
ligaments leading the elastic lens to assume a curved shape (Gray et al., 2015). 
Accommodative power is gradually lost with age secondary to increased lens size and stiffness 
of the lens nucleus.  
The iris is a circular rim structure in front of the lens, and the pupil is located at its center 
through which light passes into the lens. It is in the aqueous humor anterior to the lens and 
behind the cornea. The iris is mainly responsible for controlling the pupil diameter and size. 
Depending on the amount of light reaching the retina, iris muscles expand or contract the 
aperture at the pupil. 
 
The anterior chamber varies in depth and is surrounded anteriorly by the cornea and 
posteriorly by the pupil and iris diaphragm. It consists of aqueous humor formed by the ciliary 
epithelium in the posterior chamber. Aqueous humor is formed from the blood’s plasma by 
mechanisms of diffusion, ultrafiltration, and active transport (Goel et al., 2010). Although, 
the lens and the cornea have no blood vessels, they are tissues that absorb nutrients and 
secrete waste products. The circulating aqueous humor fulfills this function for the back of 
the cornea and lens. It is a filtrate of plasma secreted from capillaries in the ciliary body and 
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iris. The production of aqueous humor decreases with sleep, age, uveitis, retinal detachment 
and ciliochoroidal detachment (Goel et al., 2010). 
The ciliary body, which is ring-shaped, has fibers named zonules that connect with muscles in 
the ciliary body. This mechanism helps to adjust the convexity of the lens. The ciliary body 
also secretes aqueous humor (Marieb, 2008). 
 
The posterior segment 
The posterior segment of the eye occupies two-thirds of the eye and includes the following 
structures: sclera, vitreous humor, retina, macula, choroid, and optic nerve. 
The sclera is the opaque or white portion of the eye, which is fibrous in nature and forms the 
outer protective layer (Yorio et al., 2008). 
The retina (Figure 2) is a thin layer of photoreceptor cells and associated neurons. It is the 
innermost layer of the eye and consists of a multi-layered sensory tissue. It contains millions 
of rod and cone cells, also known as photoreceptors. The cones are predominant in the 
macula, which is the retinal portion responsible for central vision. The retina is divided into 
two layers: retinal pigment epithelium (outer layer) and neural retina (inner layer). These 2 
layers are separated by the fluid filled subretinal space (Yorio et al., 2008). 
Light rays entering the eye converge at the cornea and the crystalline lens making them 
intersect at a point just behind the lens (in the vitreous humor). These rays then, pass 
through nine layers and diverge back to the outermost retinal layer (pigmented epithelium), 
which is reflected back to the rods and cones. Rods are responsible for night vision. Rod and 
cone cells capture light rays and translate them into electrical impulses. These impulses 
reach the brain via optic nerve and are converted into images (Yorio et al., 2008). 
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Figure 2: Structure of the retina. Adapted from Gray’s Anatomy (public domain). 
 
The retinal pigment epithelium (RPE) is a non-visual portion located between the neural 
portion of the retina and choroid. The RPE forms the outer blood-retinal barrier and has tight 
junctions that enable the epithelium to form a barrier by connecting neighboring cells 
(Rizzolo, 2007). RPE cells are well differentiated and regulate the trans-epithelial transport 
of various molecules. RPE expresses numerous efflux transporters, which prevents the entry 
of xenobiotics into the retina (Rizzolo, 2007). 
Macula is a Latin word, which means “spot”. It is an oval-shaped, yellow spot that is highly 
pigmented and is present in the center of the retina. It has a diameter of approximately 5 
mm with two or more layers of ganglionic cells. The fovea is located at the center of the 
macula, and has the largest cone cell concentration making it responsible for the most visual 
acuity. The macular/foveal area is responsible for color discrimination. Moreover, the yellow 
color of the macula helps in the absorption of excess light entering the eye and thus acts as a 
natural form of protection (Marieb, 2008). 
The choroid is a highly vascular tissue that supplies the sclera and the outer part of the retina 
with blood and nutrients. It is also rich in pigments that absorb light so that it does not 
scatter within the eye. 
After entering the inner surface of the retina, light travels through and finally reaches the 
light-sensitive rods and cones at the outer retina, where the light is converted into 
electrochemical signals, which travel until the ganglion cells in the inner retina. The signals 
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are conducted via the optic nerve, out of the retina and eventually reach the visual cortex in 
the brain for processing, resulting in vision.  
Photoreceptor cells are distributed over the entire retina, except where the optic nerve 
leaves the eyeball at the optic disc or ‘blind spot’ (Marieb, 2008). 
There are around 100 million rods and 5 million cones in each retina (Fauci et al., 2009). As 
rods are responsible for night vision, anything that interferes with rod function causes night 
blindness (Marieb, 2008).  
Cones are specialized for high spatial resolution and allow us to see in color in good light. 
There are three varieties of cones, each most sensitive to particular wavelengths of visible 
light (Marieb, 2008). The absence of the different cone types leads to color blindness: the 
lack of three cone types lead to total color blindness, while the lack of one cone type leads to 
partial color blindness (Marieb, 2008). 
The blood–ocular barrier structure is mainly made of 2 barriers: the blood–aqueous barrier 
and the blood–retinal barrier (BRB) (Cunha Vaz, 1979). The blood-retinal barrier (BRB) forms a 
barrier between the retina and the blood supply (Cunha Vaz, 1979; Ehrhardt & Kim, 2008). It 
is formed by both the retinal blood vessels (inner BRB) and the retinal pigment epithelium 
(outer BRB) (Cunha Vaz et al., 1979; Yanoff & Duker, 2008), (Figure 3). Changes in the BRB 
lead to the development of retinal diseases. While in diabetic retinopathy (DR) we observe 
changes of the inner BRB, in age-related macular degeneration (AMD) there are changes in 
the outer BRB (Cunha Vaz, 2009); in both diseases we observe an accumulation of 
extracellular fluid. 
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Figure 3: Schematic representation of the Inner and Outer Blood–Retinal Barriers. Adapted from Cunha 
Vaz, 2009. 
 
The inner layer has tight junctions between retinal vascular endothelial cells, creating a 
barrier that is normally impermeable to proteins (Anand-Apte & Hollyfield, 2010). The 
exchange of metabolites and waste between the vascular lumen and the neural retina is 
controlled by the BRB. Damage to the retinal microvascular system may disrupt the tight 
junctions of the inner BRB. Consequently, the breakdown of the inner BRB allows the leakage 
of substances and liquids from capillaries into the extracellular space, causing accumulation 
of fluid. When this accumulation of fluid appears in the macula, it leads to the development 
of macular edema (Bressler & Wenick, 2012; Cunha Vaz, 1979). 
Sometimes, abnormal new blood vessel formation takes place in the presence of inflammation 
or low oxygen levels (hypoxia), hence making these vessels susceptible to rupture. When this 
occurs, it allows blood and fluid to leak into the retinal tissue. This is called intraretinal 
hemorrhage, and the leaking fluids are called subretinal fluid or exudates (Wu & Acón, 2017). 
The vitreous body or also called vitreous humor or simply vitreous (Figure 4) is a thin 
transparent gel, which helps transport metabolites to the lens and inner retina. Almost 80% of 
the volume of the eye is made up of this clear gel-like substance. This fluid fills up the space 
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between the lens and the retina. Vitreous humor consists of water (~99%), hyalocytes, 
hyaluronic acid, ascorbic acid, inorganic salts, sugar, and a mesh of collagen fibrils (Sebag, 
1992). The network of non-branching collagen fibers with hyaluronic acid provides viscosity to 
the vitreous humor which is two to four times higher than pure water and has a refractive 
index of 1.336. Vitreous humor is stagnant, while aqueous humor is continuously replenished 
(Tolentino, 1974). The vitreous humor is in continuous contact with the retina and adheres to 
the retina at three places: the macula, optic nerve disc, and fovea (Tolentino, 1974). 
The vitreous humor fills the center of the eye. In children, the vitreous has the consistency of 
a gel. With age, it gradually thins and becomes more liquid. As the vitreous thins, it separates 
from the parts, which is attached to the retina, causing retinal detachment. 
 
  
(a) (b) 
 
 
(c) (d) 
 
Figure 4: Schematic pictures of vitreous humor. 
(a) Intact human vitreous gel (Sebag, 2014); (b) Human vitreous (Yannuzzi, 2014); (c) Vitreous humor 
removal from the eyeball during a vitrectomy (public domain); (d) Sonographic appearance of the 
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structures of the normal eye. The vitreous gel can be visualized in the number 5 of the image (De La 
Hoz Polo, 2016). 
 
The optic disc is responsible for the conduction of visual information from the retina to the 
brain. It is composed of 1.2 million myelinated axons of retinal ganglion cells and has a 
varying diameter of approximately 1-10 μm. It is located within the orbit, and it extends from 
the eyeball to the optic foramen. The length of the optic nerve varies from 20-30 mm with a 
diameter of 5 mm (Snell & Lemp, 1998). 
 
2. Eye diseases – overview of posterior eye diseases 
The combination of an aging world population along with a dramatic decline in fertility, has 
led to a vast number of people over 65 years worldwide (West & Sommer, 2001). The loss of 
vision and blindness is increasing every year among the elderly and has become a major 
public health concern ("Age-related Macular Degeneration", 2017). 
DR, diabetic macular edema (DME), AMD, retinal vein occlusion (RVO), uveitis, glaucoma and 
cataract, are the common diseases that if left undiagnosed and/or untreated lead to 
potential blindness. All these diseases except cataract, affect the posterior eye that is 
composed by the vitreous, the retina, the retinal pigment epithelium and the choroid. The 
anterior segment of the eye includes the cornea, the anterior chamber, the iris, the posterior 
chamber, the ciliary body, and the lens. The main eye diseases involving the anterior segment 
include dry eye or keratoconjuntivitis sicca, cataract, conjunctivitis (blepharo-conjunctivitis, 
kerato-conjunctivitis and episcleritis) (Fauci et al., 2009). 
 
Diabetes mellitus (diabetes) results in considerable morbidity and premature mortality. 
Diabetes has profound effects on the structure and function of many tissues and organs in the 
body. Complications of diabetes afflict the macrovascular and microvascular structures. 
Macrovascular diseases include cardiovascular conditions such as stroke, myocardial infarction 
and peripheral vascular disease while microvascular diseases comprise of DR, diabetic 
neuropathy and diabetic nephropathy (Holt, 2010). Diabetes is one of the main public health 
issues in today’s society. The incidence of blindness is 2-3 times greater in persons with 
diabetes when compared with the non-diabetic population (Hayward et al., 2002). Visual loss 
and blindness due to diabetes are preventable in the vast majority of people, through optimal 
management of diabetes, hypertension and hypercholesterolemia and also the 
implementation of a screening program to detect DR early. 
 
Diabetic retinopathy is the most frequent microvascular complication of diabetes and the 
leading cause of blindness in the working population in developed countries worldwide. 
Approximately 75% of all diabetic patients show clinical signs of retinopathy within 15 years 
after the onset of diabetes and more than 10% of diabetic patients develop visual impairment 
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within this period (Klein et al. 1995). It is a chronic microvascular complication of diabetes, 
consisting of damage to the retina and capillaries caused by hyperglycemia and hypoxia and 
may lead to a significant loss of vision. Vision loss from DR is usually painless, progressive and 
bilateral (Bhagat et al., 2009). The initial alterations are manifested by biochemical signs of 
oxidative stress and cellular signs of subclinical inflammation (Bhagat et al., 2009). The 
earliest vascular progressions involve leukostasis, aggregation of platelets, modification of the 
blood flow, degeneration of pericytes and thickening of basement membranes. Blockage of 
the retinal capillaries may cause localized hypoxia, triggering increased tissue production of 
angiogenic factors, including VEGF-A. The release of VEGF-A and other angiogenic factors 
causes loosening of the vascular endothelial cell-cell junctions, leading to an increased 
vascular permeability. Despite the increased production of VEGF-A, a potent survival factor 
for endothelial cells (ECs), microvascular endothelial cells degenerate, leading to capillary 
closure and formation of a cellular, non-perfused capillaries. With disease progression, 
appear vascular alterations, such as micro-aneurysms, blot hemorrhages, cotton-wool spots, 
venous beading and vascular loops (Penn et al., 2008). The vascular leakage increases 
inducing blood and fluid accumulation within the retinal tissue and formation of exudative 
deposits. This condition is known as non-proliferative diabetic retinopathy (NPDR). Tissue 
swelling caused by the accumulation of excess interstitial fluid can alter metabolic processes 
and ion fluxes within retinal neurons and glia. When the edema affects the macula, it can 
result in neuronal distortion leading to decrease of visual acuity (Kent et al., 2000). In some 
patients, the NPDR progresses to proliferative diabetic retinopathy (PDR). PDR is 
characterized by the growth of new blood vessels on the surface of the retina. The new blood 
vessels are fragile and easily rupture, leaking blood into the neural retina and vitreous, thus 
clouding the vitreous and compromising vision. With advanced PDR, fibrovascular scar tissue 
grows from the retinal surface into the vitreous cavity. If untreated, this can cause retinal 
detachment resulting in blindness. Studies of clinical specimens have shown a strong 
correlation between increase in intraocular VEGF-A levels and the development of PDR (Duh & 
Aiello, 1999). 
 
The condition of diabetic macular edema (DME) is more common in patients with type 2 
diabetes (7.5%) than in patients with type 1 diabetes (5.9%), (Hirai et al., 2008). In DME there 
is accumulation of fluid within the intra-retinal layers of the macula due to exudation from 
the retinal microvasculature. DME may occur in any stage of DR and it is also a leading cause 
of blindness in the diabetic population (Bodansky et al., 1982). 
DME mainly affects people with a history of diabetes mellitus. It is characterized by the 
swelling of the retina within the macula gradually leading to leakage of fluids from blood 
vessels and breakdown of the blood-retinal barrier (Cunha Vaz, 2009; Klein et al., 2009). 
Macula is a small structure present at the center of the retina that is rich in cones and 
specialized nerve endings. Visual impairment due to DME occurs when the macula is involved, 
as this is the area responsible for high-acuity vision. Disruption of the BRB leads to leakage 
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and therefore to retinal edema. Retinal edema affecting the macular region may lead to 
blurred vision, which is a most common symptom of visual impairment in DME (Aspelund et 
al., 2011). 
Additional symptoms of visual impairment associated with DME include image distortion, 
floaters, altered sensitivity to contrast, photophobia, changes in color vision and scotomas 
(Bouhaimed et al., 2008). 
 
There are several classifications for DR and DME as seen in Table 1, all classifications emerged 
in an attempt to obtain a consensus. 
 
Table 1 - Classifications of DR and DME (Gangwani et al., 2016) 
 
ETDRS NCS (UK) AAO/ International RCOphth 
10 None R0 None No apparent retinopathy None 
20 Microaneurisms 
only 
 
R1 Background Mild NPDR Low risk 
35 Mild NPDR 
 
 Moderate NPDR - 
43 Moderate NPDR 
 
R2 Pre-proliferative - High risk 
47 Moderately 
severe NPDR 
 
- - - 
53 A-D Severe NPDR 
 
- Severe NPDR - 
53 E Very severe NPDR 
 
- - - 
61 Mild PDR 
 
R3 Proliferative PDR PDR 
65 Moderate PDR 
 
- - - 
71,75 High risk PDR  
 
- - - 
81, 85 Advanced PDR - - - 
 
AAO – American Academy of Ophthalmology; ETDRS – early treatment diabetic retinopathy study; NCS 
(UK) – National Screening committee (United Kingdom); NPDR – non-proliferative diabetic retinopathy; 
PDR – proliferative diabetic retinopathy; RCOphth – Royal College of Ophthalmologists 
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DME classification according to the International Clinical DME Disease Severity Scale is shown 
in Table 2. 
 
Table 2 - International Clinical DME Disease Severity Scale (Wilkinson et al., 2003) 
 
Proposed Disease Severity Level 
Findings observable upon dilated 
ophthalmoscopy 
DME apparently absent 
No apparent retinal thickening or hard 
exudates in posterior pole 
DME apparently present 
Some apparent retinal thickening or hard 
exudates in posterior pole 
If DME is present, it can be categorized as follows: 
Mild DME 
Some retinal thickening or hard exudates in 
posterior pole but distant from the center of 
the macula 
Moderate DME 
Retinal thickening or hard exudates 
approaching the center of the macula but not 
involving the center 
Severe DME 
Retinal thickening or hard exudates involving 
the center of the macula 
 
DME – Diabetic Macular Edema 
 
Fluorescein angiography (FA) is used to evaluate DME, providing information about the retinal 
perfusion, the BRB, and neovascularization. The angiographic classification of DME comprises 
of non-cystoid and cystoid macular edema (CME) and focal or diffuse DME (Lobo et al., 2012). 
Focal DME results from microaneurysms leakage. Diffuse DME results from the breakdown of 
BRB with leakage from microaneurysms, retinal capillaries, and arterioles (Wu et al., 2013). 
 
The ETDRS study defined DME as focal or diffuse retinal thickening in the macular area and, 
when the thickening involves the fovea, it is defined as clinically significant macular edema 
(CSME) (Panozzo et al., 2004). 
CSME was defined as “(1) thickening of the retina at or within 500 μm of the center of the 
macula; or (2) hard exudate at or within 500 μm of the center of the macula associated with 
thickening of adjacent retina; or (3) a zone of retinal thickening 1 disc area or larger, any 
part of which is within 1 disc diameter of the center of the macula” (Bandello et al., 2003).  
 
Based on optical coherence tomography, DME can assume different morphologic patterns 
(Gangwani et al., 2016, Wu et al., 2013). 
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Overall, the classification of DME can be: 
- Clinical: it is the standard classification to assess the severity of DME and it is based on the 
ophthalmoscopy observation. It may then be classified as: 1. Clinical significant macular 
edema (CSME), which is based on ETDRS or, 2. International clinical classification. 
- Angiographic: it is the classification based on the angiographic observation and can be focal, 
diffuse, ischemic, exudative and a combination of multiple patterns. 
- Based on vitreo-retinal interface alteration: It is a morphological classification and based on 
the existence of vitrogenic components. 
 
Further investigations on the pathophysiological processes of DME demonstrated that VEGF-A 
is in part the mediator of the increase in retinal capillary permeability that occurs following 
the breakdown of the blood-retinal barrier (Aiello et al., 1994). VEGF-A has a key role in the 
pathogenesis of DME due to its action in increasing vascular permeability (Figure 5), (Bhagat 
et al., 2009). 
 
 
 
Figure 5: Pathogenesis of DME (adapted from Bhagat et al., 2009). 
AII - angiotensin II, AGE - advanced glycation end, BRB - blood–retinal barrier, DAG – diacylglycerol, ET - 
endothelin, LPO - lipoxygenase, MMP - matrix metallo-proteinases, NO - nitric oxide, PKC - protein 
kinase C, PPVP - posterior pre-cortical vitreous pocket, RAS - renin-angiotensin system 
 
Age-related Macular Degeneration (AMD) is another leading cause of vision loss worldwide 
(Rosenfeld et al., 2006). The neovascular form comprises only 10% of AMD but accounts for 
90% of all cases of blindness due to AMD (Rosenfeld et al., 2006). 
AMD is a medical condition affecting older adults, which results in loss of central vision. The 
center part of the retina (macula) is affected; hence, the person loses central vision. Central 
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vision is necessary to perform certain activities like reading and driving. The disease does not 
affect peripheral vision and therefore the person does not suffer from total vision loss. AMD 
occurs in two forms, wet or exudative or neovascular and dry or non-exudative or non-
neovascular. Wet AMD is associated with the formation of new blood vessels under the retina. 
This abnormal growth of choriocapillaries results in leakage of blood and proteins, and the 
formation of scar tissue, and consequently damaging the photoreceptors of the retina. The 
wet form of the disease spreads rapidly and can result in complete vision loss if left 
untreated. Dry AMD, on the other hand, is a slow process of degeneration of the 
photoreceptors of the retina. It is characterized by the formation of drusen and deterioration 
(atrophy) of photoreceptors, RPE and the choriocapillaries in the macular area. Dry AMD 
progresses slowly with a generally better prognosis than wet AMD (Rosenfeld et al., 2006). 
Age is considered as one of the major risk factors for AMD patients. Apart from age, the other 
risk factors for AMD development include smoking, obesity, race, gender and family history 
(Chakravarthy et al., 2010). Wet AMD patients are also characterized by high levels of VEGF-A 
(Aiello et al., 1994). Figure 6 represents a schema of the pathogenesis of neovascular AMD 
(Augustin & Kirchhof, 2009). 
 
 
 
 
Figure 6: Pathogenesis of neovascular AMD (adapted from Augustin & Kirchhof, 2009) 
CFH - complement factor H, IL – interleukin, MCP - monocyte chemoattractant protein, RPE - retinal 
pigment epithelium. 
 
Retinal vein occlusion (RVO) is a potentially sight-threatening disease caused by blockage of 
the retinal vein that drains blood from the back of the eye. After DR, RVO is the second cause 
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of retinal vascular disease (Kiire & Chong, 2012). It is classified into branch RVO (BRVO) and 
central RVO (CRVO) based on the site of the venous occlusion. Branch retinal vein occlusion 
(BRVO) and central retinal vein occlusion (CRVO) affect 1.8% and 0.5% respectively, of the 
population aged 50 years or older (Klein et al., 2008). BRVO is typically caused by blockage of 
an arteriovenous crossing, whereas CRVO is caused by a blockage of the central retinal vein 
(Battaglia et al., 2009). Macular edema (ME) is also a complication of RVO that can lead to 
blindness. RVO causes increased secretion of cytokines such as VEGF-A and interleukin-6 that 
increase the permeability of the blood-retinal barrier. This generates fluid leakage into the 
retinal tissue, which results in ME.  
Hemi-retinal vein occlusion (HRVO) affects the superior or inferior retinal hemisphere.  
The two principal complications of RVO are retinal ischemia and ME, which may lead to iris 
neovascularization. Eyes with RVO contain some of the highest vitreous VEGF-A 
concentrations (Aiello et al., 1994). 
 
Glaucoma affects the optic nerve head and results in the loss of retinal ganglion cells. The 
optic nerve head carries visual information to the brain. Increase in intraocular pressure is a 
major risk factor and damage to the optic nerve head causes progressive loss of peripheral 
vision. Untreated glaucoma can even result in loss of central vision. It is a common condition 
in persons over 40 years (Weinreb et al., 2014). 
 
Uveitis means an inflammation occurring in the middle layer of the eye also known as the 
uvea (vascular layer present in between the retina and the sclera). The exact cause of uveitis 
is still not clear but studies indicate that may include infectious agents: viral (mumps and 
herpes), fungal (histoplasmosis) and bacterial (toxoplasmosis) play an important role in the 
establishment of this disease ("The Multicenter Uveitis Steroid Treatment Trial: Rationale, 
Design, and Baseline Characteristics", 2010). The cause of uveitis may also include trauma or 
autoimmunity (Forster, 2011). Based on the structures affected, uveitis can be categorized 
into anterior, intermediate, posterior and pan-uveitic forms. Anterior uveitis is the most 
common form of uveitis affecting the iris and anterior chamber while posterior uveitis affects 
mainly retina and choroid. Intermediate uveitis is characterized by inflammation in the 
vitreous cavity while pan-uveitis affects all layers of the uvea (Forrester, 2007)  
Symptoms can include blurred vision, pain, photophobia and ‘floaters’ (cellular debris in the 
vitreous which floats across the field of vision). The mainstay of treatment in non-infectious 
uveitis is corticosteroids (Forster, 2011). 
 
In this dissertation, we focus our attention on the treatment of posterior segment diseases, 
particularly AMD, RVO and DR, which are the leading causes of blindness and vision 
impairment.  
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3. Ocular drug delivery 
One important topic is the treatment of eye diseases and consequently methods of delivering 
ocular therapeutics to the eye; although not subject to discussion in this dissertation, it will 
be briefly highlighted in this section (Figure 7). 
The anatomy and physiology of the eye present unique challenges to ocular drug delivery. 
Most pharmacologic administrations to the eye use topical solutions, which are applied to the 
surface of the eye, such as drops. Depending on the physicochemical properties, the 
absorption of a drug following topical administration occurs by one or two pathways: corneal 
or non-corneal. A major fraction of the drug absorbed through the cornea enters through 
anterior ocular tissues, while the non-corneal absorption process primarily results in systemic 
drainage via the nasolacrimal duct (Geroski & Edelhauser, 2000). A typical eye drop volume 
ranges between 30–50 μL. Topical administration of an eye drop creates a rapid increase in 
the tear volume causing swift reflex blinking resulting in wash out of approximately 90% of 
the applied dose within 5-10 minutes. Furthermore, the impermeable nature of the cornea 
prevents permeant entry into the eye (Geroski & Edelhauser, 2000).  
Nevertheless, topical administration is not successful in the treatment of posterior eye 
diseases. These diseases are treated by systemic, periocular, or intravitreal administration 
(Geroski & Edelhauser, 2000). Though the systemic administration is most widely indicated, 
only 1–2% of the dose reaches the vitreous (Cunha-Vaz, 1997). Moreover, entry of therapeutic 
agents following systemic and periocular administration is challenging due to the presence of 
blood-ocular barriers (BOBs). BOB is a physical barrier between the local blood vessels and 
ocular tissues. There are two types of BOBs: blood-aqueous barrier (BAB) and blood-retinal 
barrier (BRB).  
This plays a major role in the pathophysiology of retinal drug delivery. It prevents the entry 
of large drug molecules from choriocapillaris into the retina (Cunha-Vaz, 1997). Additionally, 
the entry of xenobiotics following systemic or periocular (subconjunctival, retrobulbar, 
peribulbar and sub-tenon) administration is hindered by the BRB (Cunha-Vaz, 1997). 
These barriers along with the complex structure of the eye result in poor ocular 
bioavailability (Gaudana et al., 2010). 
However, remarkable advancements have been observed in ocular drug delivery over the last 
few decades, namely: 
(a) Intravitreal Injections: Intravitreal injection is the choice of drug delivery for the 
treatment of retinal diseases such as AMD, DR, DME and RVO. It is capable of delivering high 
concentrations of drugs into the vitreous and retina. The elimination of drugs delivered by 
intravitreal injection are correlated with their molecular weight: molecules with higher 
molecular weight have longer retention times in the vitreous humor, generally being more 
associated with various complications, such as retinal detachment, cataracts, glaucoma, 
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increase in intraocular pressure, endophthalmitis, or intravitreal hemorrhages (Marmor et al., 
1985; Patel et al., 2013; Velez & Whitcup, 1999). 
(b) Periocular Injections: retrobulbar injection; peribulbar injection, sub-tenon injection and 
subconjunctival injection. 
Furthermore, different and innovative drug delivery systems are being developed such as: 
nanoparticles, microneedles, liposomes, dendrimers, niosomes, nanosuspensions, ultrasound, 
iontophoresis and implants, which allow the control rate and duration of drug release. Ocular 
implants may be divided into two categories depending on the polymer used in the matrix: 
- Non-biodegradable implants: These delivery systems are neither metabolized nor erodible 
once they are inserted. They are usually made of an inert material not harmful to the 
organism or organ where it remains (Patel et al., 2013). 
- Biodegradable implants: They degrade in vivo into soluble components by enzymatic and/or 
non-enzymatic processes (Patel et al., 2013).  
 
 
 
Figure 7: Drug delivery pathways for the treatment of posterior ocular diseases (adapted from Geroski & 
Edelhauser, 2000).
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4. Ocular Angiogenesis and Retinal Diseases 
Angiogenesis is a process that occurs in adults under specific conditions; in physiological 
situations such as wound healing and the female reproductive cycle or in pathological states 
such as cancer and retinal diseases. The counterbalance among proangiogenic and anti-
angiogenic factors and proteins outline the occurrence of angiogenesis. This is the so-called 
“angiogenic switch” which is believed to be “on” when angiogenesis occurs (Hanahan & 
Folkman, 1996), (Figure 8). 
The VEGF family growth factors are important not only in adult vascular remodeling but also 
as factors for growing blood vessels. ECs are responsible for new blood vessel formation, 
while other cells types are responsible for vessel maturation. Macrophages and smooth muscle 
cells (SMC) secrete angiogenic factors contributing to angiogenesis (Cleaver & Melton, 2003). 
 
 
 
Figure 8: Cascade of events in angiogenesis process (adapted from 
https://angio.org/understanding/understanding.html, © 2000 The Angiogenesis Foundation, Inc. All 
rights reserved). 
 
Neovascularization, the development of new blood vessels, is a crucial process for fetal 
development and several pathological states. Vasculogenesis and angiogenesis are the two 
mechanisms responsible for neovascularization (Yamazaki & Morita, 2005). 
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VEGFs represent a set of structurally and functionally related growth factors that modulate 
critical physiological functions of ECs playing a primary role in pathological angiogenesis in 
retinal disorders. Angiogenesis is critical for the progression of many different diseases, 
including ocular diseases, representing the main cause of irreversible vision loss in developed 
countries.  
The blood vasculature forms by two processes: vasculogenesis, the differentiation of 
precursor cells (angioblasts) into ECs and the de novo formation of a primitive vascular 
network, and angiogenesis, the growth of new capillaries from pre-existing vessels (Olofsson 
et al., 1999). The development of blood vessels (angiogenesis) and the vascular supply is a 
requirement for organ development and differentiation during embryogenesis. In addition to 
normal physiological processes, such as wound healing, tissue regeneration, organ 
regeneration, and intervention in the reproductive cycle in women, pathological angiogenesis 
occurs in neovascular eye disorders and are recognized to be dependent on the development 
of new blood vessels. The process of blood vessel formation is complex and highly coordinated 
and dependent on a series of interactions between receptors and ligands (Nash et al., 2006). 
VEGF-A is the most studied growth factor of the VEGF family and has been proven to have a 
substantial role in the process of vascularization and angiogenesis. Evidence shows that there 
are increased levels of VEGF-A in the retina and in the vitreous of patients with retinal 
diseases, supporting the existence of significantly higher levels of VEGF-A in diabetic 
patients, AMD and RVO patients (Aiello et al., 1994). VEGF-A promotes angiogenesis in each of 
the studied ocular conditions making it an exceptional therapeutic target (Ferrara et al., 
2003). Contrary, VEGF-B is the least studied and the most enigmatic molecule of the VEGF 
family concerning its role (Li et al., 2009). Furthermore, and to the best of our knowledge, 
the contribution of PlGF in neovascularization has received little attention, but it may also 
represent a significant target (Rakic et al., 2003). 
Intraocular neovascularization occurs in numerous ischemic retinal disorders, including DR, 
ischemic RVO and AMD. This proliferation often results in visual loss (Amadio et al., 2016).  
Relative to the role of the VEGF family in ocular diseases, it is known that endothelial growth 
factors and their receptors provide important therapeutic pathways for the treatment of 
disorders characterized by an abnormal angiogenesis. VEGF-A is a critical angiogenic growth 
factor for vasculogenesis and angiogenesis in the healthy state and in the presence of 
pathological conditions.  
However, not only VEGF-A has an important role in angiogenesis and consequently in the 
development of neovascular eye diseases. We believe that VEGF-B as well PIGF is strongly 
implied in this process.  
In summary, there are three main reasons to identify other molecules of the VEGF family 
besides VEGF-A as important factors in the pathogenesis of intraocular diseases:  
1) Pathological transformations of the retinal vasculature are associated with an increased 
expression of VEGF-A, VEGF-B, and PlGF as well other factors (Cabral et al., 2017); 
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2) VEGF-A alone is sufficient to trigger neovascularization, but other growth factors also act 
together in this process (Penn et al., 2008); 
3) Inhibition of VEGF-A, VEGF-B and PIGF is associated with anatomical and functional 
improvements in the affected eye (Cabral et al., 2017). 
 
 
5. Vascular Endothelial Growth Factor Family  
The VEGF family consists of seven members: VEGF-A (sometimes referred to as only VEGF), 
VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PlGF (placental growth factor), (Figure 9a). 
Alternative splicing results in several VEGF variants (Penn et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: (a) Interactions between VEGF isoforms and VEGF receptors or between co-receptors; (b) 
VEGF-A isoforms formed by alternative splicing (adapted from Penn et al, 2008). 
 
Although all VEGF structures are different, they are related and include a normal feature, 
called the VEGF homology domain as seen in Figure 9b. 
The nomenclature used to designate the various isoforms refers to the number of amino acids 
that comprise the mature, secreted protein; human VEGF165, for example, consists of 165 
amino acids. All VEGF isoforms discovered till date contain exons 1 to 5, with various 
combinations of the remaining exons 6 to 8. Exons 3 and 4 contain the vascular endothelial 
A 
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growth factor receptor 1 (VEGFR-1) and vascular endothelial growth factor receptor 2 
(VEGFR-2) binding domains, respectively. All isoforms that are able to bind to these receptors 
are biologically active (Ng et al., 2006). 
 
Alternative exon splicing generates VEGF-A, VEGF-B, and PlGF. Each VEGF subtype selectively 
binds to some of these receptors or to the co-receptors, neuropilins 1 and 2 (NRP-1 and NRP-
2), often with different affinity and selectivity, demonstrating the diversity of their biological 
functions. They are dimeric glycoproteins that act through three cell surface receptor 
tyrosine kinases, known as the VEGF receptors (VEGFRs). VEGF-A, VEGF-B, and PIGF bind to 
VEGFR-1 (or Flt-1); VEGF-A and VEGF–E bind to VEGFR-2 (or Flk-1); VEGF-C and VEGF–D bind 
to VEGFR-3; and VEGF-F binds to both VEGFR-2 (or Flk-1) and VEGFR-1 (or Flt-1), (Olsson et 
al., 2006). 
 
 
5.1 VEGF-A 
Vascular Endothelial Growth Factor-A (VEGF-A) or as initially named, Vascular Permeability 
Factor, (VPF) was discovered nearly two decades ago as an angiogenesis stimulating and 
permeability factor (Leung et al., 1989). VEGF-A was the first VEGF to be discovered and is 
currently the most well characterized member of the VEGF family. While physiological 
angiogenesis due to VEGF-A is predominantly restricted to wound healing, bone formation, 
hematopoiesis, development and the female reproductive cycle, it also plays a key role in the 
pathogenesis of several human diseases, including cancer, eye diseases and inflammation 
among other disorders (Ferrara et al., 1998). VEGF-A is produced by several kinds of cells: 
tumor cells (Itakura et al., 2000), macrophages (Sunderkotter et al., 1994), platelets (Verheul 
et al., 1997), keratinocytes (Frank et al., 1995), and renal mesangial cells (Iijima et al., 
1993). The VEGF-A gene is comprised of eight exons and seven introns. Alternative exon 
splicing generates six isoforms: VEGF121, VEGF145, VEGF165, VEGF165b, VEGF183, VEGF189 and 
VEGF206 (Tong & Yao, 2006). Each isoform is characterized by the respective number of amino 
acids after cleavage of the signal sequence variants (Tong & Yao, 2006), (Figure 10). VEGF-A 
is produced in various cell types, including ECs and leucocytes and binds to both VEGFR-1 and 
VEGFR-2 and neuropilins (Favier et al., 2006). Hypoxia is the most common inducer of VEGF-A 
synthesis. However, VEGF-A is not only regulated by hypoxia. Its function is also affected by 
Insulin-like growth factor 1 (IGF-1), which plays an important role in retinal vascularization 
(Penn et al., 2008). 
VEGF-A is important for vasculogenesis (blood vessel growth from endothelial progenitor cells) 
and angiogenesis (blood vessel growth from pre-existing vessels). If there is inactivation of a 
VEGF-A allele, embryonic lethality occurs at embryonic day 11-12 in mice and tetraploid 
embryos, resulting in vascular defects and cardiovascular abnormalities (Carmeliet et al., 
1996). VEGF-A expression is down-regulated after embryogenesis but is upregulated during 
physiological and pathological angiogenesis (Breier et al., 1992). 
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Figure 10: VEGF-A structure, splice variants and receptors (adapted from Miller et al., 2012) 
 
Regarding its biological activity, VEGF-A induces proliferation and migration of ECs and 
vascular permeability, resulting in angiogenesis in vivo. Most of the major biological activities 
of VEGF-A are mediated by VEGFR-2, which shows stronger ligand-dependent tyrosine 
phosphorylation than VEGFR-1. VEGFR-1 is believed to function as a “decoy” receptor for 
secreted VEGF-A and its activation is also reported to result in inhibition of VEGFR-2 (Ferrara 
et al., 2003; Yamazaki & Morita, 2006). 
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To summarize, the vegf-a gene expression is regulated by: 
1. Hypoxia through the hypoxia-inducible protein complex HIF-1; 
2. Oxidative stress and the reactive oxygen species (ROS), 
3. Hyperglycemia; 
4. Advanced glycation end-products (AGEs), 
5. Growth factors and cytokines, such as insulin growth factor (IGF), tumor necrosis factor –
alpha, tissue growth factor-β, epidermal growth factor and platelet-derived growth factor-BB. 
6. Hormones: estrogens and progestins. 
 
VEGF-A plays a key role in: 
1. Stimulating angiogenesis (Penn et al., 2008); 
2. Acting as a direct proinflammatory mediator. VEGF-A is a potent inducer of vascular 
inflammation. In vitro, VEGF-A treatment increases intercellular adhesion molecule-1 (ICAM-
1) and monocyte chemoattractant protein-1 (MCP-1). It is thought that VEGF165 isoform is the 
most implicated in this process (Penn et al., 2008). Angiogenesis and inflammation are 
dependent processes (Ferrara et al., 2003). Inflammatory mediators have significant effects 
on angiogenesis and the inverse is also true (Oura et al., 2003); 
3. Increasing vascular permeability (Penn et al., 2008); 
4. Anti-apoptotic effect (Bachelder et al., 2001). 
For example, in cancer, the stimulation of tumor cells by VEGF-A may protect the cells from 
apoptosis (Harmey & Bouchier-Hayes, 2002). It also, plays a key role in the support of 
neuronal and endothelial cell integrity in the survival of retinal neurons after ischemia. 
Moreover, it was described by Duh and Aiello (1999) that the function of VEGF-A was also as a 
promoter of ECs survival (Duh & Aiello, 1999). Therefore, Anti-VEGF therapies block two 
functions of VEGF-A: the pro-angiogenic activity and the anti-apoptotic/pro-survival action 
(Duffy et al., 2004). 
VEGF-A is induced in various diseases of the central nervous system with a neuroprotective 
role. Also, in cardiovascular pathology, VEGF-A may be useful to increase collateral vessel 
formation during ischemic heart disease. However, its use as therapeutic agent may fail in 
cardiovascular diseases due to two reasons; first the VEGF-A driven angiogenesis in 
progressive ischemic disease may not be sufficient since the vessels formed may not be 
functional and second, the permeability function of VEGF-A will cause serious side effects 
(Tammela et al., 2005). 
Moreover, the effects of VEGF-A appear to be dependent of local concentration (Figure 11). 
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Figure 11: Biological response of VEGF-A (adapted from Ylae-Herttuala et al., 2007) 
 
The influence of VEGF-A in retinal diseases is well known. Aiello et al. (1994) reported 
detectable concentrations of VEGF-A in ocular fluids from patients with active retinal 
neovascularization associated with several ocular diseases coupled with underlying retinal 
ischemia (Aiello et al., 1994). VEGF-A is associated with highly prevalent eye pathologies, 
such as AMD, DR, retinopathy of prematurity (ROP), RVO and neovascular glaucoma (Penn et 
al., 2008).  
 
Taken together, we can conclude that overexpression of VEGF-A as a response to the 
presence of retinal ischemia, leads to intraocular proliferation, increased vascular 
permeability and inflammation and thus, consequently becomes an important target in the 
treatment of neovascular diseases. 
 
 
5.2 VEGF-B 
VEGF-B was discovered nearly 20 years ago as a factor related to VEGF-A, however, its 
function was unknown (Olofsson et al., 1996). It is by far the most charismatic and mysterious 
vascular endothelial growth factor of the VEGF family. It is now recognized to have an amino 
acid sequence of the VEGF homology domain of VEGF-B 47% and 37% equal to VEGF165 and 
PlGF (placental growth factor), respectively (Li & Eriksson, 2001). Alternative splicing of exon 
6 generates, two isoforms of VEGF-B, VEGF-B167 and VEGF-B186 (Figure 12). 
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Figure 12: Schematic illustration of the domain structures of some members of the VEGF family, 
including VEGF-A, VEGF-B and PlGF. Adapted from Li and Eriksson, 2001. 
 
VEGF-B specifically binds to VEGFR-1 with high affinity, but not to VEGFR-2 or VEGFR-3, 
competing with VEGF-A for VEGFR-1 binding (Olofsson et al., 1998). VEGF-B also binds to NRP-
1 (Olofsson et al., 1998). VEGF-B167 has a molecular mass of 21 kDa while VEGF-B186has a 
molecular mass of 26 kDa (Olofsson et al., 1996). VEGF-B167 and VEGF-B186 differ in their C-
terminals. The C-terminal domain of VEGF-B167 is hydrophilic and this domain interacts with 
the co-receptor, NRP-1. The C-terminal domain of VEGF-B186 is hydrophobic and the binding to 
NRP-1 is regulated by limited proteolysis. VEGF-B isoforms can form heterodimers with VEGF-
A165. VEGF-A165/VEGF-B167 heterodimers exist in the bound form, while the heterodimers 
VEGF-A165/VEGF-B186 heterodimers are freely secreted. The presence of heterodimers will 
affect the equilibrium between homo- and heterodimers and consequently VEGF-A signaling. 
The expression of VEGF-B is not regulated by hypoxia, or other known stimuli including 
growth factors, cytokines, hormones, or oncogenes. To date, the mechanisms behind 
regulation of VEGF-B expression remains poorly understood.  
VEGF-B is highly expressed in several tissues and organs. In adult tissues, VEGF-B expression is 
abundant in heart and skeletal muscles. The high expression in heart and brain indicate that 
the neovascularization in these organs is very extensive and that both VEGF-A and VEGF-B are 
active in this process (Bry et al., 2014).  
VEGF-B167 is the most commonly existing isoform of VEGF-B with ample distribution among 
tissues and organs while VEGF-B186 is expressed less extensively than VEGF-B167 (Li et al., 
2001). As mentioned previously, the function of VEGF-B is stable and it is not upregulated by 
factors that affect and regulate the production of VEGF-A. However, the expression of VEGF-B 
was found to be increased in tumor cells lines, making this molecule a potential target to 
treat cancer (Enholm et al., 1997; Li et al., 2001). The gain and loss of function studies 
suggest it plays a role in the functioning of the heart or in angiogenesis (Aase et al., 2001). 
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Moreover, the role of VEGF-B either in normal or in pathological situations is still unclear and 
needs to be studied further. 
VEGF-B was reported as angiogenic in some studies but not in others. VEGF-B was shown to be 
involved in blood vessel growth under some situations while under other situations or in an 
environment where there is a high concentration of growth factors, VEGF-B inhibited tumor 
growth and angiogenesis (Li et al., 2012). In a review by Li et al., (2012) VEGF-B is referred to 
as multifunctional safeguarding molecule displaying a functional ambiguity role. For example, 
under degenerative conditions when cells are dying, this molecule acts as a survival factor to 
rescue the cells from death. In contrast, in the presence of high levels of potent growth 
factors, this molecule acts as a growth-inhibiting factor and prevents overgrowth, possibly 
through VEGFR-1 which acts as a decoy receptor suppressing angiogenesis (Li et al., 2012). 
Karpanen and Mould demonstrated the role of VEGF-B in gain and loss-of-function studies 
using transgenic mice and showed that VEGF-B under normal conditions does not display 
activity (Karpanen et al., 2008; Mould et al., 2003). Interestingly, VEGF-B was the only 
member of the VEGF family that does not stimulate angiogenesis or lymphangiogenesis (Li et 
al., 2012). 
Sands et al. (2011) reported that VEGF-B does not promote vascular endothelial cell 
proliferation and migration in cultured cells. In vivo administration of an intravitreal injection 
of VEGF-B167 recombinant protein in adult mouse did not induce ocular angiogenesis or other 
abnormalities. VEGF-B167 does not induce blood vessel permeability, unlike all the other VEGF 
family members (Li et al., 2012). Li and co-workers showed that the administration of an 
injection of VEGF-B167 recombinant protein into mouse brain or eye did not instigate blood 
vessel permeability (Li et al., 2008). However, there is a contradictory study, reported by 
Zhong et al (2011) where an intraocular injection of adeno-associated virus (AAV) encoding 
VEGF-B186, but not VEGF-B167, stimulated retinal vascular permeability. Looking at these data, 
we can conclude that VEGF-B167 does not induce blood vessel permeability while VEGF-B186 
does (Zhong et al., 2011). 
Li et al (2012) refer to VEGF-B as a survival factor. VEGF-B was shown to be a survival factor 
for vascular ECs, pericytes (PCs), and smooth muscle cells (SMCs) (Figure 13), (Li et al., 
2012). In fact, increased apoptosis was observed in ECs and SMCs lacking VEGF-B when the 
cells were tested by oxidative stress or serum starvation (Zhang et al., 2009). In vivo, VEGF-B 
targeting inhibited both choroidal and retinal neovascularization, implicating VEGF-B as an 
important target in anti-angiogenic therapy (Li et al., 2012). The vascular survival effect of 
VEGF-B is achieved by regulating the expression of vascular prosurvival genes via both NRP-1 
and VEGFR-1 (Li et al., 2012). The function of VEGF-B in the vascular system is defined as a 
‘‘survival factor’’ instead of an ‘‘angiogenic’’ factor (Li et al., 2012). It has a potent 
survival/anti-apoptotic effect, while having a deficient angiogenic activity (except in the 
heart). Being abundantly expressed in the heart, VEGF-B has a specific role in the 
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cardiovascular system, with a critical function for cardiac blood vessel survival (Li et al., 
2001; Olofsson et al., 1996). VEGF-B treatment increased cardiac blood vessel density in the 
ischemic myocardium (mouse model), where blood vessels suffered serious degeneration, 
(Claesson-Welsh, 2008). Besides, VEGF-B treatment reduced the stroke volume in an in vivo 
stroke model (Li et al., 2008). Additionally, VEGF-B plays a role in vessel growth in ischemic 
retinas (Li et al., 2012). Also, VEGF-B selectively promotes angiogenesis in the ischemic 
myocardium, warranting further investigations of the therapeutic potential of VEGF-B in 
promoting functional recovery of myocardial infraction and being described as having a 
cardioprotective effect. Apart from the survival effect of VEGF-B on blood vessels, VEGF- B 
may also have a direct protective effect on cardiac myocytes (Karpanen et al., 2008), 
suggesting that it could be used as a therapy in treating cardiac ischemic diseases. 
VEGF-B has also been shown to be a powerful neuroprotective survival factor for several types 
of neurons, including brain cortical neurons, retinal neurons, and motor neurons in the spinal 
cord (Claesson-Welsh, 2008; Li et al., 2008; Sun et al., 2004). In a retina model, VEGF-B 
treatment increased the survival of retinal ganglion cells and protected neurons (Li et al., 
2008), also suggesting its use as a therapeutic agent for neurodegenerative diseases. 
 
 
 
Figure 13: Illustrations showing the pro-angiogenic activity of VEGF-B under pathological conditions. 
Adapted from Trends in Molecular Medicine, (Li et al., 2012). 
 
VEGF-B is expressed in the eye, and its expression can be upregulated in a pathological retina 
(Li et al., 2008). Subretinal injection of adeno-associated viruses encoding VEGF-B167 or VEGF-
B186 increased retinal and choroidal neovascularization (Zhong et al., 2011). Another study 
demonstrated that targeted inhibition of VEGF-B by shRNA (short hairpin RNA) and intravitreal 
injection of a neutralizing antibody suppressed choroidal and retinal neovascularization in 
mice (Zhang et al., 2009). Therefore, VEGF-B targeting inhibited retinal neovascularization. 
It seems that the ‘angiogenic’ activity of VEGF-B during ocular neovascularization is probably 
due to its potent survival effect on vascular and non-vascular cells. Also, it is known that both 
NRP-1 and VEGFR-1 play a role in mediating the vascular survival effect of VEGF-B. Therefore, 
despite VEGF-B having minimal angiogenic activity in blood vessel growth, the vascular 
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survival activity of VEGF-B, which protects the neo-vessels from apoptosis, may play a 
significant role in enhancing ocular neovascularization. Thus, targeted VEGF-B inhibition may 
also have therapeutic implications in the treatment of ocular neovascular disorders (Zhang et 
al., 2009). 
In conclusion, several studies indicate that VEGF-B is critically required for blood vessel 
survival under pathological conditions. As a result of its antiapoptotic effect or potent 
survival effect and the fact that it is capable of remaining inactive under normal conditions, 
VEGF-B appears to be a valuable therapeutic option for the treatment of neurodegenerative 
and cardiovascular diseases with an attractive safety profile. Once the expression of VEGF-B 
is altered in neovascular diseases, the administration of a VEGF-B antagonist may result in 
promising outcomes either in monotherapy or in combination with other drugs. 
 
 
5.3 PIGF 
Another member of the VEGF family of growth factors is the PlGF. It is 53% identical to VEGF-
A and binds to VEGFR-1 (Park et al., 1994). PlGF like VEGF-A is a dimeric glycoprotein 
structurally related to the platelet-derived growth factors A and B (PDGF-A and PDGF-B). 
Compared with VEGF-A, the mitogenic or permeability-enhancing activities of PlGF are weak 
but PlGF is able to potentiate the actions of VEGF-A (Park et al., 1994).  
Although primarily expressed in the placenta, PlGF is also detected in significant levels in the 
heart and lungs (Persico et al., 1999). PIGF binds specifically to VEGFR-1 and to NRP-1 and 
NRP-2 (Maglione et al., 1991). Alternative splicing of the human primary transcript generates 
four isoforms: PlGF-1 (PlGF131), PlGF-2 (PlGF152), PlGF-3 (PlGF203), and PlGF-4 (PlGF224) 
(Maglione et al., 1991). PlGF- 2 is able to bind to both NRPs (NRP-1 and NRP-2) and heparin, 
while PlGF-1 does not (Hauser & Weich, 1993). 
Gene targeting revealed that PlGF is dispensable for physiological angiogenesis during 
development and reproduction in mice but genetic loss of PlGF consistently impairs 
pathological angiogenesis, as well as other disorders such as ischemia, inflammation, and 
cancer, suggesting its role in several pathological conditions (Carmeliet et al., 2001). 
The overexpression of PlGF in the skin results in increased vessel formation and permeability 
(Oura et al., 2003). 
PlGF plays a significant role in pathophysiological neovascularization and in EC growth and 
migration (Rakic et al., 2017). PIGF is a pleiotropic factor affecting different types of cells 
and regulating several biological responses, as illustrated below (Figure 14), (Dewerchin & 
Carmeliet, 2012). 
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Figure 14: Scheme illustrating the pleiotropic activity of PlGF: survival, migration, proliferation, 
metabolism and activation effects on vascular (endothelial cells, pericytes/smooth muscle cells) and 
nonvascular cells (macrophages, bone marrow–derived progenitors, tumor cells, dendritic cells, 
fibroblasts, hepatic stellate cells, epithelial cells, neurons, Shwann cells, astrocytes), (adapted from 
Dewerchin & Carmeliet, 2012). 
BM - Bone marrow, SMC - smooth muscle cell, TAM - tumor-associated macrophage  
 
There are several proposed mechanisms for PlGF function (Dewerchin & Carmeliet, 2012): 
1. PlGF may stimulate EC growth indirectly by the displacement of VEGF-A from VEGFR-1 and 
releasing VEGF-A to bind to VEGFR-2. It acts as a co-factor potentiating the activity of VEGF-A 
(De Falco, 2012); 
2. PIGF may up-regulate the expression of other angiogenic factors such as VEGF-A, basic 
fibroblast growth factor, platelet derived growth factor B, and matrix metalloproteinases; 
3. The release of PlGF leads to VEGFR-1 activation which induces an intermolecular cross-talk 
between VEGFR-1/VEGFR-2, amplifying VEGF-A/VEGFR-2 signaling; 
4. The heterodimers formed between VEGF-A/ PlGF are thought to have pro-angiogenic and 
not anti-angiogenic activity. VEGF-A and PlGF form a heterodimer that binds to VEGFR-1, 
activating this receptor (Cao et al., 1996). However, this heterodimer’s activity is not clear 
and only becomes evident when PlGF is overexpressed.  
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PlGF is induced in response to ischemic, inflammatory, and malignant conditions and is 
increased in pathological angiogenesis in the systematic vascular system by binding to VEGFR-
1, (Autiero et al., 2003; Fischer et al., 2008). 
In the retina, PlGF expression is not upregulated by hypoxia but in a model of retinopathy of 
prematurity (ROP) PlGF deficiency reduced the extent of retinal neovascularization by 60%. 
Additionally, PlGF was considered as proangiogenic on retinal ECs (Carmeliet et al., 2001; 
Khaliq et al., 1998; Simpson et al., 1999). Finally, PlGF was detected in the vitreous and in 
neovascular membranes in PDR (Khaliq et al., 1998). 
When conditions comparable to the hypoxic-ischemic retinopathy were induced, the loss of 
PlGF protects mice against intravitreous neovascularization (Carmeliet et al., 2001). Thus, 
the low concentration of PlGF is still able to support these pathological events. In addition, 
the hypoxic conditions highly upregulate VEGF-A, but not PlGF. Therefore, PlGF can be a 
selected target for the inhibition of angiogenesis, in comparison with VEGF-A (Carmeliet et 
al., 2001). 
Recent work from Inoue and colleagues (2013) investigated the effects of PlGF on retinal 
neuronal cells. It is known that PlGF is present in the retina; however, the neuroprotective 
role of the PlGF in the retina is still unclear. Their work suggested that PIGF may be an 
important protective factor in the retina (Inoue et al., 2013). 
Sandro De Falco and colleagues (2012), described the role of PlGF in cardiovascular diseases 
and suggested three main functions for PlGF in the cardiovascular system: 1) its role in 
myocardial angiogenesis that seems to be synergistic with that of VEGF-A; 2) its role as a 
mediator of macrophage chemotaxis, being involved in the regulation of vascular growth in 
pathological conditions; 3) its selective action as a modulator of pathological rather than 
physiological vascular development making this molecule an attractive candidate for 
therapeutic angiogenesis (De Falco, 2012). 
There are two contradictory requirements for the therapeutic regulation of angiogenesis:  
1) To inhibit angiogenesis in pathological conditions such as tumors, inflammatory disorders, 
and diabetic retinopathy;  
2) To stimulate angiogenesis in ischemic cardiovascular disease. One of the main limitations 
in using VEGF-A as a therapeutic stimulation of angiogenesis is its potent activity on vascular 
permeability (that leads to significant inflammation). PlGF could be an alternative 
therapeutic option for ischemia. The advantage would be that PlGF works by amplifying the 
physiological concentration of VEGF-A but as PlGF is less potent than VEGF-A, it would lead to 
potentially fewer side effects. 
Additionally, the important role of PlGF/VEGFR-1 in the activation and sustainment of 
inflammation strongly prompts investigations in the search of an inhibitor of PlGF not only for 
ocular pathologies but also for other diseases (De Falco, 2012). 
Further research on the suppression of PlGF is needed in order for it to be useful as an 
alternative target for anti-angiogenic strategies in ocular neovascularization. 
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5.4 VEGF-C 
VEGF-C (also known as VEGF Related Protein, VRP) was discovered in 1996 and does not have 
splice variants. It is expressed in the heart, placenta, ovary, small intestine and thyroid gland 
(Joukov et al., 1996). Its expression is not increased by hypoxia and many oncogenes; 
however, interleukin 1 and tumor necrosis factor do upregulate VEGF-C levels. VEGF-C binds 
to VEGFR-2 and VEGFR-3, but not to VEGFR-1. It has a significant role in the formation of 
venous and lymphatic vessels during embryogenesis. It stimulates the growth of lymphatic 
vessels and blood vessels by activation of VEGFR-2 and VEGFR-3 (Jeltsch, 1997). VEGF-C is 
required not only for the initial sprouting of lymphatic vessels but also for the survival of 
lymphatic ECs (Karkkainen et al., 2003). Furthermore, loss-of-function studies demonstrated 
that vegf-c-/- mice die and vegf-c+/-mice have flaws in lymphatic vascular development. VEGF-
C is expressed in numerous types of cancer, namely breast cancer, cervix and prostate 
cancer, lung cancer, colon and stomach cancer, and is associated with metastases, vascular 
invasion, and therefore with a poor prognosis and often related to poor patient survival (He et 
al., 2004). 
 
 
5.5 VEGF-D 
VEGF-D (or c-Fos-induced growth factor) is the most closely related member to VEGF-C, both 
structurally and functionally. VEGF-D is able to bind to both VEGFR-2 and VEGFR-3 and 
capable activating these receptors (Stacker et al., 1999). Like VEGF-C it does not bind to 
VEGFR-1. Loss and gain of function studies demonstrated that vegf-d-/- mice are normal, 
displaying normal lymphangiogenesis and functional lymphatic vessels during embryogenesis, 
development and in adult life (Baldwin et al., 2005).It is a mitogen for ECs and plays a role in 
EC growth, lymphangiogenesis and angiogenesis. It also alters vascular permeability. It is 
expressed in the colon, heart, lung, skeletal muscle, small intestine and also in small amounts 
in the ovary, prostate and spleen (Achen et al., 1998). VEGF-D promoted tumor metastasis in 
lymph nodes and it is expressed in human melanoma in vessels near tumor cells (Achen et al., 
2001; Stacker et al., 2001). 
 
 
5.6 VEGF-E 
VEGF-E (Orf Virus), a gene encoding a VEGF homologue was discovered in the genome of 
parapoxvirus Orf virus (OV) (Lyttle et al., 1994). Similar to VEGF-A, VEGF-E binds to VEGFR-2 
with high affinity, but does not bind to VEGFR-1 nor VEGFR-3. It is a potent angiogenic, able 
to stimulate angiogenesis. Like VEGF-A, VEGF-E stimulates proliferation of the ECs and vessel 
permeability (Lyttle et al., 1994). 
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6. Vascular Endothelial Growth Factor Receptors and 
Neuropilins 
The VEGF receptors are cell surface tyrosine kinase receptors (Figure 15). They can be 
membrane-bound (mbVEGFR) or soluble (sVEGFR). VEGFR-1, also called Flt-1, acts as a decoy 
receptor by sequestering VEGF-A and regulates the interaction between VEGF-A and VEGFR-2 
(Flk-1) (Wirostko et al., 2008). VEGFR-1 plays an important role not only for blood vessel 
development during embryogenesis but also in pathological angiogenesis and wound healing 
by interaction with VEGFR-2 (Cébe-Suarez et al., 2006). VEGFR-1 has poor catalytic activity 
compared to VEGFR-2 and the downstream signaling pathways upon its activation are not well 
known. VEGFR-2 is involved in permeability, angiogenesis, vasculogenesis, and proliferation 
(Wirostko et al., 2008).  
VEGFR-3 is important for wound healing, and sFlt-1 (soluble VEGFR-1) search for available 
VEGF-A (Wirostko et al., 2008). VEGFR-2 and VEGFR-3 are also involved in lymphatic 
angiogenesis (Cébe-Suarez et al., 2006). There are several VEGFR inhibitors under 
investigation for the treatment of different types of cancer. Actually, Pazopanib and 
Regorafenib are approved and are being used in the treatment of renal cell carcinoma and 
colorectal cancer respectively- 
The neuropilin receptors are transmembrane glycoproteins important for axonal guidance, 
angiogenesis, tumorigenesis, and are involved in the immunologic response (Sulpice et al., 
2008). NRP-1 and NRP-2 act as co-receptors for class III semaphorins and growth factors of the 
VEGF family. The neuropilin receptors are involved in both physiological and pathological 
angiogenesis (Sulpice et al., 2008). 
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Figure 15: Interactions between VEGF and VEGF receptors, and their biological functions.  
Flt - fms-like tyrosine kinase, Flk - fetal liver kinase, NRP – neuropilin, KDR - kinase insert-domain 
containing receptor, PIGF - placenta growth factor, VEGF - vascular endothelial growth factor, VEGFR - 
vascular endothelial growth factor receptor (adapted from Bae et al., 2015). 
 
 
6.1 VEGFR-1 
VEGFR-1 otherwise known as Flt-1 (Fms-like tyrosine kinase-1) is a receptor for VEGF-A, 
VEGF-B and PlGF. It is known to play a role in vascular development and homeostasis (Li et 
al., 2012). VEGFR-1 acts as a decoy receptor for other growth factors. Its function in 
angiogenesis is to act as a VEGF-trap to modulate VEGFR-2 function (Rahimi, 2006). 
 
 
6.2 VEGFR-2 
VEGFR-2 also called Flk1 (fetal liver kinase 1), or KDR (kinase insert domain containing 
receptor) is a receptor for VEGF-A, VEGF-C, VEGF-D and VEGF-E and the principal receptor 
responsible for angiogenesis. VEGFR-2 upregulate tumor angiogenesis and ocular angiogenesis, 
making it an interesting target for tumor growth and ocular disorders involving 
neovascularization (Campochiaro & Hackett, 2003; Cross et al., 2003). 
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6.3 VEGFR-3 
VEGFR-3, also known as Flt-4 (Fms-like tyrosine kinase 4) or tyrosine-protein kinase receptor 
FLT4, is a receptor for VEGF-C and VEGF-D playing a critical role in blood vessel and 
lymphatic vessel development. VEGFR-3 is required for lymphatic vessel survival and 
maintenance during human embryogenesis (Mäkinen et al., 2001). It is capable of forming 
heterodimers with KDR/ VEGFR-2. It promotes proliferation, survival and migration of ECs. It 
is also able to regulate angiogenic sprouting, playing a significant role in tumor angiogenesis. 
It is upregulated in the blood vessels of many tumors even though it is normally expressed 
only in lymphatic vessels (Partanen et al., 1999; Zarkada et al., 2015). 
 
 
6.4 Neuropilins 
NRP-1 and NRP-2 are co-receptors for semaphorins and VEGFs. NRP-1 is expressed at the 
endothelium of arteries while NRP-2 is expressed in veins and lymphatic vessels (Herzog et 
al., 2001; Yuan et al., 2002). NRP-1 is a co-receptor capable of regulating angiogenesis, 
arteriogenesis and vascular permeability during development and in pathological conditions. 
It acts essentially through the binding to other receptors. However, Roth and co-workers 
reported NRP-1 as self-sufficient to mediate vascular permeability alone without binding to 
VEGFR-2 (Roth at al., 2016). Expression of NRP-1 is upregulated in several tumor types, 
namely, brain, prostate, breast, colon, and lung cancers. Levels of NRP-1 are also known to 
be positively correlated with the presence of metastasis (Parikh et al., 2004). NRP-2 plays a 
role in cardiovascular development. In cancer, it is considered to be involved in 
tumorigenesis. Therefore NRP-1 can mediate angiogenesis, and malignant tumor progression 
(Chen et al., 1997). 
 
 
7. Treatment of retinal diseases 
There is a variety of retinal diseases (Figure 16), some involve only the macula such as AMD, 
macular hole, or macular pucker (epiretinal membrane) while others can impact the entire 
retina, as for example retinal detachment or DR. 
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Figure 16: Visualization of images of retinal pathologies. (Adapted from Montgomery, 2017).  
 
The main goals of the treatment of retinal diseases are to stop or slow down disease 
progression and to preserve, improve or restore vision. In many cases, the damage that has 
already occurred cannot be reversed, making early detection an important factor in the 
treatment of these pathologies. Treatment of retinal diseases may be complex and sometimes 
a) Age-related macular degeneration
 
b) Age-related macular degeneration
 
c) Branch retinal artery occlusion
 
d) Branch retinal vein occlusion
 
e) Central retinal vein occlusion
 
f) Epiretinal membrane
 
g) Diabetic retinopathy
 
h) Diabetic retinopathy
 
i) Retinal detachment
 
j) Macular hole 
 
Introduction 
 
 
37 
 
urgent. Visual impairment is a considerable health problem for older adults and has a 
significant impact on functional status and quality of life. For example, it limits the ability to 
read, to safely drive a car, to have an independent way of life and is also associated with 
increased rates of falls and hip fractures in patients suffering from these diseases (Lord & 
Dayhew, 2001). 
There is a wide range of treatment options for retinal diseases, from administration of eye 
drops to surgical procedures such as intraocular injections, laser therapy, and vitreoretinal 
surgery. In all instances, the aim is to maintain the integrity of the retina, especially the 
macula. However, despite the development of innovative therapeutic options for retinal 
diseases, published data of many pivotal studies, clinical knowledge and the real-world 
experience, treatment of these patients remains a challenge (Amandio et al., 2016).  
 
Neovascular (wet) AMD treatment: 
Ten years ago, before injections for wet macular degeneration became available, most of the 
affected patients lost their central vision. Later, verteporfin (Visudyne®) was made available. 
Actually, due to extensive medical research, patients can be treated with anti-VEGF 
intravitreal injections such as ranibizumab (Lucentis®), aflibercept (Eylea®), conbercept 
(Lumitin®) or with the off-label drug, bevacizumab (Avastin®), as summarized in table 3.
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Table 3 – Main characteristics of current anti-VEGF agents used for the treatment of diabetic 
retinopathy and wet age-related macular degeneration (adapted from Horton and Guly, 2007; Lu and 
Sun, 2015). 
Anti-VEGF 
therapy 
Class 
 
MW Mode of action Binding 
affinity 
to VEGF165 
Key relevant 
clinical trials 
Targets 
 
Bevacizumab 
(Avastin®) 
 
 
Monoclonal 
Ab* 
149 
kDa 
Humanized full-length 
monoclonal antibody 
derived from the same 
antibody as 
ranibizumab. Bind to all 
VEGF-A as ranibizumab 
with different affinity. 
58 pM AMD studies: CATT 
and IVAN (non-
inferiority studies 
against 
ranibizumab) 
DME studies: 
Protocol T from 
DRCRnet. 
All 
VEGF-A 
isoforms 
Ranibizumab 
(Lucentis®) 
 
 
Fab** 48 
kDa 
Humanized Fab 
fragment of a 
monoclonal antibody 
that binds to and 
inhibits the action of all 
isoforms of VEGF-A. 
46 pM AMD studies: 
MARINA, ANCHOR 
(superiority studies 
against sham 
injection and 
verteporfin, 
respectively). 
DR / DME studies: 
RESOLVE, RESTORE, 
RETAIN 
 
 
All 
VEGF-A 
isoforms 
Aflibercept 
(Eylea®) 
 
 
VEGF-
Trap/ 
Fusion 
protein 
115 
kDa 
Fusion protein that 
inhibits all isoforms of 
VEGF-A, VEGF-B and 
PIGF. 
Fusion protein: domain 
2 of VEGFR-1 and 
domain 3 of VEGFR-2 
fused with IgG1 Fc 
0.5 pM AMD studies: VIEW 
1/ VIEW 2 (non 
inferiority studies 
against 
ranibizumab) 
DME studies: VIVID 
and VISTA. 
All 
VEGF-A 
isoforms
, VEGF-B 
and 
PIGF 
Conbercept 
(Lumitin®) 
 
Fusion 
protein 
143 
kDa 
Fusion protein that 
inhibits all isoforms of 
VEGF-A, VEGF-B, VEGF-
C and PIGF 
Fusion protein: domain 
2 of VEGFR-1 and 
domains 3 and 4 of 
VEGFR-2 fused with 
IgG1 Fc 
0.5 pM AMD studies: Phase 
II AURORA and the 
phase III PHOENIX 
RVO studies: 
currently recruiting 
participants. 
All 
VEGF-A 
isoforms
, VEGF-
B, VEGF-
C and 
PIGF 
*Ab - antibody; **Fab - antibody fragment; MW - molecular weight. 
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For several patients with wet AMD, the anti-VEGF treatments offer good outcomes; however, 
these drugs are frequently injected into the eye leading to a significant burden of injections 
and visits not only for the patient, but also for caregivers, physicians, and the healthcare 
system. Long-term and continued release medications are required and are now in clinical 
trials for wet AMD in order to decrease the number of intravitreal injections needed to obtain 
and maintain functional as well structural outcomes (Horton & Guly, 2017):  
1. Sustained Release Lucentis: it is in phase II clinical trials. The study is called LADDER. It has 
received “fast track” label from the FDA, in order to obtain a faster approval. The device is 
implanted into the eye and can be refilled every 4-6 months.  
2. Sustained Release Eylea: it is in development but not yet in clinical trials. In this system, 
aflibercept is incorporated into a gel and after intravitreal injection releases the drug slowly. 
3. Other therapies are in research for wet AMD, such as Abicipar Pegol, which is being 
developed by Allergan. This protein remains for longer periods in the eye. During the phase II 
studies, the study medication was injected quarterly. It is now in phase III trials, a comparative 
study of Abicipar Pegol with ranibizumab with final data collection date for primary outcome 
measure aimed at May 2019 ("Safety and Efficacy of Abicipar Pegol in Patients With Neovascular 
Age-related Macular Degeneration - Full-Text View - ClinicalTrials.gov", 2017). 
 
RVO treatment  
There are several reported methods for the clinical treatment of RVO (Sivaprasad, Amoaku, 
Hykin & Guideline Group, 2016): 
1. Laser photocoagulation;  
2. Anti-VEGF agents are used to treat macular edema due to CRVO or BRVO, once VEGF-A has 
shown to be increased in this pathology mediating vascular leakage and therefore causing 
macular edema. The most common anti-VEGFs used are ranibizumab, aflibercept and 
bevacizumab (off-label). 
3. Intravitreal steroids. Corticosteroids are potent anti-inflammatory drugs that reduce retinal 
capillary permeability and inhibit the expression of VEGF-A. The Score clinical trial 
demonstrated that patients treated with intravitreal triamcinolone (IVTA) showed anatomical 
and functional improvements of macular edema related to CRVO or BRVO, but due to the short 
half-life of this drug, the effects are short and patients may experiment a rebound of the 
edema. Another drug used to treat macular edema associated with RVO is dexamethasone. 
Although the rationale for the use of intravitreal dexamethasone is similar to that of IVTA, 
dexamethasone is a more potent corticosteroid. Nevertheless, the free form of intravitreal 
dexamethasone also has a short half-life. To overcome this issue, the pharmaceutical company, 
Allergan, developed a biodegradable implant, containing 0.7 mg of dexamethasone (Ozurdex®) 
that was investigated in the GENEVA study program. Based on this program, Ozurdex® was 
approved by the FDA and EMA for the treatment of macular edema following CRVO or BRVO. 
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DR and DME treatment: 
The current treatment for DR and DME undergoes through a strict systemic and ocular control 
(Bhavsa et al., 2017). Concerning the systemic treatment, this may include the control of 
glucose, blood pressure, and blood lipid, besides other multifactorial interventions. The 
maintenance of HbA1c levels between of 6-7% is one of the goals for an ideal management of 
diabetes and their complications. The Diabetes Control and Complications Trial/Epidemiology 
of Diabetes Interventions and Complications Study (DCCT/EDIC) included approximately 1,441 
subjects, 726 had no DR at the baseline (primary prevention cohort) and 715 had mild DR at 
baseline (secondary intervention cohort). One of the objectives was to evaluate whether 
intensive or traditional treatment aiming to achieve glucose blood levels as near as possible to 
non-diabetic patients decrease the risk of progression of DR (Figure 17a& 17b). Indeed, it was 
concluded that in patients capable of preserving HbA1c values at a low and sustained level, the 
progression of diabetic retinopathy was reduced (Nathan, 2013). Moreover it was shown that 
the progression of DR was associated with HbA1C levels (Figure 18). 
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a) 
 
b) 
 
 
Figure 17: a) Cumulative incidence of DR progression (three-step or greater) in the primary prevention 
cohort of the DCCT; b) Cumulative incidence of DR progression in the secondary intervention cohort of the 
DCCT (adapted from Aiello, 2014). 
In 76% risk reduction for DR 
progression after mean 
follow-up of 6.5 years with 
the intensive treatment 
Small difference in % of patients 
with DR progression between the 
intensive vs. and conventional 
treatment in the first 3 years 
54% reduction in the risk of 
retinopathy (≥ three-step) 
progression for patients in 
the intensive treatment 
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Figure 18: Relation between the risk of progression of DR and Hba1c (adapted from Aiello, 2014). 
DCCT - Diabetes Control and Complications Trial; HbA1c – glycosylated hemoglobin; PYR – patient-years 
 
Regarding the ocular treatment, there are currently various drug and non-drug treatments, 
although none of them treat the diseases, DR or DME, but only ameliorate symptoms and 
decrease disease progression. The most current and available treatment options are laser 
photocoagulation, pharmacological agents, and vitrectomy. 
 
Laser photocoagulation was one of the first non-invasive treatments with relatively low rates of 
associated complications and with great accomplishment. The Early Treatment Diabetic 
Retinopathy Study (ETDRS) was a memorial clinical trial and achieved a milestone 
demonstrating the benefit of the focal macular laser in the treatment of DR and DME ("Early 
Treatment Diabetic Retinopathy Study", 1981). This study defined the criteria for the 
treatment of "clinically significant macular edema” (CSME) used to select which patients should 
be treated with macular laser. The results from the ETDRS demonstrated that laser 
photocoagulation decreased the risk of moderate vision loss by approximately 50% and 
improved the vision of approximately 30% of the patients. However, a percentage of the 
patients still suffer from vision loss despite treatment photocoagulation (Early Treatment 
Diabetic Retinopathy Study Research Group., 1985; Jampol et al., 2014).  
 
The rationale for the use of photocoagulation is based on the fact that the photoreceptors use 
more oxygen than any other cells of the organism and so destroying them would be an effective 
way to reduce the oxygen consumption by the retina. The mechanism of action of the 
traditional laser photocoagulation destroys the photoreceptors of the retina, decreasing the 
oxygen consumption and restoring the balance between the supply and the demand of oxygen 
(Figure 19). 
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Figure 19: Schematic drawing showing the oxygen flow from choroid through laser scar into the inner 
retina (adapted from Stefánsson, 2009).  
 
Funatsu and co-workers proposed the following mechanism of action for the laser 
photocoagulation: 
1. The oxygen provided to the retina comes from the choriocapillaris and disseminates into the 
outer retina. The outer retina photoreceptors have high oxygen consumption. 
2. If oxygen is consumed by the photoreceptors of the outer retina it will not reach other parts 
of the retina where it is needed. 
3. The laser will cause the destruction of the photoreceptors of the outer retina, opening a 
path that allows the penetration of oxygen, without being consumed by the outer retina 
photoreceptors, reaching the inner retina. 
4. This action decreases the metabolic function of the outer retina and decreases the oxygen 
consumption, ultimately leading to an improvement of hypoxia and re-establishing of the 
balance between oxygen demand and supply to the inner retina. 
3. An improvement of hypoxia will decrease the production and secretion of neovascular 
growth factors (as VEGF-A).  
Hypoxia stimulates VEGF-A production, and neovascularization, therefore laser treatment is an 
efficient process to correct this hypoxia, (Figure 20), (Funatsu et al. 1996, Stefánsson, 2009). 
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Figure 20: Flow diagram explaining the mechanism of effect of retinal photocoagulation on retinal 
neovascularization and macular edema (adapted from Stefánsson, 2009).  
RPE - retinal pigment epithelial; VEGF-A = vascular endothelial growth factor A. 
 
To date, dramatic evolutions in the type of laser treatments from the conventional lasers to 
more advanced technologies, such as the micropulses, has been observed, thus increasing the 
treatment benefits associated with laser usage and decreasing retinal damage. 
 
The two-year outcomes of the protocol I, a “Randomized Trial Evaluating Ranibizumab Plus 
Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema”, 
from the Diabetic Retinopathy Clinical Research Network (DRCRnet), showed that the 
ranibizumab groups in combination with prompt or deferred laser treatment achieved greatest 
structural (OCT) and functional (visual acuity) outcomes than laser monotherapy (Elman et al., 
2010). Both ranibizumab groups showed an improvement of 10 or more letters in approximately 
50% of eyes and a vision gain of 15 or more letters in 30% of the studied eyes (Bandello, 2012). 
The IVTA study arm in combination with laser treatment did not demonstrate superior visual 
acuity outcomes compared with laser alone whereas in a subgroup of pseudophakic eyes, the 
results achieved were similar between corticosteroids and anti-angiogenics (Elman et al., 
2011). This is due to the fact that corticosteroids accelerated the progression of cataracts, 
Visible (laser) light 
Light absorption in melanin in retinal pigment epithelium and thermal coagulation of RPE cells and 
adjacent photoreceptors 
Decreased oxygen consumption of outer retina in laser scars (photoreceptors replaced by glia) 
Choroidal oxygen diffuses through laser scars and reaches inner retina 
Increased oxygen tension of inner retina 
Decreased VEGF-A Production 
Decreased endothelial 
Proliferation 
Decreased 
neovascularization 
Decreased 
permeability of vessels 
Auto-regulatory arteriolar 
Vasoconstriction 
Decreased hydrostatic pressure in capillaries 
and venules 
Decreased water flux from 
vascular to tissue compartment 
(Starling’s law) 
Decreased edema formation 
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apparently worsening the vision. However, it is known today from the results of the FAME study 
with fluocinolone acetonide 0.2 μg/day that patients recover vision gains after surgically 
removal of cataracts (Campochiaro et al., 2012). 
 
Another conventional treatment is vitrectomy. A vitrectomy is a surgical procedure that is 
performed to remove the vitreous gel. The Diabetic Retinopathy Vitrectomy Study (DRVS) 
aimed to compare early versus delayed pars plana vitrectomy (PPV) in patients with PDR, 
active neovascularization, and vitreous hemorrhage (Chang & Sarraf, 2008). The study group 
endorsed early PPV for vitreous hemorrhage in patients with diabetes mellitus type I or for eyes 
with advanced PDR and compromised visual acuity. Even though medical practice varies, a 
vitrectomy is commonly performed in patients with vitreous hemorrhage, tractional retinal 
detachment or mixed tractional and rhegmatogenous retinal detachment, epiretinal membrane 
and macular dragging. The goal of surgical treatment is: 1) to remove the blood, 2) release 
traction, 3) repair retinal detachment, and 4) to eliminate the scaffold to avoid the 
development of neovascular complexes. 
 
VEGF inhibition has been vastly used and become the gold standard for the treatment of DR 
and DME. The anti-VEGFs agents bevacizumab, ranibizumab and aflibercept are commonly used 
in the treatment of retinal diseases (Table 3).  
The similar properties between the monoclonal antibodies, bevacizumab and ranibizumab with 
respect to VEGF-A binding are due to the fact that the two molecules originated from the same 
precursor, the murine monoclonal antibody, however it should be noted that they are not the 
same molecule: 
• Bevacizumab is indicated for the treatment of patients with metastatic cancer of the 
colon, rectum or breast, and patients with non-small cell lung cancer or metastatic renal 
cell cancer. Bevacizumab vials are intended for single use as an intravenous infusion but 
when used off-label in ophthalmology, vials are split into multiple doses increasing the 
potential for contamination (particulate or microbial), for human error and incorrect dose 
or incorrect drug, during preparation of the intravitreal injections. 
•  Bevacizumab has two VEGF-A binding sites, whereas ranibizumab has only a VEGF-A 
binding site.  
• Bevacizumab is a full-length recombinant humanized monoclonal antibody (3 times larger 
than ranibizumab), with both Fc and Fab regions. It is produced in mammalian expression 
system (glycosylated molecule) and has a greater serum and vitreous half-life than 
ranibizumab. The Fc antibody domain has a role in immune activation. Moreover, it is also 
known that glycosylated proteins have a higher immunogenic potential compared with non-
glycosylated proteins. 
• Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab), produced in 
an Escherichia coli expression system (and thus not glycosylated). It was genetically 
engineered to increase its affinity for binding and inhibition of VEGF-A. 
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• Further, the two molecules differ in size (149 kDa for bevacizumab vs. 48 kDa for 
ranibizumab), in affinity for binding to VEGF-A (bevacizumab being lower affinity) and 
plasma half-life (which is 17 to 21 days for bevacizumab vs. 9 days for ranibizumab). 
• Ranibizumab is a drug designed specifically to be used intravitreally, having been approved 
by the FDA and EMA for the treatment of various diseases of the retina. 
 
3. Aflibercept or VEGF-Trap is a fusion protein that combines the ligand-binding components 
from the extracellular domains of VEGFR-1 and VEGFR-2 merged to the Fc portion of IgG. This 
anti-angiogenic abolishes tumor growth and vascularization, resulting in almost completely 
avascular tumors. Moreover, this anti-VEGF (Zaltrap® and Eylea®, from Regeneron) binds to all 
isoforms of VEGF-A, VEGF-B, and PlGF. In this case, the molecule aflibercept, used for the 
treatment of cancer is the same as that used in the treatment of neovascular eye diseases 
(Simó et al., 2014). 
 
In the DRCRnet clinical trials, specifically in the T protocol, which compared the 3 anti-
angiogenic drugs, Eylea® (aflibercept), Lucentis® (ranibizumab), and Avastin® (bevacizumab) in 
the treatment of DME, patients who initially at the start of the study had a visual acuity of 
20/50 or worse, had better outcomes with aflibercept at the end of the first year. However, in 
patients who had a baseline vision of 20/40 to 20/32, there were no differences in the results 
between the three drugs at the end of the first year. Likewise, at the end of the second year of 
protocol T, there was no significant difference in the outcomes among the three drugs. In 
addition, regarding drug safety, there were no major differences observed between 
bevacizumab, ranibizumab and aflibercept in the treatment of DME (Baker et al., 2016). 
Nevertheless, not all patients responded sufficiently to anti-VEGF therapy, leading to new 
research approaches in the fight against DR and DME. 
 
Corticosteroids have a significant role in the treatment of DME. Despite the large benefits of 
steroids therapy, all steroids are associated with the risk of adverse events such as the 
occurrence of increased intraocular pressure and cataract (Chang & Sarraf, 2008). The most 
well-known corticosteroids for this indication are triamcinolone acetonide (off-label), 
dexamethasone, and fluocinolone acetonide. The role of corticosteroids in the treatment of 
DME is multifactorial. Corticosteroids act not only as powerful anti-inflammatory drugs but also 
antagonize the action of VEGF-A, inhibit leukostasis and decrease inflammatory cytokines. All 
the above three corticosteroids have an elimination half-life inside the vitreous of 2–3 hours in 
animal models (Schwartz, Flynn & Scott, 2013), consequently being swiftly cleared from the 
eye. In order to extend the half-life and duration of the corticosteroids in the eye, researchers 
developed diverse strategies. In the case of triamcinolone acetonide, it was found that it could 
be dissolved slowly from a crystal structure. For dexamethasone and fluocinolone acetonide, 
drugs were deposited in a specific matrix and inserted in a particular slow release device that 
is intravitreally injected into the eye. 
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IVTA suspension is a powerful and effective drug for remaining for approximately 3 months in a 
non-vitrectomized eye, so it is necessary to repeat injections to preserve the treatment effect 
(Schwartz et al., 2013). In order to reduce the burden of injections, and the associated risks 
with the frequent intravitreal injections, pharmaceutical companies investigated extended 
release steroid implants. There are two steroid implants for the treatment of DME: a shorter 
acting steroid implant for dexamethasone, lasting up to 6 months according to the MEAD study 
and a longer acting steroid implant for fluocinolone acetonide lasting for at least 3 years 
(Bonfiglio et al., 2017, Boyer et al., 2014, Campochiaro et al., 2012, Cunha-Vaz et al., 2014). 
Besides, according to Schwartz and co-authors, a long acting and continuous release of low 
corticosteroids dosage is more effective than a discontinuous and sporadic bolus delivery of 
high doses. Also in general, non-bioerodable implants are associated with more precise control 
of drug release than the bioerodable implants (Schwartz et al., 2013). 
 
Similar to AMD and RVO, future treatments behind anti-VEGF therapy and besides the ones 
currently used are being investigated for the treatment of DR and DME (Shamsi et al. 2013), 
namely: 
1. Anti-tumor necrosis factor alpha (or tumor necrosis factor antagonist), such as the 
monoclonal anti-TNF antibody infliximab used for inflammatory arthritic conditions and Crohn’s 
disease. In a first small phase III study conducted with infliximab in patients at risk of vision 
loss secondary to DME refractory to laser photocoagulation, an improvement of visual acuity 
was observed and the treatment was well tolerated (Sfikakis et al., 2010; Wu et al. 2011). 
However, the outcomes obtained with additional studies were not encouraging. The role of TNF 
inhibition in patients with DME is unknown and still needs to be studied. Adalimumab (Humira®, 
Abbvie) is another TNF-inhibitor and an anti-inflammatory agent approved for the treatment of 
non-infectious intermediate, posterior, and panuveitis in adult patients. It binds to tumor 
necrosis factor-alpha reducing the inflammatory response. It is administered by a subcutaneous 
injection. Adalimumab received CHMP positive opinion in July 2017 for the treatment of 
pediatric patients with chronic non-infectious anterior uveitis (HUMIRA EPAR, 2017). Still, its 
benefits in DME patients are uncertain. 
2. Protein Kinase-C beta-isoform inhibitors (PKC-b or ruboxistaurin) regulate EC permeability 
and triggers VEGF-A (Tsilimbaris et al., 2007). Ruboxistaurin is an oral PKC-b inhibitor that 
demonstrated inconsistent results in the treatment of DME. In animal models, ruboxistaurin 
improved diabetic retinopathy and DME (Suzuma et al., 2002). In a phase II study with oral 
ruboxistaurin tested in DR patients, it increased visual acuity in NPDR patients, decreased 
moderate visual loss, macular edema progression and the need for laser treatment for macular 
edema. Ruboxistaurin was well tolerated but did not receive approval from the FDA (Aiello et 
al., 2006). 
3. Nicotinic acetylcholine receptor antagonist (mecamylamine). The topical ocular formulation 
of mecamylamine was tested in a multicenter phase I/II clinical trial in patients with chronic 
DME. The results showed an improvement of visual acuity with no safety problems 
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(Campochiaro et al., 2010). Further clinical trials comparative with anti-VEGFs are needed in 
order to establish its efficacy. 
4. AKB-9778 (Aerpio Therapeutics) is a small molecule inhibitor of vascular endothelial-
phosphotyrosine phosphatase (VE-PTP) that is administered by a subcutaneous injection. VE-
PTP is a member of protein tyrosine phosphatase (PTP) family and targeting VE-PTP activates 
TEK receptor tyrosine kinase (Tie2) stabilizing the ocular vasculature (Shen et al., 2014). The 
TIME-2 study provided proof-of-concept for treatment of diabetic eye disease, both DME and 
DR, by activation of Tie2 with AKB-9778. The TIME-2 is a phase 2 double-masked, placebo-
controlled study to assess the safety and efficacy of subcutaneously administered akb-9778 
15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe NPDR. 
This study has an estimated primary completion date for May 2019 (final data collection date 
for primary outcome measure ("The TIME-2b Study: A Study of AKB-9778, a Novel Tie2 
Activator, in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) - Full Text View - 
ClinicalTrials.gov", 2017). 
5. ARP-1536 is a novel humanized monoclonal antibody that targets the extracellular domain of 
VE-PTP. With a mechanism of action that activates Tie2, this intravitreal drug can be 
administered stand-alone or in combination with anti-VEGF therapy to target wet AMD and 
DME. Pre-clinical studies established a similar biologic activity to AKB-9778 (Frye at al., 2015; 
"Pipeline – Aerpio Pharmaceuticals", 2017). 
6. Nesvacumab (Regeneron) is a fully human monoclonal antibody that was designed for the 
treatment of cancer. It targets the protein angiopoietin 2. The phase II clinical trial RUBY (anti-
vascular endothelial growth factor plus anti-angiopoietin 2 in fixed combination therapy: 
evaluation for the treatment of diabetic macular edema) was completed in July 2017 ("Anti-
vascular endothelial growth factor plus Anti-angiopoietin 2 in Fixed combination therapy: 
Evaluation for the Treatment of Diabetic Macular Edema - No Study Results Posted - 
ClinicalTrials.gov", 2017). 
7. Adeno-associated virus based platform is a method that will make use of AAV vector to 
induce anti-VEGF production by transduced cells. 
8 Implantation of encapsulated modified cells. 
9. Stem cell therapy. 
 
Several algorithms and guidelines have been proposed for the treatment of this multifactorial 
disease to improve patients’ vision and quality of life for all involved in this disease. There is a 
resilient need to understand the disease, its treatments, regimens available and convenience 
for all those involved to propose an adequate algorithm for the treatment of DR and DME in an 
individualized regimen and probably taking advantage of the combination therapy in the near 
future (Figure 21), (Henriques et al., 2017).  
 
Introduction 
 
 
49 
 
 
 
Figure 21: Algorithm of DME treatment, proposed therapeutic schema. Guidelines of Diabetic Macular 
Edema (DME) the GER perspective towards a more personalized treatment (used with permission). 
 
Despite the emergence of consensus guidelines as well as algorithms, DR and DME remain 
challenging to treat. Further understanding of the biochemical, genetic and environmental, 
factors that contribute to the development and progression of DR should continue to bring new 
discoveries and promising new targets for more effective and better-tolerated treatments. 
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A B S T R A C T
Vision loss due to disease or degeneration of the eye (retina, choroid, retinal veins, or macula) is a leading cause
of blindness worldwide. In most cases, vision-threatening ocular diseases are accompanied by abnormal changes
in the vasculature of the eye, especially the retina, and these conditions are collectively referred to as retinal
vasculopathies. Impaired blood supply or hypoxia stimulates angiogenesis in the vascular and non-vascular
sections of the eye, which results in neovascularization, leading to conditions such as diabetic retinopathy or
age-related macular degeneration. Studies show that vascular endothelial growth factors: VEGF-A, VEGF-B, and
placental growth factor (PlGF) are elevated in these diseases, and hence, these factors could be used as markers
for disease prognosis and therapy. In this review, we discuss the function of these growth factors in normal
development and disease, with focus on ocular disorders and emphasize the importance of accurately de-
termining their levels in the vitreous and serum of patients for correct diagnosis and therapy.
1. Introduction
Growth factors are naturally occurring molecules, usually proteins
or steroids, which stimulate cellular growth, proliferation, and differ-
entiation [1] . Typically, growth factors act as signaling molecules be-
tween cells and bind to cell surface receptors to initiate signaling cas-
cades that affect gene expression and cell fate. For example, bone
morphogenetic protein induces bone differentiation [2] , whereas fi -
broblast growth factor [ 3] and vascular endothelial growth factors
(VEGF) stimulate angiogenesis, i.e., growth of blood vessels [4,5] .
For the last two decades, growth factors are also being extensively
used in medicine for treating hematologic, oncologic, and cardiovas-
cular diseases [6–9] . In particular, the VEGF family of growth factors
are finding increasing use in the treatment of cardiac [10] , renal [ 11] ,
and bone-related diseases [12] as agonists and in ophthalmic diseases
[13,14] and cancer as antagonists [15] . Angiogenesis plays important
roles in normal and pathological proliferative processes. It is involved
in normal growth, wound healing [16–18] as well as in tumor growth
and metastases [19] , which makes regulators of angiogenesis critical
biomedical molecules.
The VEGF family consists of seven secreted dimeric proteins,
namely, VEGF-A (or VEGF), B, C, D, E (or viral VEGF), F (snake venom
VEGF) and the placental growth factor (PlGF) [20] . VEGF-A has several
isoforms that arise via alternative splicing of the eight-exon VEGF-A
gene. All VEGFs function by binding to cell surface-bound tyrosine ki-
nase receptors called vascular endothelial growth factor receptors
(VEGFRs), causing them to dimerize and be activated through trans-
phosphorylation, albeit with different specificities. VEGF ligands bind
to three main transmembrane endothelial receptors namely, VEGFR-1,
VEGFR-2, and VEGFR-3 [21] . In addition, neuropilins, neuropilin 1
(NRP-1), and neuropilin 2 (NRP-2) provide co-receptor function in
endothelial cells [ 22] . Among the growth factors of the VEGF family,
VEGF-A is well-studied and PlGF less studied in terms of function and
clinical application, whereas the physiological role of VEGF-B was
ambiguous until recently and is just beginning to be understood.
Nonetheless, the effect of these three factors in ophthalmic develop-
ment and diseases is relatively less investigated. In this review, we
would first discuss the roles of VEGF-A, VEGF-B, and PlGF in general
development, followed by discussion of their emerging functions in
ophthalmic disorders, as well as targeted molecules.
https:/ / doi.org/ 10.1016/ j.cytogfr.2017.11.005
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2. Vascular endothel ial growth factors in development and
disease
2.1. VEGF-A
VEGF-A, which signals via VEGFR-1 and 2 and NRP-1 and 2 [23,24] ,
is essential for vascular development. Mice lacking any of the VEGF
allele die during embryogenesis due to impaired angiogenesis [25] .
Alternative exon splicing produces seven VEGF-A isoforms: VEGF121,
VEGF145, VEGF165, VEGF165b, VEGF183, VEGF189, and VEGF206. Each
isoform is characterized by the respective number of amino acids after
cleavage of the signal sequence variants [26] . Initial in vitro studies
showed that capillary endothelial cells proliferate and form tubular
structures in the presence of VEGF-A [27] . VEGF-A expression is
downregulated after embryogenesis [28] , whereas it is upregulated
during physiological and pathological angiogenesis [29] and also
during exercise and muscle contraction [30] . Increased blood flow
during exercise along with VEGF-A also stimulates the production of its
receptors, which initiates a massive signaling cascade leading to the
production of nitric oxide (for vessel permeability), FGF (for cell pro-
liferation), and ICAM/ VCAM/ matrix metalloproteases (for migration)
all of which contribute to the formation of new blood vessels. In ad-
dition, VEGF and VEGFR-1 are upregulated in hypoxic conditions via
hypoxia inducible factor (HIF) 1-α-dependent [31] and independent
pathways [32] , highlighting the close relationship between blood
oxygen levels, angiogenesis, and tissue metabolism. Similarly, the levels
of VEGF-A and its corresponding receptors arise immediately after a
traumatic injury to the central nervous system and decline with time,
which corresponds to endogenous post-injury revascularization [33] .
Rheumatoid arthritis (RA) is an autoimmune disease, and synovial
angiogenesis is critical for inflammation and immune activation asso-
ciated with RA pathogenesis. A recent study showed that serum VEGF-A
levels and VEGF-A polymorphisms were strongly associated with in-
cidence of RA in the Polish population [34] . Cancer cells require high
nutrient and oxygen supply for rapid proliferation and dissemination
(metastasis), which necessitates de novo angiogenesis inside the tumor;
thus, cancer may be categorized as an “angiogenic” disease. Studies
have shown that VEGF-A overexpression is implicated with poor
prognosis of breast cancer, which acts as an angiogenic switch that
induces metastasis [35] . Similarly, VEGF-A has been found to be up-
regulated in hepatic, gastric, pancreatic, ovarian, bladder, colorectal,
myeloid, and thyroid cancers and medulloblastoma [7] . Thus, VEGF-A
is a good candidate for anti-cancer treatment, and an anti-VEGF-A
monoclonal antibody called bevacizumab was clinically approved for
cancer treatment in 2004. VEGF-A is also involved in renal and pul-
monary disorders. Patients with pulmonary emphysema have decreased
VEGF-A levels in pulmonary arteries [36] . VEGF-A is also a biomarker
of asthma and compulsive obstructive airway disease [37] . In contrast,
increased VEGF-A expression is associated with glomerular hyper-
trophy and proteinuria [38] although physiological levels of VEGF-A
are required for renal development and maintenance of glomerular
capillary structure.
2.2. VEGF-B
VEGF-B is highly related to VEGF-A, although it signals via the
VEGFR-1 receptor unlike that of VEGF-A, which uses both VEGFR-1 and
2, thereby competing with VEGF-A for VEGFR-1 binding [39] . VEGF-B
also binds with NRP-1 [39] . Despite similarity in structure, the phy-
siological role of VEGF-B is ambiguous. VEGF-B has two isoforms:
VEGF-B167 and VEGF-B186. Both VEGF-B isoforms can form hetero-
dimers when co-expressed with VEGF-A165 in cells; however, whether
heterodimers exist in nature is not known. Despite being cell-bound, the
VEGF-A165/ VEGF-B167 heterodimers can be freely secreted by en-
dothelial cells. The balance between homo- and heterodimers can affect
VEGF-A signaling if heterodimers are formed [40] .
VEGF-B possesses low angiogenic potential; hence did not induce
vessel formation or sprouting when delivered in muscle or peri-
adventitial tissue [41] , whereas transgenic overexpression of VEGF-B
minimally increased vasculature. In contrast, VEGF-B overexpression
was reported to potentiate and not initiate angiogenesis in endothelial
cells of transgenic mice [42] . VEGF-B was therefore considered as a
survival factor of endothelial cells that regulated the expression of pro-
survival genes via VEGFR-1 and NRP-1 signaling [43] .
Unlike VEGF-A, VEGF-B is not induced by hypoxia, other growth
factors, cytokines, hormones, or oncogenes [44,45] . Although a recent
study has reported that hypoxia induces VEGF-B in the retina [46] .
However, VEGF-B is expressed in a wide range of tissues; being most
abundant in tissues with high metabolic activity, such as the myo-
cardium, skeletal muscle, vascular smooth muscle, brown adipose
tissue, kidney, brain, and parietal cells of the stomach [47,48] . This
indicates a role of VEGF-B in coordinating angiogenesis with metabo-
lism. A study demonstrated that VEGF-B is highly expressed in meta-
bolically active tissues, such as the heart and skeletal muscle, sug-
gesting its function in maintaining oxidative metabolic and contracti le
function in these tissues [49] . VEGF-B is expressed on the cell surface of
cardiomyocytes, which are released for downstream signaling after
cleavage with endothelial cell-secreted heparanase. The bidirectional
interaction between endothelial cells and cardiomyocytes could provide
the diabetic heart protection against cell death and may be a critical
tool for delaying or preventing cardiomyopathy. However, VEGF-B and
heparanase production decline under sustained hyperglycemic condi-
tions and VEGF-B signaling declines albeit upregulation of VEGFR-1,
which results in diabetic cardiomyopathy [49] . Another study identi-
fied VEGF-B to be a coronary growth factor in rats where it induced
cardiac hypertrophy via the endothelium [50] . VEGF-B also induced
angiogenesis and arteriogenesis in myocardium of patients via VEGFR-1
and NRP-1 signaling [51] . Moreover, VEGF-B selectively promotes an-
giogenesis in ischemic myocardium. Several studies have shown that
VEGF-B has a speci fic role in the revascularization of ischemic myo-
cardium in different disease models of mice, pigs, and rabbits. There-
fore, VEGF-B might have a cardioprotector effect and might harbor
therapeutic potential for ischemic heart diseases [42,48] .
Studies in VEGF-B knockout mice show that VEGF-B is dispensable
for embryonic growth and survival, unlike VEGF-A knockouts that die
during embryogenesis. However, the hearts of the VEGF-B knockout
mice were smaller and displayed vascular dysfunction after coronary
occlusion and impaired recovery from experimentally-induced myo-
cardial ischemia, indicating a role of VEGF-B in coronary vasculature
development [52] .
Diabetic kidney disease (DKD) is a severe renal disease that is
characterized by defects in glomerular fi ltration, proteinuria, and
steatosis. DKD tissues show high VEGF-B expression. Since VEGF-B
controls muscle lipid accumulation through regulation of endothelial
fatty acid transport [ 53] , therefore therapeutic reduction in VEGF-B
levels ameliorates symptoms of DKD, such as renal lipotoxicity and
insulin insensitivity [ 54] .
VEGF-B also has a crucial role in neuroprotection. VEGF-B-deficient
mice showed impaired recovery from cerebral ischemic injury and
neurogenesis was seen to be stimulated in adult mice on administration
of VEGF-B [55] . VEGF-B is also required for nerve regeneration, sensory
recovery, and trophic functions of injured corneal peripheral nerves,
but is not present in a mouse model having no nerve injury [56] . In
addition, VEGF-B was shown to increase angiogenesis in a mouse model
of arthritis as Vegfb-/ - mice exhibited decrease in inflammation-asso-
ciated synovial angiogenesis [57] .
The role of VEGF-B in cancer remains unclear. However, Yang and
colleagues demonstrated that VEGF-B promotes cancer metastasis
through remodeling of tumor microvasculature and a VEGF-
A–independent mechanism [58] . The function of VEGF-B is multi-
faceted, thus it was considered by Li and co-workers as a survival factor
rather than an angiogenic molecule [59] .
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2.3. PlGF
PlGF is a pleiotropic factor that affects different cell types and
regulates various biological processes via signaling through VEGFR-1.
PlGF has four splice variants that are generated via alternative splicing:
PlGF-1 (PlGF131), PlGF-2 (PlGF152), PlGF-3 (PlGF203), and PlGF-4
(PlGF224) [ 60] . The PlGF-2 and PlGF-4 isoforms also bind to neuropi-
lins. PlGF can also form heterodimers with VEGF-A [61] . One of the
primary functions of PlGF is regulation of vessel growth and matura-
tion, and therefore, this cytokine is associated with pro-angiogenic
activities similar to VEGF-A. PlGF recruits myeloid progenitors to
growing sprouts and collateral vessels; it attracts macrophages, which
release angiogenic and lymphangiogenic factors. In addition, PlGF
regulates ossi fication, wound healing, retinal pigment cell chemotaxis,
and survival of cortical neurons, etc. [ 62] PlGF overexpression in
murine epidermal cells elicited severe inflammatory response asso-
ciated with pronounced edema, inflammatory cell infi ltration, and
vascular enlargement indicating direct role of PlGF in cutaneous in-
flammatory response [63] .
Sandro De Falco and colleagues described the role of PlGF in car-
diovascular diseases and suggested three major functions for PlGF in the
cardiovascular system: 1) myocardial angiogenesis, 2) mediating mac-
rophage chemotaxis, 3) selective action in modulating pathological
rather than physiological vascular development, which makes this
protein an excellent candidate for therapeutically modulated angio-
genesis [64] .
PlGF levels are low in normal adult tissues; however, it was upre-
gulated in 4 out of 16 menangioma tumors, whereas VEGF-A level was
upregulated in 3 out of 16 samples. There was no signi ficant correlation
between PlGF and VEGF-A expression levels. VEGF-B was uniformly
expressed in all tumor samples. In a PlGF-positive tumor sample, im-
munoreactive VEGFR-1 and VEGFR-2 were detected in endothelial cells
of the blood vessels and PlGF was detected in most tumor capillaries.
Thus, PlGF might be yet another marker for tumor angiogenesis in
human menangiomas [65] . Interestingly, supra physiological levels of
PlGF have been documented to inhibit angiogenesis of tumors co-ex-
pressing VEGF-A. This possibly occurs because of heterodimerization of
PlGF with VEGF-A, which outnumbers the biologically active VEGF-A
homodimer [66] . Indeed, Yang et al. demonstrated that PlGF can affect
tumor angiogenesis in both positive and negative ways in a VEGF-A-
dependent manner. In one tumor model, PlGF remodeled tumor vas-
culature to a normalized phenotype, whereas ablation of VEGF-A in a
PlGF-positive tumor accelerated tumor angiogenesis and growth [67] .
3. Vascular endothel ial growth factors in ophthalmic diseases
3.1. VEGF-A
The eye possesses a special anatomy where completely avascular
and highly vascular structures lie in close apposition. Stringent reg-
ulation of the balance between vascular growth and quiescence main-
tains this structure. Vascular growth occurs mainly during embryonic
development and is almost absent in the adult eye. Therefore, oph-
thalmic diseases associated with angiogenesis represent cases where
this delicate balance has been disturbed by external conditions, such as
hyperglycemia, oxidative stress and other factors (Fig. 1) [ 68] .
Vitreous levels of VEGF-A were high in several retinal diseases, such
as diabetic retinopathy (DR), age-related macular degeneration (AMD),
and retinal vein occlusion (RVO) [69] . Among diseases contributing to
ocular anomalies, diabetes has been studied extensively owing to its
manifold effects on healthcare [70] . The deleterious effects of diabetes
mellitus on macro and microcirculation underline the morbidity and
mortality associated with this disease. Research on pathological factors
related to diabetes mellitus have highlighted the involvement of VEGF-
A in conditions, such as DR, diabetic macular edema (DME) and AMD,
which are the major causes of blindness worldwide [68] . DR is
accompanied by loss of the retinal barrier function and increased vas-
cular permeability. Several blood-borne proteins might contaminate the
vitreous and show an elevated level; therefore, simultaneous testing of
protein levels in both serum and vitreous is crucial for correctly inter-
preting whether the increased vitreal expression is due to upregulation
of gene expression or vascular leakage. An accurate interpretation of
vitreal pro-angiogenic protein levels is important for the development
of correct biomarkers and therapies for retinal diseases [71] .
Proliferative DR (PDR) is characterized by progressive loss of retinal
capillaries, followed by hypoxia and hypoxia-induced VEGF-A expres-
sion, which stimulates neovascularization of the retina, disc, angle, and
iris. Several clinical studies have confi rmed the correlation between
ischemic retinopathies and RVO and VEGF-A levels [69,72] . Elevated
VEGF-A levels were observed in the aqueous and vitreous samples of
143 patients with proliferative retinopathies undergoing intra-ocular
surgery [73] . On the other hand, laser surgery considerably reduced the
intraocular VEGF-A levels [74] . VEGF-A levels were considerably lower
in individuals with non-neovascular disease or diabetes without re-
tinopathy. Similar results were reported by Aiello et al. [ 69] , who de-
tected high levels of VEGF-A in 69/ 136 ocular fluid samples from pa-
tients with DR, 29/ 38 iris samples with neovascularization, and 3 of 4
samples from patients with ischemic occlusion of the central retinal
vein, compared to 2 of 31 samples from patients with no neovascular
disorders. Other studies showed that advanced glycation end products
and decreased anti-oxidant status correlated with DR pathogenesis via
VEGF-A induction [75] . A quantitative proteomic study using the
vitreous of patients with PDR and non-PDR and those treated with anti-
VEGF-A therapy revealed 230 proteins involved in inflammation,
complement activation, cell adhesion, and the coagulation cascade, and
apolipoproteins, immunoglobulins, etc. to be overexpressed in PDR
than in non-PDR [76] . This reflects the multifactorial nature of DR and
suggests new possibilities for developing therapeutics. Elevated levels
of various cytokines, such as interleukin- (IL-) 1β, IL-2, IL-4, IL-5, IL-6,
IL-10, interferon-γ, tumor necrosis factor-α, and VEGF were observed in
the aqueous humor of patients with DR, and the levels increased with
the severity of the disease [77] .
Neovascularization of the angle leads to neovascular glaucoma
(NVG), which is currently being treated with anti-VEGF-A therapy in
clinical trials [ 78] as VEGF-A isa marker for NVG in the aqueous humor
and serum of such patients [78] . However, it is noteworthy that VEGF-A
expression is observed in both normal and diabetic retina photoreceptor
and ganglion cells, indicating a physiological role of this growth factor
in ocular angiogenesis [79] . A proteomic analysis showed that VEGF-A
was upregulated in AMD [80] and that vitrectomy, followed by retinal
Fig. 1. Factors involved in upregulation of VEGF-A and main repercussions. Hypoxia is
one the most important through HIF-1, followed by hyperglycemia; AGEs and pro-in-
flammatory cytokines are other stimulating factors that increase VEGF-A production. The
main consequences for retinal diseases are the BRB breakdown with increasing vascular
permeability and neovascularization.
AGEs – Advanced glycation end products; BRB – Blood retinal barrier; HIF-1α – Hypoxia-
inducible factor 1-alpha; IGF-1–Insulin–l ike growth factor 1; FGF – Fibroblast growth
factor; PDGF – Platelet-derived growth factor.
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photocoagulation, decreased VEGF-A levels [81] .
DME is a vision-threatening complication of DR, with a prevalence
rate of 20% and 25% in patients with type I and type II diabetes, re-
spectively. DME is caused by macular thickening and cyst formation
post retinal-blood barrier breakdown, increased vascular permeability,
and fluid accumulation in hyperglycemic condition. Optical coherence
tomography (OCT) and enzyme-linked immunosorbent assay (ELISA) of
the vitreous of 71 patients with DME revealed a concentration gradient
of VEGF-A in DME from the macula to the periphery and from the
posterior to the anterior globe [82] . Laser treatment as well as in-
travitreal anti-angiogenics, such as ranibizumab, afl ibercept, and bev-
acizumab (off-label) have been widely used for the treatment of dis-
eases targeting VEGF-A and are considered as the gold standard for
treatment of angiogenic disorders. Intravitreal corticosteroid adminis-
tration is also used to reduce VEGF levels and angiogenesis in patients
with DME [83] . Moreover, other revolutionary modes of treatment,
such as dexamethasone and fluocinolone acetonide corticosteroid im-
plants are being used for the treatment of angiogenic and inflammatory
diseases [84] .
In addition to DR and AMD, VEGF-A causes multiple age-related eye
diseases such as cataracts and neovascular and non-exudative AMD-like
pathologies. High VEGF-A levels induce age-related opaci fications in
the lens, which is accompanied by ERK activation, inflammation, and
oxidative damage. Targeting of inflammasome components con-
siderably downregulated VEGF-A-stimulated cataract formation.
Elevated VEGF-A also causes choroidal neovascularization [85] .
It is noteworthy that VEGF-A is the most studied growth factor ti ll
date. However, other growth factors are also involved in these angio-
genesis-associated pathologies, such as VEGF-B and PIGF, which are
gradually gaining attention in basic and clinical research.
3.2. VEGF-B
Previously, the role of VEGF-B in ophthalmic development and
diseases was obscure; however, recent studies have shed light on the
function of this enigmatic molecule. For example, the overexpression of
VEGF-B promoted pathological retinal and choroidal neovasculariza-
tion and blood-retinal barrier disruption without inflammation, unlike
VEGF-A [85] . Thus, VEGF-B could be involved in the progression of DR
and AMD in an inflammation-independent way and could therefore be
used for developing anti-angiogenic therapies [86] . Interestingly,
Reichelt et al. [ 87] reported that VEGF-B was not required for the de-
velopment of retinal vasculature under normal conditions or in oxygen-
induced retinopathy.
In a study performed by our research group, the measurement of
VEGF-B levels in patients with DR and rhegmatogenous retinal de-
tachment revealed that VEGF-B levels were signi ficantly higher
(p = 0.006) in the vitreous of diabetic patients with ocular disease, and
the levels increased in advanced stages of DR [88] . In another study, we
estimated VEGF-A and VEGF-B levels using ELISA in the vitreous and
serum of patients with proliferative ocular disorders (POD), which in-
cluded patients with DR, AMD, and retinal vein occlusion (n = 10), and
compared it with a control group of patients with non-proliferative
ocular disorders (NPOD) (n = 4). Similar to the results of earlier stu-
dies, we observed that VEGF-A and B levels were elevated in POD than
in NPOD mainly because of DR, and that the serum and vitreous levels
of VEGF-A and B showed high correlation [89] .
We also performed ELISA to estimate the levels of VEGF-B and PlGF
in the vitreous of 42 patients with DR undergoing vitrectomy. OCT was
used to estimate macular volume (MV) and central retinal thickness
(CRT). The results showed elevated VEGF-B levels in these patients,
which showed moderate (p < 0.05) and robust (p < 0.01) correlation
with CRT and MV, respectively. PlGF, however, did not show any sta-
tistically signi ficant correlation. Thus, VEGF-B targeting in these pa-
tients might offer beneficial therapeutic outcomes [90] .
VEGF-B is expressed in the eye and its expression is upregulated
after pathological challenge of the retina [48] . A recent study showed
that subretinal injection of adeno-associated viruses encoding VEGF-
B167 or VEGF-B186 increased ischemia and laser injury-induced retinal
and choroidal neovascularization, respectively [86] . Another study
showed that targeted inhibition of VEGF-B by shRNA (short hairpin
RNA) or intravitreal injection of neutralizing antibody suppressed
choroidal and retinal neovascularization in mice [43] . Thus, it can be
concluded that VEGF-B targeting inhibited retinal neovascularization.
It appears that the ‘angiogenic’ activity of VEGF-B during ocular
neovascularization is probably because of its potent survival effect on
vascular and nonvascular cells. In addition, both NRP-1 and VEGFR-1
participate in mediating the vascular survival effect of VEGF-B.
Therefore, even though VEGF-B has a minimal role during the initial
phase of blood vessel growth, the vascular survival activity of VEGF-B,
which protects the neovessels from apoptosis may play a signi ficant role
in enhancing ocular neovascularization. Thus, targeted VEGF-B in-
hibition may also have therapeutic implications for the treatment of
ocular neovascular diseases [43] . VEGF-B is currently receiving atten-
tion because of recent exciting advances in VEGF-B biology. Owing to
its antiapoptotic and potent survival effect, and its ability to remain
inactive under normal conditions, VEGF-B appears to possess valuable
therapeutic potential for the treatment of degenerative diseases with an
attractive safety profi le.
3.3. PlGF
PlGF, originally isolated from the human placenta, participates in
pro-angiogenic processes not only by direct signaling through VEGFR-1,
but also indirectly by amplifying VEGF-A angiogenesis through reg-
ulation of the VEGFR-1 and VEGFR-2 cross-talk [91] . Although PlGF
and VEGF-A are both expressed during neonatal retinal development,
they have different modulatory influences on retinal vascular devel-
opment [92] . Studies show that PlGF synergizes with VEGF-A for an-
giogenesis-associated eye diseases. Indeed, PlGF levels were elevated in
the vitreous [93] and aqueous humor of patients with DR and NVG
[94] . Another comparative study of vitreal PlGF levels in patients with
proliferative DR with or without bevacizumab (anti-VEGF therapy)
treatment showed that PlGF level was high in DR patients irrespective
of the status of bevacizumab therapy and that it correlated strongly
with VEGF-A levels. Thus, PlGF is implicated in DR pathogenesis in
parallel to the involvement of VEGF-A, and use of afl ibercept (anti-
PlGF) might be beneficial in such cases [95] . Interestingly, PlGF dele-
tion in a diabetic mouse model inhibited Akt signaling and HIF1 alpha-
dependent VEGF-A activation, indicating that PlGF is required for
VEGF-A-mediated DR pathogenesis [96] . Furthermore, intraocular in-
jection of PlGF gene or protein causes retinal vessel disorganization,
dilatation, microaneurysm formation, retinal-blood barrier disruption,
and edema [97] .
Although high VEGF-A levels is one of the main risk factors for
angiogenic eye diseases, more factors are currently indicated in the
development of subretinal angiogenic pathogenesis. Consequently,
Rakic et al. showed that PlGF levels were elevated in cases of choroidal
neovascularization, whereas a VEGF-A isoform was present in the early
stages of angiogenesis [98] . Huo et al. [ 99] used a laser burn mouse
model of choroidal neovascularization to show that both PlGF and
VEGF-A levels were elevated in mouse eyes and that these two factors
coordinated to regulate choroidal neovascularization during ocular in-
jury; anti-PlGF therapy alone did not stem the increase in vessel density
post laser burn, but it augmented the anti-angiogenic function of anti-
VEGF-A in their model.
We analyzed vitreous and serum PlGF levels in diabetic and non-
diabetic patients undergoing vitrectomy (n = 17 for diabetic and
n = 21 for non-diabetic) using ELISA. Results showed that vitreous
PlGF levels were higher in the diabetes group and that it increased with
severity of the disease, i.e., levels were higher in proliferative DR and in
non-proliferative DR. Serum PlGF levels were also elevated in the
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diabetes group, although the mean difference was not statistically sig-
nificant. In this work, we did not observe any correlation between
vitreous and serum PIGF levels [100] .
4. Targeting VEGF in retinal diseases
4.1. Current drugs
Ocular angiogenesis isa cause of severe visual loss. The treatment of
ocular neovascular diseases is challenging and has improved dramati-
cally in the last few years with the development of anti-VEGFs, which
transformed the treatment of eye disorders. However, currently there is
no cure, only therapies that slow down the progression of the disease.
According to a review by Tah and colleagues [101] , anti-VEGF
started its appearance approximately in 1948, however only after sev-
eral years later the vascular permeability factor (VPF) was described
and in 1989 it was named, as we know, VEGF.
Despite not being an angiogenic agent, one of the first pharmaco-
logical therapies to treat AMD was verteporfin (Visudyne®, Novartis
Pharmaceuticals Corporation, East Hanover, New Jersey), an angiooc-
clusive drug that in 2000 changed the course of AMD [102] . The aim of
verteporfin therapy was to occlude vessels within the choroidal neo-
vasculature while preserving the overlying retinal tissue.
A short time after, anti-angiogenic agents clinical trials began with
powered outcomes of VEGF inhibition. VEGFs were recognized as an-
giogenic regulators of neovascularization and promoters of vascular
permeability reasons for key targets for treating neovascular diseases.
They become the standard care therapy for conditions involving neo-
vascularization. The fi rst phase I clinical trials in colon cancer with an
anti-angiogenic drug were performed in 1997 by Genentech with the
drug called bevacizumab (Avastin®, Genentech, Inc., San Francisco,
California, USA), which was granted approval by U.S. Food and Drug
Administration (FDA) in 2004 for the treatment of colon cancer as
adjuvant to chemotherapy [102] .
Additionally, in December 2004, FDA approved pegaptanib sodium
(Macugen®, OSI Pharmaceuticals, Inc., Melville, New York) that was the
fi rst anti-VEGF therapy for neovascular AMD [102] . However, after
bevacizumab approval for cancer therapy, ophthalmologists began to
use this molecule intravitreally to treat ocular neovascularization (off-
label). Furthermore, Genentech designed a new molecule from the same
precursor as bevacizumab, generating a different molecule, specifically
for intravitreal use. This new molecule, ranibizumab (Lucentis®, Gen-
entech Inc., San Francisco, California, USA) is believed to penetrate
better into the retina [101] . Additionally, to decrease systemic adverse
events, the portion Fc of the monoclonal antibody was removed from
the original precursor. This new molecule showed to be safe and ef-
fective in the first clinical trials: MARINA (Minimally Classic/ Occult
Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of
Neovascular Age-Related Macular Degeneration) and ANCHOR (Anti-
VEGF Antibody for the Treatment of Predominantly Classic Choroidal
Neovascularization in Age-Related Macular Degeneration) [102] .
In November 2011, another anti-angiogenic agent, afl ibercept
(Eylea®, Regeneron Pharmaceuticals Inc., Tarrytown, New York) de-
veloped by Regeneron was approved by FDA [102] based on the VIEW
studies, which showed to be a safe and an effective drug like ranibi-
zumab. Currently, there are four therapies involving VEGF inhibition
[103] :
1. Pegaptanib sodium intravitreal injections, (Macugen®), a pegylated
VEGF aptamer. A single strand of nucleic acid that binds with spe-
cificity to the 165 isoform of VEGF-A was approved in 2004 by FDA
for the treatment of neovascular AMD [102] .
2. Bevacizumab (Avastin®) is a humanized anti-VEGF-A monoclonal
IgG antibody developed as an anti-angiogenic agent for colon-rectal
cancer, lung cancer, glioblastoma, and renal-cell carcinoma. It was
approved for medical use in the United States in 2004 [102] .
Bevacizumab has been used intravitreally (off-label) in the treat-
ment of proliferative eye diseases.
3. Ranibizumab (Lucentis®) is a fully humanized monoclonal antibody
fragment targeted against human VEGF-A, with high affinity for all
isoforms of VEGF-A. Until the arrival of ranibizumab, the primary
endpoint in clinical trials was the proportion of subjects losing < 15
letters. Ranibizumab changed the landmark of treatment with an
unexpectable vision gains and a turnover of the clinical trials pri-
mary endpoint to the proportion of subjects gaining ≥ 15 letters.
The binding of ranibizumab to VEGF-A at the receptor-binding site
prevents the interaction of VEGF-A with its receptors VEGFR-1 and
VEGFR-2 on the surface of the endothelial cells, inhibiting the cas-
cade of events that leads to increased vascular permeability, in-
creased activity and proliferation of endothelial cells and in-
flammation. Ranibizumab granted FDA approval in June 2006
[102] .
4. Afl ibercept (Eylea®) is a fusion protein of key domains from the
human VEGFR-1 and VEGFR-2 and the human immunoglobulin G
(IgG) Fc domain that was originally developed for oncology use. It
binds to all isoforms of VEGF-A, to VEGF-B and PIGF. Afl ibercept
was approved for ocular use as Eylea®, and for metastatic colorectal
cancer as Zaltrap®[ 102] . Eylea®was approved in 2011 by the FDA.
VEGF inhibitors are promising drugs in the treatment of neovascular
eye diseases, however, should be of noted that there are some limita-
tions of its usage [103] :
1. The unknown duration of anti-neovascular effects. Anti-angiogenics
reduce regression of neovascularization after treatment and improve
structural and functional parameters, but the duration of the effect is
limited to a short period of time.
2. The mode of drug delivery, an intravitreal injection. There are
complications after intravitreal injections, such as endophthalmitis,
intraocular inflammation, rhegmatogenous retinal detachment,
acute intraocular pressure elevation and ocular hemorrhage.
3. Anti-VEGF therapy requires frequent injections and assessments to
determine patient response to a treatment. This fact leads to a sig-
nificant burden of injections and visits for all involved in the
treatment of those patients. The solution for this problem would be a
medication that improves visual and structural outcomes, simulta-
neously increasing drug effectiveness and lengthening the durability
of the treatment.
4. The frequent anti-angiogenic therapy may be associated with the
progression of geographic atrophy.
5. Another issue is the systemic safety. Several pharmacovigilance re-
ports have been generated with the administration of either sys-
temic or ocular anti-VEGFs: thromboembolic events, myocardial
infarction, stroke, hypertension, gastrointestinal perforations, and
kidney disease which lead to the inclusion of a black box in the
summary of product characteristics. Moreover, intravitreal anti-
angiogenic drugs were found at detectable levels in the systemic
circulation, capable to suppress VEGF-A systemic levels. This fact
suggests a rationale for the cardiovascular reports of serious adverse
events. Although the death rates did not seem to be increased due to
the use of angiogenic drugs, the long-term consequences are still
unknown.
Furthermore, VEGF-A, VEGF-B, and PIGF play critical roles in
neuroprotection and cardioprotection [103] . Therefore, their blockage
may also have consequences in the long run. Nevertheless, not all pa-
tients respond sufficiently to anti-VEGF intravitreal injections despite
frequent treatments. About 50% of patients have an insufficient re-
sponse to angiogenic therapy and accordingly with an analysis per-
formed by Gonzalez and colleagues, a percentage of patients would
benefit from an early therapy switch as shown in the EARLY study
[104] . Therefore, and despite not being an angiogenic therapy,
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corticosteroids treatments are invaluable and one of the oldest treat-
ments available in ophthalmology for the treatment of persistent or
recurrent diseases. Steroids have proven to be powerful and effective in
suppressing inflammation and also playing a significant role in inhibi-
tion of several cytokines inclusively antagonizing the action of VEGF-A.
The best-studied steroids are triamcinolone acetonide (off-label),
dexamethasone, and fluocinolone. Dexamethasone implant (Ozurdex®,
Allergan, Dublin, Republic of Ireland) is a bioerodable, extended-re-
lease of 700 μg of dexamethasone in a solid, bioerodable polymer [84] .
Fluocinolone acetonide (Iluvien®, Alimera Sciences, Alpharetta,
Georgia) is the smallest, non-bioerodable, slow extended-drug release
implant lasting 3 years of duration [84] . Notwithstanding the well-
known side effects caused by steroids, cataract formation and increase
of intraocular pressure, efficacy and benefi ts usually outweighed risks.
Moreover, there is an enormous advantage of corticosteroids once
systemic side effects of locally administered steroids occur rarely. Al-
though laser photocoagulation, anti-VEGFs and steroids pathways es-
tablished as successful target treatments, new therapeutical enhance-
ments are being developed, holding promises in the improvement of eye
pathologies.
4.2. Drug discovery – searching for promising molecules
Several diseases are accompanied by dysregulated angiogenesis and
by excessive formation of blood vessels, such as in cancer, RA, AMD,
RVO, and PDR or by deficiency in blood vessels, such as in heart and
limb ischemia. These diseases can be life-threatening as they cause
severe pain and reduce the quality of life. They are also considered to be
a burden to the society, not only because of costs incurred but also due
to the time-consumed by the physicians, patients, and respective fa-
milies.
It is therefore of great importance with regard to improve and de-
velop better treatments. The VEGF family and the anti-angiogenics are
fascinating molecules that had been receiving interest and research
efforts all over the world. Researchers and pharmaceutical companies
have been involved in the search for the critical need for new therapies
to be given early on in the disease to cure or delay its progression or to
prevent. However, there is sti ll a lack of therapeutically viable options
for intervention.
Regardless, a remarkable selection of compounds has been de-
scribed in recent years, targeting different molecules in the signaling
pathway, from VEGF-A, VEGF-B, PIGF, and platelet derived growth
factor (PDGF), and tyrosine kinase inhibitors (TKIs) to VEGFRs and
tyrosine kinase receptor (TKR) inhibitors (Fig. 2). These compounds
comprise not only the above described pegaptanib, bevacizumab, ra-
nibizumab, and afl ibercept, but also other new molecules such as abi-
cipar pegol, various siRNA, avancincaptad pegol, brolucizumab, multi
VEGF-PDGF DARPin, TB-403, and 5D11D4 and TKIs such as lapatinib,
sunitinib, sorafenib, axitinib, and pazopanib. Some of those drugs are
approved and are used against retinal diseases; however, others are in
the clinical or pre-clinical stage. Table 1 summarizes the anti-angio-
genic drugs currently approved and available, the molecules on pre and
post clinical trials, and possible drugs never studied in ophthalmology
that may be considered in the future as targeted molecules.
Signi ficant progress has been made in the understanding of the
molecular pathogenesis of retinal neovascular disorders and new tar-
gets have been investigated for therapeutic interventions.
5. Outcome and future perspectives
We reviewed literature regarding the involvement of VEGF growth
factors, especially VEGF-A, VEGF-B, and PlGF in normal development
and diseases with special emphasis on ocular disorders. We showed that
accurate estimation of vitreous/ aqueous and serum levels of these
factors are critical for elucidating their roles in ocular disease patho-
genesis. Studies are mainly focused on the involvement of vitreous and
serum VEGF-A levels with the prognosis of AMD, DR, and RVO, whereas
the role of VEGF-B and PlGF as biomarkers for these conditions is be-
ginning to be understood (Table 2). Table 2 shows that elevated vitr-
eous and/ or serum levels of VEGF-A were detected in patients with
different ocular disorders, and the levels increased with the severity of
the disease [108,110] . The angiogenic potential of VEGF-A aggravates
the pathology of the diseases and anti-VEGF-A therapy is often bene-
ficial for ameliorating or regressing the symptoms. However, certain
Fig. 2. The VEGF family, receptors and current anti-angiogenic drugs that target VEGF/ VEGFR signaling.
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cases are also characterized by high VEGF-B and PlGF levels in the
vitreous of the diseased eye. Our work and few other studies have re-
vealed the importance of screening patient samples for VEGF-B and
PlGF levels as future prognostic markers or targeted therapies
[88–90,100] . Reports show that PlGF often synergizes VEGF-A sig-
naling in retinal pathologies and therefore, targeting PlGF should be
critical for completely containing the symptoms [62,66] . Similarly,
VEGF-B is an emerging druggable candidate for the treatment of an-
giogenic ocular disorders [59] . Finally, caution should be exercised
while interpreting the vitreous and serum levels of these growth factors
as high vitreous levels may sometimes be due to increased vascular
permeability, which allows serum proteins to leak inside the vitreous
and result in false positive results. [ 124] . Contrary to this, some authors
describe that vitreous levels are independent of serum levels as it is not
easy to find a positive and robust correlation between them [119] .
Further, caution must be exercised during interpretation of serum levels
and growth factors as other systemic diseases may increase VEGF levels.
Therefore, robust correlation between vitreous and serum levels of
these growth factors would increase the confidence level of the ap-
proach.
Multiple challenges in the treatment of ocular diseases include: 1)
identi fication of biomarkers before diagnosis and appearance of clinical
symptoms, which would enable treatment of early stages of the dis-
eases, 2) identi fication of markers to monitor disease progression, and
3) identi fication of new targeted therapies. More clinical trials in
ophthalmology are required to test the efficacy and safety of new
therapies targeting VEGF-B and/ or PIGF, either in combination with
existing therapies or in monotherapy.
Future research should continue to focus on new anti-VEGF strate-
gies in the treatment of ocular diseases linked to abnormal vascular-
ization. Discovery of new isoforms of the VEGF family reveal an in-
creased biological complexity and has faced many obstacles that must
be overcome while exploring new targets. The blockage selectivity is
one of the most important factors to be considered when testing the
new anti-VEGF molecules.
Understanding the detailed molecular mechanisms underlying an-
giogenesis and physiology is of vital importance for the future devel-
opment of drugs, which can regulate angiogenesis. However, there are
many unanswered questions that need to be explored as well as new
and innovative molecules to be discovered before the full potential of
these strategies can be understood, which would result in better out-
comes for patients with pathological ocular angiogenesis.
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Global aims 
 
The aims of this study were to investigate the levels of VEGF-A, VEGF-B and PlGF in vitreous 
humor and serum among different ocular pathologies: neovascular pathologies (diabetic 
retinopathy, age-related macular degeneration and retinal vein occlusion) and compare with 
non-neovascular pathologies (rhegmatogenous retinal detachment or vítreo macular traction 
syndrome of idiopathic etiology) by: 
1. Comparing serum and vitreous VEGF-A, VEGF-B and PIGF levels between ocular 
diseases  
2. Comparing serum and vitreous VEGF-A, VEGF-B and PIGF levels with disease 
progression 
2. Correlating growth factors levels in vitreous or in serum; 
3. Correlating growth factors between vitreous and serum 
4. Correlating vitreous growth factors with structural (central retinal thickness and 
macular volume) and functional (visual acuity) parameters 
 
A better understanding of these cytokines and their correlation in serum and vitreous humor 
may lead us to: 
1. Better-targeted precise and specific therapies 
2. Early intervention in disease prevention before clinical symptoms appear and 
before the occurrence of ocular neovascularization 
3. Effective therapeutic interventions 
 
Ultimately, 
1. Leading to the prevention of blindness 
2. Avoiding unnecessary blindness 
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Abstract 
 
Purpose: This study aimed to evaluate serum and vitreous placental growth factor (PIGF) 
levels in diabetic retinopathy (DR) vs. non-DR patients. Correlation between serum and 
vitreous PIGF levels and between vitreous PIGF levels in DR patients and optical coherence 
tomography (OCT) parameters was also performed. 
 
Methods: Serum and vitreous samples were collected from patients undergoing vitrectomy 
(n=38): 21 DR and 17 non-DR, and PIGF analyzed by ELISA. OCT scans from DR patients were 
evaluated to measure central retinal thickness (CRT) and macular volume (MV). 
 
Results: Mean vitreous PIGF was significantly higher in DR vs. non-DR patients: 70.0 ± 39.2 vs. 
46.47 ± 9.7 pg/mL (mean ± standard deviation), p=0.004. Mean serum PIGF level was higher in 
DR vs. non-DR patients but result was not statistically significant. Comparison between 
retinopathy stages showed that proliferative DR patients had significantly higher PIGF vitreous 
levels compared to non-proliferative DR patients: 76.5 ± 41.0 vs. 42.5 ± 5.0 pg/mL, p=0.009, 
respectively. There was no correlation between vitreous and serum PlGF levels. Vitreous PIGF 
vs. OCT parameters showed a tendency for positive correlation. 
 
Conclusions: PIGF plays an important role in neovascularization and it is overexpressed in 
vitreous of DR patients; moreover PIGF levels increase with the severity of the disease. The 
absence of correlation between vitreous and serum PIGF may demonstrate dissociation 
between the eye and other organs and also suggest intravitreal synthesis of PIGF in case of 
neovascular eye disease. Therefore, targeting PIGF may offer an additional strategy for ocular 
pathologies with a neovascular component.  
 
 
 
Keywords: Diabetic retinopathy; Placental Growth Factor; Vascular endothelial growth 
factor; Vitreous humor, Serum PIGF
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1. Introduction:  
The incidence of diabetes mellitus is increasing every year. A common complication linked 
with the onset of diabetes is diabetic retinopathy (DR), which is a microvascular complication 
and a major cause of blindness in the working-age population [1]. DR can be characterized 
clinically as non-proliferative DR (NPDR) or proliferative DR (PDR). NPDR presents 
microaneurysms, retinal hemorrhages, hard exudates, cotton wool spots, venous beading and 
intra-retinal microvascular abnormalities (IRMA), whereas the presence of retinal 
neovascularization due to retinal ischemia, hypoxia and vascular endothelial growth factor A 
(VEGF-A) stimulation is the hallmark of PDR. The new blood vessels proliferate, leak and 
bleed, and can lead to vitreous hemorrhage, tractional detachment or neovascular glaucoma, 
which may result in in irreversible visual loss [2]. 
VEGF-A is the most studied and influential molecule in the DR process. However, there are 
other growth factors, such as the placental growth factor (PIGF), besides VEGF-A that seem to 
be implied in this process [3,4,5].  
PIGF was discovered after VEGF-A, and it was considered the second member of the VEGF 
family [6]. It’s alternative splicing generates four isoforms (PIGF-1, PIGF-2, PIGF-3 and PIGF-
4). PlGF binds to vascular endothelial growth factor receptor 1 (VEGFR-1), soluble fms-like 
tyrosine kinase-1 (sFLT1) and neuropilins (NRP) -1 and -2 [7,8]. 
PlGF binds specifically to VEGFR-1; however, it may activate VEGFR-2 through other 
mechanisms; for example, PlGF may bind VEGFR-1 dislocating VEGF-A from VEGFR-1 and 
freeing VEGF-A and making it available to bind to VEGFR-2 [9]. Or else, PlGF and VEGF-A may 
produce heterodimers capable to bind and activate VEGFR-1 [10]. 
PIGF seems to have a significant role in pathologies involving ischemia, malignancy, 
inflammation, and increase in vascularization. In fact, the role of PIGF has been observed in 
pathological states rather than in physiological states [11]. Several studies showed that PlGF 
is a superfluous molecule during normal vascular development and maintenance but has an 
important role in the angiogenic and inflammatory switch of some diseases [10]. 
Pharmacological studies focused on loss-of-function and gain-of-function that led to the 
characterization and identification of therapeutic needs in delivering and blocking PIGF [8]. 
Some pathological conditions may improve due to delivering of PIGF: (a) in the cardiovascular 
system: to preserve cardiac performance after an infarction, PlGF induces revascularization 
of ischemic myocardium and vessel enlargement, playing a significant role in myocardial 
angiogenesis, regulation of vascular growth in pathological states and a selective action in 
modulating pathological rather than physiological vascular development; (b) in the nervous 
system: during cerebral ischemia, PIGF is upregulated in neurons and vascular cells having 
neuroprotective properties; and (c) in the skin: PIGF is overexpressed during wound healing. 
The increased PIGF levels lead to an increase in angiogenesis, thus, improving wound healing 
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and ultimately skin regeneration. Also during bone fracture repair, colitis, sepsis and 
preeclampsia, where healing angiogenesis is present, PIGF therapy delivery may help to 
restore normal functions [8]. While some pathological conditions improve with upregulation of 
the PIGF, others, such as ocular neovascularization, become worse [12]. In fact, PIGF 
deficiency or PlGF receptor neutralization leads to a decrease in choroidal neovascularization 
in animal models [13]. Moreover, the intraocular delivery of PIGF promotes progression of DR. 
The pharmacological inhibition of PIGF as suggested by Van de Veire et al., (2010) inhibits 
neovascularization by inhibiting angiogenesis and vascular leakage and improving ocular 
inflammation [14]. 
The role of PIGF has been documented controversially, but after studies, it is now possible to 
confirm its role not only in angiogenesis but also in modulating inflammation [5,10]. 
Huo et al. (2015) suggested that the effect of PIGF on choroidal neovascularization is case-
dependent, through a mechanism of co-inhibition of PIGF that reinforces the effect of anti-
VEGF-A inhibition [15]. 
There has been a great improvement in the treatment of ocular diabetic disease and 
consequent outcomes due to the use of anti-VEGF therapies and use of corticosteroids (not 
subject of discussion here). However, disease recurrence is common within these patients. 
The long-term consequences of anti-VEGF therapy, despite seeming safe, are still not 
completely known. Given the increasing incidence of diabetes mellitus and consequent DR, 
and taking into account the enormous disease burden associated with DR treatments, focusing 
on other contributory molecules as well as developing new targeted therapies is critical to 
fight vision loss. 
In our study, we evaluated serum and vitreous PIGF levels by enzyme-linked immunosorbent 
assay (ELISA) in diabetic patients (with DR) and compared them with a control group of non-
diabetic patients (with rhegmatogenous retinal detachment). The study aimed at finding 
correlations between this parameter and the severity of the disease. We also correlated PIGF 
levels between vitreous and serum and PIGF vitreous levels with structural measurements 
(central retinal thickness and macular volume) performed by optical coherence tomography 
(OCT). A better understanding of the expression and behavior of this molecule in eye diseases 
and its correlation with functional and structural outcomes will contribute to the 
development of better-targeted therapies. 
 
2. Materials and Methods 
 
2.1 Participants: 
Undiluted samples of vitreous humor and serum were collected from patients who were 
submitted to pars plana vitrectomy (PPV) due to different ocular pathologies. 
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Samples from patients were selected for analysis and included for PIGF quantification based 
on the following criteria: 
1. Sufficient sample volume collected to allow the confirmation of the results through 
repeated ELISA tests; 
2. Patients with a confirmed diagnosis of DR; 
3. Patients last treated (anti-VEGF, corticosteroid or laser) for their eye condition more than 
3 months from PPV surgery and; 
4. Naïve patients to aflibercept, either systemically or intravitreally. 
Hemolyzed samples were also excluded from analysis. 
At the end of the selection, a total of 38 patients were included: 21 with DR (12 female and 9 
male patients), and 17 with rhegmatogenous retinal detachment (5 female and 12 male 
patients). Rhegmatogenous retinal detachment patients with retinal tears secondary to 
posterior vitreous detachment or trauma and with no reports of other eye disease or disorders 
that may confound the results were selected to serve as a control sample, minimizing the bias 
caused in the interpretation of the results. For the correlation of vitreous PIGF levels with 
central retinal thickness (CRT) and macular volume (MV), only patients with DR and 
completed data were included in this analysis. Only one eye from each patient was studied. 
 
2.2 Collection of samples and data from patients 
The collection of undiluted vitreous humor samples, as well as the serum samples, was 
performed in a public hospital to patients submitted to PPV.  
Serum samples were collected in an appropriate serum sterile tube just before the surgery 
and prepared to be frozen at -80°C for further analysis. Vitreous humor was collected at the 
beginning of the PPV (core vitrectomy). Tubes from the vitrectomy were disconnected and 
connected to a syringe (in coordination with vitrectomy aspiration at the beginning of the 
surgery). Before turning on the intravitreal infusion, an undiluted sample of vitreous was 
obtained by aspiration into a 2 mL syringe attached to the vitreous cutter. The sample was 
transferred to sterilized tubes and placed immediately on ice and frozen at -80°C until it was 
required for analysis. All collection procedures, either serum or vitreous humor, were 
performed in a room attached to the surgery room to minimize sample damage. 
Additionally, patients’ clinical history was investigated to re-confirm patient diagnosis, 
baseline characteristics and associated concomitant diseases. Patients under concomitant 
medications that could influence the results, such as drugs that bind to PIGF (for example: 
aflibercept) were removed from the study. All information about additional drugs to treat 
patients’ eye condition even performed 3 months from vitrectomy and although not 
interfering with the analysis were collected and are available in table 1. 
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2.3 Measurement of vitreous and serum placental growth factor levels 
Quantification of vitreous and serum PIGF levels was performed by ELISA kit for human 
samples (ABIN1379954, Assay Biotechnology, San Francisco, California, United States of 
America), according to the protocol specified by the manufacturer. Detection range was 
between 32-2000 pg/mL, and the sensitivity or the minimum detectable level was less than 
32 pg/mL.  
 
2.4 Quantitative analysis of optical coherence tomography 
OCTs were evaluated to measure CRT (μm) and MV (mm3) from DR patients through the 
interpretation of the macular map. The same Spectralis OCT (Heidelberg Engineering, 
Heidelberg, Germany) was used for the duration of the study. 
 
2.5 Statistical analysis 
Statistical analysis was performed with SPSS (Statistical Package for the Social Sciences) 
version 22.0 for Windows (Armonk, New York, United States of America). The Mann-Whitney 
test was used because variables did not have a normal distribution (analyzed with the 
Shapiro-Wilk test). For ease of interpretation, the values of the means and not the values of 
the mean orders were presented in the descriptive statistics. A level of significance (α) ≤ 0.05 
was set to accept or reject the null hypothesis. Spearman's ordinal correlation coefficient was 
used to analyze the relationship between the quantitative variables. 
 
2.6 Ethical Statement 
The study was approved by the Institutional Review Board, Ethics Committee for Health of 
Centro Hospitalar de Leiria (reference - CHL-15481). All patients included in this study, which 
adhered to the tenets of the Declaration of Helsinki, gave their informed consent. 
 
3. Results 
 
3.1 Study population 
This analysis included serum and vitreous samples from 38 patients. Concerning the baseline 
characteristics, the mean age between diabetic (n=21) and control group (n=17) was 
60.0025.35 and 68.659.69 years, respectively. From the total of 21 DR patients, 17 (80.9%) 
had PDR and the remaining 4 diabetic patients (19.1%) had NPDR. A summary of the 
demographic and clinical characteristics of the study population, as well as the concomitant 
medications and non-drug therapies performed by patients 3 months before vitrectomy are 
presented in Table 1.  
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Table 1 - Baseline demographic and clinical characteristics of subjects. Previous treatments. 
 DR patients Non-DR patients 
Sample size (%) 21 (55.3%) 17 (44.7%) 
Mean ageSD 60.0025.35 68.659.69 
Other Characteristics of DR patients 
PDR patients % (n) 80.9 % (17) Not applicable 
NPDR patients % (n) 19.1% (4) Not applicable 
Previous treatments for diabetic 
ocular disease performed more than 
3 months from PPV and therefore 
from collection of samples date 
Laser % (n) 
Ranibizumab % (n) 
Triamcinolone acetonide % (n) 
 
 
 
100 % (21) 
14.3% (3) 
14.3% (3) 
 
 
 
Not applicable 
Not applicable 
Not applicable 
 
NPDR-non-proliferative diabetic retinopathy; PDR-proliferative diabetic retinopathy; PPV-Pars 
Plana Vitrectomy, SD-standard deviation 
 
 
3.2 Comparison of vitreous and serum placental growth factor levels between diabetic 
retinopathy and control group  
Vitreous samples of DR patients had significantly higher concentration values of PIGF in 
comparison with non-diabetic patients: 70.0 ± 39.2 pg/mL vs. 46.47 ± 9.7 pg/mL, respectively 
(Z = -2.847, p=0.004), as seen in Figure 1. 
Concerning the serum samples, DR patients had higher PIGF concentration levels than non-
diabetic patients: 50.5 ± 2.18 pg/mL vs. 48.8 ± 6.0 pg/mL, (Z = -1.196, p=0.232), although 
this difference was not statistically significant, as seen i n Figure 1. 
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Figure 1 – Comparison of placental growth factor (PIGF) levels in vitreous and serum between 
diabetic retinopathy (DR) patients (n=21) and a control group of non-diabetic patients, 
(n=17), (p=0.004 and p=0.232, respectively), analyzed with Mann-Whitney test. DR: diabetic 
retinopathy; Non-DR: Non-diabetic retinopathy; PIGF: placental growth factor 
 
 
3.3 Comparison of vitreous and serum placental growth factor levels between patients 
with proliferative diabetic retinopathy and non-proliferative diabetic retinopathy 
PDR presented a significantly higher concentration value of PIGF when compared to patients 
with NPDR in vitreous samples: 76.5 ± 41.0 pg/mL vs. 42.5 ± 5.0 pg/mL, respectively (Z = -
2.612, p=0.009), as seen in Figure 2. 
Regarding serum samples, PDR patients showed PIGF concentration levels lower than NPDR 
patients: 50.0 ± 0.0 pg/mL vs. 52.5 ± 5.0 pg/mL, respectively (Z = -2.062, p=0.039); this 
difference was considered as statistically significant (Figure 2). 
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Figure 2 – Comparison of placental growth factor (PIGF) levels in vitreous and serum samples 
between proliferative diabetic retinopathy (PDR) patients (n=17) and non-proliferative 
diabetic retinopathy (NPDR) patients (n=4), (p=0.009 and p=0.039, respectively), analyzed 
with Mann-Whitney test. 
 
 
3.4 Correlation coefficient between vitreous and serum placental growth factor samples 
The correlation coefficient between vitreous and serum PIGF levels (n=38) was not 
statistically significant (p=0.645), and the result obtained was near zero (rsp = 0.077). 
Moreover, the correlation coefficient of PIGF levels between vitreous and serum samples in 
the DR patients group (n=21) and non-diabetic patient group (n=17) was not statistically 
significant (p=0.614; rsp = -0.117 and p=0.354; rsp = 0.240, respectively). 
 
3.5 Correlation between vitreous placental growth factor levels in diabetic retinopathy 
patients and quantitative measurements by optical coherence tomography 
The correlation coefficient between vitreous PIGF levels from DR patients and CRT (μm) was 
weak (rsp = 0.175, p= 0.488). Concerning the MV (mm
3), the correlation was also weak (rsp = 
0.288, p=0.262), however, a tendency of a positive correlation was observed between PIGF 
and MV (Figure 3). 
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Figure 3 – Correlation between placental growth factor (PIGF) vitreous levels and macular 
volume (MV) (mm3), in diabetic retinopathy (DR) (n=21) patients, analyzed with Spearman’s 
correlation coefficient. 
 
 
4. Discussion 
DR is the most frequent complication of diabetes and the leading cause of blindness in the 
working-age population in developed countries worldwide. Most of the patients diagnosed 
with diabetes show clinical signs of retinopathy, approximately 15 years after the onset of 
diabetes, and more than 10% develop visual impairment [16]. 
PIGF is a growth factor important for vasculogenesis but indispensable for angiogenesis during 
ischemia, inflammation, wound healing, cancer and certain ocular diseases involving 
neovascularization. It appears to be inert in health; however, in pathological conditions, it 
has an active function. Oura et al. (2003) reported a critical role for PIGF in the induction of 
cutaneous inflammation and vascular permeability, and consequently, edema formation [17]. 
However, the vascular permeability reported by this molecule showed that PIGF was less 
potent than VEGF-A alone or VEGF-A/PIGF heterodimers. Nevertheless, it was suggested that 
for this cutaneous condition, inhibition of PIGF could be considered as a potential therapeutic 
approach acting as an anti-inflammatory drug. It must be emphasized that the under or 
overexpression of PlGF did not affect normal vascular development or function, suggesting 
that the conception of an anti-PIGF therapy would be safer than other anti-angiogenic 
molecules. However, concerning the role of PIGF in pathological neovascularization in cancer, 
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Sheibani (2013) noted that inhibition activity of PIGF may be tumor specific and not all anti-
PIGF have antagonist activity due to an unknown and still to be discovered reason; if this fact 
is extrapolated to ocular disease, it may suggest that not all anti-PIGF may have an effective 
action [12]. 
In our study, we observed a significant increase in vitreous PIGF concentration values in DR 
patients when compared to a control group of non-diabetic patients. This fact confirms the 
studies of Khaliq et al. (1998) that found high levels of PIGF in diabetic vitreous samples, 
suggesting a role in the pathogenesis of PDR [18]. 
Additionally, the comparison of vitreous PIGF levels among DR patients, specifically between 
patients with PDR and NPDR, showed higher levels of PIGF in the vitreous humor of the 
former. Confirming our finding, Mitamura et al. (2002) also referred to significantly higher 
intravitreous levels of PlGF in active PDR than in quiescent PDR, suggesting involvement of 
this molecule in the developing stages of PDR [19]. Thus, it might be suggested that PIGF 
values are high in patients with DR and these values tend to increase with the severity of the 
disease, so an efficient PIGF antagonist would be desirable in all disease stages but 
indispensible for late stages. 
In serum samples, there was no difference between DR and non-diabetic patients, however an 
interesting finding was the higher serum concentration of PIGF in NPDR patients than in PDR 
patients. There are several hypotheses why this may happen: 1. Concurrent systemic diseases 
not diagnosed or reported by the patients; 2. Different diabetic therapies may interfere with 
the obtained serum PIGF values; 3. Systemic levels may not be related to the production of 
vitreous cytokines by the retina [20]. 
Another interesting revelation was the lack of correlation between vitreous and serum 
samples of PIGF, which may indicate dissociation between the eye and other systems. This 
finding in PIGF was similar to the ones regarding the lack of serum vs. vitreous correlation 
between VEGF-A and VEGF-B, suggesting that the administration of a drug intravitreally may 
have minimally effects systemically [5,21]. Moreover this dissociation maybe the result of an 
intravitreal synthesis of PIGF. 
PlGF plays an important role in neovascularization; it is found to be increased in the vitreous 
of DR patients. In addition, its levels were higher in more advanced disease states. Therefore, 
targeting PIGF should offer an additional treatment strategy for ocular pathologies with a 
neovascular component.  
Treatment with anti-angiogenic agents for the ocular pathologies arose a few years ago, 
initially with pegaptanib, then bevacizumab (off-label) followed by ranibizumab and 
aflibercept intravitreal injections. These anti-angiogenic therapies rapidly became the gold 
standard for the treatment of neovascular eye diseases. The efficacy of the new drugs 
inhibiting VEGF, and consequently angiogenesis, is not in debate. However, in order to 
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improve the outcomes in treating those pathologies, avoid resistance and minimize toxicity, 
particularly due to the lack of available of long-term safety data of VEGF inhibition and 
possible side effects that may occur, additional therapeutic agents should be investigated. In 
light of this, the inhibition of PlGF is a possible intervention once PIGF regulates angiogenesis 
and vascular permeability in pathological conditions, and deletion of PlGF leads to the 
suppression of diabetic complications [22]. Also, according to Mitamura et al. (2002), PIGF 
acts indirectly by potentiating the activity of VEGF in pathological angiogenesis, suggesting 
the cooperative role of these two molecules in the progression of DR [19]. 
Additionally, not all anti-PlGF antibodies are functional and demonstrate antagonistic activity 
[8]. Several anti-PIGF have been tested for cancer treatment. Van de Veire and colleagues 
(2010) demonstrated in an animal experiment that the monoclonal antibody 5D11D4, which 
specifically targets PIGF, inhibits choroidal neovascularization, ocular angiogenesis, and 
inflammation by blocking PlGF [14]. Another advantage is that 5D11D4 do not have to be 
injected directly into the eye, as in the case of other VEGF inhibitors, which are too toxic for 
systemic administration. Therefore, this avoids the increased risk of adverse events that may 
occur due to the need of frequent intravitreal administrations.  
TB-403 or THR 317 is another monoclonal antibody that binds to PlGF and blocks the binding 
to VEGFR-1. The results of the phase I clinical trials showed that TB403 was well tolerated 
without increased risk of adverse effects in healthy volunteers and terminal cancer patients 
[14,23]. The phase II study in pediatric subjects with relapsed or refractory medulloblastoma 
is currently recruiting, and the results are expected by December 2017 at the time of primary 
end point completion (clinicaltrials.gov) [5,24]. This anti-PlGF monoclonal antibody is in 
Phase II for diabetic macular edema and it is at preclinical stage for diabetic retinopathy 
(http://adisinsight.springer.com/drugs/800019736) [5,25], thus new efficacy and safety 
outcomes are expected. 
Clinical trials are needed to assess and confirm the efficacy and safety of monoclonal 
antibodies against PIGF in the treatment of ocular pathologies.  
In contrast to the essential role of VEGF-A in physiological and pathological angiogenesis, the 
role of PlGF is restricted to pathological conditions being considered for this reason a specific 
target for therapy. Of all evidence presented here, PlGF may represent a preferred target for 
the inhibition of angiogenesis with respect to VEGF-A. The safety profile of anti-PlGF needs 
preclinical studies and human clinical trials to confirm the possibility of systemic delivery of 
anti-PlGF monoclonal antibodies and also its effectiveness and safety, in combination with an 
anti-VEGF therapy or as a partial replacement of anti-VEGF.  
A better and deep understanding of all mechanisms, interactions and specific functions 
between the members of the VEGF family and its receptors, in both normal states and 
diseases is needed. Also, new experimental and clinical trials targeting therapies against PIGF 
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will allow development of more specific, precise, safe and effective therapies, resulting in 
better outcomes for patients suffering from diseases with pathological angiogenesis. 
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Abstract 
 
VEGF-A and VEGF-B are proangiogenic factors and key regulators of blood vessel growth. This 
study aimed to evaluate serum and vitreous VEGF-A and VEGF-B levels in patients with 
neovascular pathology vs. a control group with non-neovascular pathology. Our findings 
showed that vitreous VEGF-A and VEGF-B are consistently overexpressed in patients with 
neovascular disease, with higher levels of expression of VEGF-A compared to VEGF-B 
(p≤0.05).  In the neovascular group, higher vitreous VEGF-A or VEGF-B levels were found in 
proliferative diabetic retinopathy (PDR) than in non-PDR. An important finding was the strong 
correlation found between VEGF-A vs. VEGF-B that suggests a simultaneous pathological 
increase in those cytokines (p<0.001). There was no correlation between vitreous vs. serum 
VEGF-A or VEGF-B. However there was a correlation between vitreous (VEGF-A or VEGF-B) vs. 
macular volume (p<0.05) in DR patients. Targeting VEGF-A and VEGF-B in macular and retinal 
vascular diseases, involving neovascularization, may improve treatment outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: ELISA, neovascular, retinal diseases, VEGF-A, VEGF-B, vitreous humor 
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Introduction 
Angiogenesis is one of the mechanisms responsible for neovascularization, in which new blood 
vessels sprout from the pre-existing (Roy, Bhardwaj & Ylä-Herttuala 2006). Neovascularization 
is a crucial process for embryonic development and several pathological states. While 
angiogenesis is a normal and an essential physiological process, it is also a pathological 
process involved in tumor growth, rheumatoid arthritis, psoriasis and neovascular ocular 
diseases such as age-related macular degeneration (AMD), retinal vein occlusion (RVO) and 
diabetic retinopathy (DR) (Ferrara, Gerber & LeCouter 2003). The resulting proliferation often 
ends in visual loss (Mesquita et al., 2017a). 
The vascular endothelial growth factor (VEGF) family consists of seven members: VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor (PlGF) (Li et al., 
2009). Alternative splicing results in several VEGF variants (Penn et al., 2008). 
VEGF-A is implicated in the angiogenesis of pathological eye conditions and is, thus, a highly 
significant therapeutic target (Witmer, 2003). Carmeliet et al. (1996) and Ferrara et al (1996) 
showed the essential role of VEGF-A in embryonic vasculogenesis and angiogenesis. VEGF-A 
induces an angiogenic response. It also plays a significant role in inflammation due to its 
capacity to increase vascular permeability and induce vascular leakage (Amadio, Govoni & 
Pascale, 2016). VEGF-A exists in four different isoforms formed due to alternative exon 
splicing: VEGF121, VEGF165, VEGF189, and VEGF206; VEGF165 is the most predominant isoform 
(Houck et al., 1991). VEGF-A binds to two receptor tyrosine kinases, i.e., VEGF receptor 1 
(VEGFR-1) and VEGF receptor 2 (VEGFR-2), and also binds to neuropilin-1 (NRP-1) and 
neuropilin-2 (NRP-2). VEGFR-1 and VEGFR-2 regulate physiological and pathological 
angiogenesis and are responsible for signaling angiogenesis (Shibuya, 2006). Binding to VEGFR-
1 promotes tumor growth, metastasis, and inflammation (Shibuya, 2006).  
Contrarily, VEGF-B, a closely related molecule to VEGF-A, is one of the least studied members 
and the most controversial protein of the VEGF family (Li et al., 2009). The biological 
function of VEGF-B is enigmatic. Li and co-workers (2012) referred to VEGF-B as a 
multifunctional safeguarding molecule having a functional ambiguity role. VEGF-B plays a 
specific role in angiogenesis during the repair process after brain injury and myocardium 
revascularization after myocardial infarct (Li et al., 2008; Nag et al., 2002). In vivo, VEGF-B 
targeting inhibited choroidal and retinal neovascularization (Zhang et al., 2009). The 
‘angiogenic’ activity of VEGF-B during ocular neovascularization is due to its vascular survival 
effect rather than a genuine angiogenic effect, mediated by both NPR-1 and VEGFR-1, which 
safeguards the neovessels from apoptosis (Zhang et al., 2009). Therefore, direct VEGF-B 
inhibition may be a potential therapy for the treatment of ocular neovascular diseases (Zhang 
et al., 2009). Alternative splicing of exon 6 resulted in two isoforms of VEGF-B: VEGF-B167 and 
VEGF-B186. VEGF-B binds with high affinity to VEGFR-1 but not to VEGFR-2 or VEGF receptor 3 
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(VEGFR-3), competing with VEGF-A for VEGFR-1 binding (Olofsson et al., 1998). This selective 
binding is due to electrostatic surface potentials (Iyer, Darley & Acharya, 2010). 
Moreover, VEGF-A may also generate heterodimers with VEGF-B, affecting the formation of 
VEGF-A homodímers and bioavailability of VEGF-A to bind to its receptors and exert its 
activity (Olofsson et al., 1996).  
Evidence shows that patients with retinal diseases, such as DR, AMD, and RVO, have increased 
levels of vitreous VEGF-A (Aiello et al., 1994). Our research group has shown increased 
vitreous levels of VEGF-B in DR and its association with disease severity (Mesquita et al., 
2017b). 
The main role of VEGF-A and VEGF-B in both normal and pathological angiogenesis, including 
the diverse isoforms and receptors, is beginning to be clarified. With the growing interest in 
the use of anti-angiogenics in the treatment of different diseases related to anomalous 
angiogenesis, inflammation, and vessel hyperpermeability, more consideration must be paid 
to understand the accurate roles of the molecules of the VEGF family in vascular pathologies 
(Li et al., 2009). 
In the present study, we investigated two cytokines (VEGF-A and VEGF-B) in vitreous and 
serum associated to neovascular eye pathologies: DR, AMD and RVO. Quantitative results of 
VEGF-A and –B and baseline clinical characteristics were then compared between 2 groups of 
patients (neovascular vs. non-neovascular). For further exploration, the serum and vitreous 
concentration levels of VEGF-A or VEGF-B were correlated between each other and between 
neovascular vs. non-neovascular groups with respect to neovascular pathologies, stage of 
diabetic retinopathy for diabetic patients, previous treatments and changes assessed by 
optical coherence tomography (OCT) and visual acuity (VA) measurements. A better 
knowledge of these cytokines and their correlation can lead us to better-targeted precise and 
specific therapies. This may also lead to early intervention in disease prevention through 
detention of ocular neovascularization before the appearance of clinical symptoms, 
subsequently leading to the prevention of blindness.  
 
Materials and Methods 
Participants 
This retrospective study involved 20 patients divided in two groups: (1) A neovascular group 
(n=17) comprising RVO (n=2), AMD (n=2) and DR (n=13) patients and (2) A non-neovascular 
group (or control group), which included patients with vitreomacular traction (VMT) syndrome 
(n=3) of idiopathic etiology but without any other ocular disorder (including neovascular 
disease). 
The neovascular ocular disease was defined for this study as a retinal disease associated with 
abnormal blood vessel growth, which may lead to blindness however, may differ in the local 
of neovascularization. 
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The DR group was classified into patients with proliferative diabetic retinopathy (PDR) (n=8) 
and non-proliferative diabetic retinopathy (NPDR) (n=5). 
For the DR group, the diabetes mellitus duration was defined as the duration from the first 
diagnosis of diabetes mellitus to the time of vitrectomy and sampling collection. None of the 
patient samples selected to be studied performed either pharmacological (intravitreal 
injections) or laser treatments within the 3 months of vitrectomy. Moreover, diabetic therapy 
remained unchanged for at least 3 months before vitrectomy. 
A treatment naïve patient was defined as a patient that has never been treated before with 
any drug or non-drug therapy to treat their ocular disease, including laser photocoagulation, 
bevacizumab, ranibizumab, aflibercept or triamcinolone.  
Only one eye of each patient was studied. 
 
Collection of samples and storage 
Whole blood samples were collected from patients before the surgery. After allowing the 
blood to clot at room temperature for 30 minutes, the clot was removed by centrifugation at 
3,000 rpm for 10 minutes. After serum withdrawal, it was immediately frozen at -80 °C. Each 
patient underwent Pars Plana Vitrectomy (PPV) for treatment of the current disease. The 
undiluted vitreous samples were collected at the beginning of the PPV in sterilized tubes, 
placed immediately on ice and frozen at -80 °C until it was required for analysis. 
The inclusion criteria for the selection of samples were as follows: 
Patients with a confirmed diagnosis of neovascular ocular disease (for the neovascular group); 
For the control group, nondiabetic patients with no PDR and no signs of neovascularization, 
retinal vascular occlusion or other ocular disorder, except VMT syndrome, were included; 
4. For the diabetic population, all samples selected included patients with diabetic 
treatments stable or unchanged for at least 3 months before the vitrectomy procedure; 
Patients with a sample volume that would allow the confirmation of the results through 
repeated enzyme-linked immunosorbent assay (ELISA) for the determination of VEGF-A and 
VEGF-B levels simultaneously in the same patient sample, both in vitreous and in serum. 
Patient samples were excluded from the analysis if: 
The patients performed any intravitreal treatment (with anti-VEGFs and/or corticosteroids) or 
laser therapy less than 3 months of vitrectomy. 
Collection of retrospective data from patients 
Clinical history of the patients was collected to confirm the diagnosis and concurrent diseases 
as well as baseline and clinical characteristics. Despite the exclusion of patients from the 
study, information on previous concomitant treatments administered for their eye condition 
was collected. 
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Measurement of vitreous and serum VEGF-A and VEGF-B levels 
ELISA was performed to measure the vitreous and serum levels of VEGF-B (VEGF-B ELISA Kit; 
Ref, E-EL-H2164; Elabscience; Wuhan, Hubei, China) and VEGF-A (VEGF-A ELISA Kit; Ref, E-EL-
H0111; Elabscience; Wuhan, Hubei, China). Both analyses were conducted in accordance with 
the manufacturer instructions. 
 
Measurement of structural parameters  
OCT examinations were performed before PPV using the Heidelberg equipment (Heidelberg 
Engineering, Heidelberg, Germany). Thickness mapping of retinal layers was used to measure 
central retinal thickness (CRT) and macular volume (MV) associated with retinal pathologies. 
 
Measurement of functional parameters 
Best Corrected Visual Acuity (BCVA) was measured with early treatment diabetic retinopathy 
study (ETDRS) charts (Precision Vision, La Salle, Illinois, United States of America) at 4-
meters. 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS version 24.0 (IBM Corp., Armonk, New York, 
United States of America) for Windows. A level of significance (α) ≤ 0.05 was set to reject the 
null hypothesis. Pearson test was used to correlate quantitative variables with a normal 
distribution while Spearman's correlation coefficient test was used to correlate quantitative 
variables without normal distribution. The Mann-Whitney was used to compare two groups in 
quantitative dependent variables, without normal distribution. 
 
Ethical Statement 
The study was approved by the Institution Review Board, named Ethics Committee for Health 
of Centro Hospitalar de Leiria (CHL-15481) and Portuguese National Data Protection 
Commission. All patients included in this study, which adhered to the tenets of the 
Declaration of Helsinki, gave their informed consent after appropriate explanation. 
 
Results 
Study Population – baseline characteristics 
In this retrospective study, samples from 20 patients (5 women and 15 men) with a mean age 
of 70.3 years were selected to be analyzed based on specific inclusion and exclusion criteria. 
Two of the patients with RVO submitted to PPV surgery had active neovascularization. From 
the 2 AMD patients included, one had active neovascularization and the other had reminiscent 
neovascularization at the time of surgery, confirmed by fluorescein angiography. The patient 
presented with reminiscent neovascularization was previously treated (despite more than 3 
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months before surgery) with 8 bevacizumab intravitreal injections (before approval of the 
license drug ranibizumab), 4 ranibizumab injections (after approval of ranibizumab by health 
authorities) and 5 aflibercept injections. 
Moreover from the 13 diabetic patients analyzed: 8 had PDR and 5 had NPDR. 
The majority of the diabetic patients had DM type 2, with exception of 1 patient who had DM 
type 1. This patient (with DM type 1) had PDR and was under insulin treatment to control 
diabetes. The other 12 patients with DM type 2 were under insulin therapy (n=2); oral therapy 
(n=8) or both insulin and oral therapy (n=2). 
Concerning the previous treatments performed by the patients (3 months before the PPV), in 
the neovascular group, 8 patients were naïve to treatment: 1 RVO, 1 AMD and 6 DR (2 
patients had PDR and 4 had NPDR), and 9 patients were non-naïve to treatments. The non-
naïve patients include 1 RVO, 1 AMD and 7 DR patients (6 patients with PDR and 1 with NPDR). 
The control group did not have any ocular neovascular pathology besides VMT syndrome. 
Characterization of the baseline demographic and clinical characteristics are summarized in 
Table 1. 
 
Table 1 - Patient baseline clinical and demographic characteristics 
 
Total 
(n=20) 
 
RVO  
(n=2) 
AMD  
(n=2) 
DR  
(n=13) 
Control 
group 
(n=3) 
Demography 
     Age (yrs) (Mean, SD) 70.3 ± 10.7  78.0 ± 5.6 77.0 ± 7.0 68 ± 11.9 71.0 ± 6.2 
Other variables 
BCVA (ETDRS letters) at 
baseline (Mean, SD) 
-  65.0 ±1.5 48.0 ± 3.5 62.1 ± 19.2 57.5 ± 3.5 
CRT at baseline (Mean, SD) -  328.5 ± 30.4 480.5 ± 140.7 413.8 ± 65.7 - 
MV at baseline (Mean, SD) -  8.07 ± 0.06 11.79 ± 3.08 9.59 ± 1.67 - 
Diabetes Mellitus Type (n; %) in DR patients group 
            DM 1 (n, %) -  - - 1, 8.3% - 
            DM 2 (n, %) -  - - 12, 91.7 % - 
Diabetes treatment (n; %) stable for at least 3 months before vitrectomy procedure 
Insulin therapy -  - - 3 27.3 - 
Oral therapy  -  - - 8 54.5 - 
Insulin and oral therapy -  - - 2 18.2 - 
Other DR characteristics 
Duration of DR (yrs) (Mean, 
SD) 
- 
 
- - 1.6 ± 1.5 - 
PDR (n; %) -  - - 8, 38.5 - 
NPDR (n; %) -  - - 5, 61.5 - 
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After characterization, this pool of patients was re-grouped into the neovascular group and 
non-neovascular group as defined previously. 
 
Comparison of vitreous and serum VEGF-A and VEGF-B levels between patients with 
neovascular disease vs. non-neovascular disease 
A statistically significant difference was observed between vitreous VEGF–A in the neovascular 
group (343.30 ±543.82pg/mL), (mean ± standard deviation) vs. vitreous VEGF-A in the non-
neovascular group (7.04 ± 1.35 pg/mL), (Z=-1.958, p=0.050). Likewise, the mean difference of 
vitreous VEGF–B concentration was significantly higher in the neovascular group (208.83 ± 
353.58 pg/mL) vs. control group of non-neovascular disease (1.94 ± 0.61 pg/mL) (Z=-2.170, 
p=0.030) (Figure 1). 
Regarding the analysis of the serum, there were differences between the two groups 
(neovascular and non-neovascular), although these differences were not statistically 
significant (Figure 1). 
 
Previous treatments for ocular condition (performed more than 3 months before vitrectomy) 
Laser photocoagulation (n) -  1 0 7 - 
Bevacizumab (n) -  0 1 0 - 
Ranibizumab (n) -  0 1 3 - 
Aflibercept (n) -  0 1 0 - 
Triamcinolone (n) -  0 0 2 - 
VEGF-A - vascular endothelial growth factor A; VEGF-B - vascular endothelial growth factor B; 
BCVA – best corrected visual acuity; CRT – central retinal thickness; MV – macular volume; RVO – 
retinal vein occlusion; AMD – age macular degeneration; DR – diabetic retinopathy; PDR – 
proliferative diabetic retinopathy; NPDR – non-proliferative diabetic retinopathy; DM1 – diabetes 
mellitus type 1; DM2 – diabetes mellitus type 2; Control group – patients with vitreomacular 
traction syndrome of idiopathic etiology and without other ocular disorders; yrs – years; SD – 
standard deviation 
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Figure 1 - Mean serum and vitreous VEGF-A and VEGF-B concentrations between the neovascular (n=17) 
and non-neovascular (n=3) study arm, analyzed with Mann–Whitney test (p<0.05). 
 
Comparison of VEGF-A and VEGF-B levels in vitreous and serum of studied pathologies 
The comparison between vitreous VEGF-A and vitreous VEGF-B levels showed increased levels 
in both DR and RVO patients. AMD patients revealed lower vitreous levels of both cytokines 
(VEGF-A and VEGF-B), suggesting that this result is due to one patient that has reminiscent 
neovascularization (Figure 2). 
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Figure 2 - Mean vitreous and serum levels of VEGF-A and VEGF-B among different studied pathologies vs. 
control group of patients, analyzed with Mann-Whitney test (p>0.05). VEGF-A – vascular endothelial 
growth factor; VEGF-B – vascular endothelial growth factor B; RVO – retinal vein occlusion (n=2); DR –
diabetic retinopathy (n=13); AMD – age macular degeneration (n=2). The control group included patients 
with VMT syndrome with no other ocular disorders (n=3). 
 
Serum levels of VEGF-A and VEGF-B did not reveal any significant difference between 
pathologies and control group. 
 
Comparison of vitreous and serum levels of VEGF-A and VEGF-B between PDR and NPDR 
patients 
Analysis of the DR patients (PDR vs. NPDR patients) revealed statistical differences in VEGF-A 
and VEGF-B levels: a) Vitreous VEGF-A levels were higher in PDR (576.88 ± 681.15 pg/mL) 
than in NDPR (39.11 ± 71.13 pg/mL), Z=-2.342, p=0.019; b) Vitreous VEGF-B levels were also 
higher in PDR (357.55 ± 453.22 pg/mL) than in NDPR (17.75 ± 34.92 pg/mL), Z=-2.342, 
p=0.019; c) Serum VEGF-A levels were increased in NPDR (95.08 ± 47.37 pg/mL) compared to 
PDR (36.02 ± 28.05pg/mL), Z=-2.196, p=0.028; d) Serum VEGF-B levels were higher in NPDR 
(46.38 ± 22.35 pg/mL) than in PDR (17.29 ± 14.74 pg/mL), Z=-2.049, p=0.040 (as seen in 
Figure 3). 
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Figure 3 - Comparison of the mean vitreous and serum levels of VEGF-A and VEGF-B between NPDR (n=5) 
and PDR (n=8), analyzed with Mann-Whitney test (p<0.05). PDR – proliferative diabetic retinopathy, 
NPDR - non-proliferative diabetic retinopathy. 
 
Comparison of vitreous VEGF-A vs. VEGF-B levels between naïve and non-naïve patients 
with neovascular pathology 
For this analysis, as defined previously, a non-naïve was a patient that never underwent any 
drug or non-drug therapy to treat their ocular disease, including laser photocoagulation, 
bevacizumab, ranibizumab, aflibercept or triamcinolone.  
Although the analyzed patients had performed intravitreal treatments and /or laser therapy 3 
months before vitrectomy, a comparison of the mean values between naïve (n=8) and non-
naïve (n=9) patients in the neovascular group (n=17) demonstrated a statistically significant 
difference (p<0.05) between vitreous VEGF-A and VEGF-B levels with higher levels of vitreous 
VEGF-A and VEGF-B in the group of non-naïve patients (Table 2). 
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Table 2 - Comparison of the mean concentration levels of vitreous VEGF-A and vitreous VEGF-
B in the neovascular group between naïve and non-naïve patients (p<0.05). 
 
 
 
 
 
 
VEGF-A – vascular endothelial growth factor A, VEGF-B – vascular endothelial growth factor B, SD – 
Standard deviation 
 
Analyze of vitreous VEGF-A and VEGF-B levels in the group of patients with neovascular 
disease per treatment group 
For this analysis, we grouped the non-naïve neovascular patients (n=9) per treatment groups 
into 5 groups, describing the treatments performed since they were diagnosed until 
vitrectomy (note that the selected samples for the neovascular group did not perform any 
treatment 3 months before the surgery): Group A – patients who performed only laser; Group 
B – patient who performed bevacizumab, ranibizumab and aflibercept; Group C – patients who 
performed ranibizumab and laser; Group D – patients who performed laser and triamcinolone; 
Group E – patients who performed laser, triamcinolona and ranibizumab. 
Overall, the results revealed high vitreous levels of the either growth factors as seen in Figure 
4.  
  
Patients in the neovascular group (n=17) 
 Non-naïve (n=9) Naïve (n=8) Z p 
 Mean SD Mean SD   
Vitreous VEGF-B 321.48 441.11 82.09 169.42 -1.925 0.054 
Vitreous VEGF-A 516.26 665.50 148.71 296.79 -2.021 0.043 
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Figure 4 - Mean vitreous concentration levels of VEGF-A and VEGF-B among the 5 treatment groups in 
the neovascular patients group (non-naïve patients, n=9), using descriptive analysis. VEGF-A – vascular 
endothelial growth factor; VEGF-B – vascular endothelial growth factor B; Group A – Patients that only 
performed laser treatment; Group B - Patients that performed either or, ranibizumab, bevacizumab, 
aflibercept; Group C – Patients treated with ranibizumab plus laser; Group D – Patients treated with 
triamcinolone and laser; Group E – patients treated with ranibizumab plus triamcinolone plus laser; SD – 
standard deviation. 
 
 
Correlation between vitreous VEGF-A vs. vitreous VEGF-B and serum VEGF-A vs. serum 
VEGF-B in the neovascular group of patients 
There was a statistically significant, positive and strong correlation between vitreous VEGF-A 
vs. vitreous VEGF-B in patients with neovascular pathology (n=17), i.e., rsp=0.983, p<0.001. 
Likewise, there was a positive and strong correlation between serum VEGF-A vs. serum VEGF-
B (r=0.970, p<0.001) in the neovascular group (Figure 5). 
 
Paper IV 
 
 
122 
 
Figure 5 - Correlation between a) vitreous VEGF-A vs. vitreous VEGF-B and b) serum VEGF-A vs. serum 
VEGF-B (in patients with neovascular pathology, n=17), analyzed by Spearman’s correlation (in vitreous 
samples) and by Pearson correlation coefficient (in serum samples) (p<0.001). 
 
Similarly, the correlation coefficient between VEGF-A and VEGF-B in vitreous and serum for 
DR patients (n=13) was statistically significant, positive and strong; rsp=0.984, p<0.001 and 
rsp=0.973, p<0.001, respectively (Figure 6).  
 
 
Figure 6 - Correlation between: a) vitreous VEGF-A vs. vitreous VEGF-B and b) serum VEGF-A vs. serum 
VEGF-B, in DR patients, (n=13), analyzed by Spearman's correlation coefficient (p<0.001). 
 
Correlation between vitreous vs. serum VEGF-A and between vitreous vs. serum VEGF-B 
in the neovascular group of patients 
The correlation coefficient between vitreous VEGF-A vs. serum VEGF-A for the neovascular 
group was not statistically significant (n=17; rsp=-0.051; p=0.844). Also, there was no 
correlation between vitreous VEGF-A vs. serum VEGF-A in the DR patients group (n=13; rsp= -
0.209; p=0.494). 
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Similarly, the correlation coefficient between vitreous VEGF-B vs. serum VEGF-B levels was 
not statistically significant for neovascular patients’ population (n=17; rsp= 0.027; p=0.918). 
Relatively to DR patients, there also was no correlation between vitreous VEGF-B and serum 
VEGF-B (n=13; rsp = - 0.110; p=0.721). 
 
Correlations of vitreous VEGF-A or vitreous VEGF-B vs. structural and functional 
parameters in DR patients 
In the DR patients group, a statistically significant, positive and moderate correlation was 
observed between vitreous VEGF-A and MV (rsp=0.560, p=0.046) and between vitreous VEGF-B 
and MV (rsp=0.588, p=0.035). No statistical significant correlation was found either for the 
visual acuity or CRT (Table 3). 
 
Table 3 - Correlations between structural (CRT and MV), functional parameters (VA) vs. 
concentration levels of vitreous VEGF A and B in a group of DR patients (n=13), analyzed by 
Spearman’s correlation coefficient (p<0.05). 
 
 CRT MV BCVA 
Vitreous VEGF-B levels (pg/mL) 0.008 0.588* -0.103 
Vitreous VEGF-A levels (pg/mL) -0.041 0.560* -0.118 
*P≤0.05 
VEGF-A - vascular endothelial growth factor A; VEGF-B - vascular endothelial growth factor; CRT – 
central retinal thickness; MV – macular volume; BCVA – best corrected visual acuity 
 
Discussion 
VEGF-A is the prototype angiogenic factor and is a mediator of angiogenesis and vascular 
permeability in inflammatory disorders (Amadio, Govoni & Pascale, 2016). VEGF-B, unlike 
VEGF-A, does not play a significant role in angiogenesis or vascular permeability (Li et al., 
2012). Its role is to be a survival factor in pathological processes in several body systems, 
such as the eye, brain, heart and others (Zhang et al., 2009). 
Our results demonstrated that vitreous VEGF-A and VEGF-B are increased in patients 
with neovascular diseases in comparison with a control group of patients with non-
neovascular diseases. The pathologies with higher vitreous concentrations of VEGF-A and 
VEGF-B were RVO and DR, supporting the assumptions of these cytokines as important 
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contributors for the pathogenesis of neovascular eye diseases and their increased levels in the 
presence of active neovascularization (Li et al., 2009). 
Although an increased concentration of these cytokines was expected in AMD 
patients, those results were not observed. This was probably due the fact that one AMD 
patient was in a reminiscent phase of the disease, despite being treated more than 3 months 
before the PPV, providing an explanation for the observed low vitreous VEGF-A and VEGF-B 
levels in this group of patients. Moreover, the greater increase of VEGF-A levels in comparison 
with VEGF-B levels demonstrated that the development of new drugs are in the right 
direction when inhibiting this growth factor for the treatment of neovascular pathologies. 
Nevertheless, the combined inhibition of VEGF-A with a drug specifically targeting VEGF-B 
should be beneficial due to the apoptotic proprieties of the growth factor B (Li et al., 2012). 
Relatively to the analysis of diabetic patients in different stages of DR, the results of 
our investigation demonstrated statistically significant and high values of vitreous VEGF-A and 
VEGF-B in PDR patients. Similarly, Funatsu et al. (2002), Gao et al. (2016) and Watanabe et 
al. (2005), and showed a significantly higher concentration of vitreous VEGF-A in eyes with 
active PDR. 
Intriguingly, the results obtained with serum samples in the DR patients showed 
higher VEGF-A and VEGF-B levels in NPDR than in PDR. Serum VEGF-A levels have been 
determined in other studies without any significant differences between PDR and control 
groups or between PDR and NPDR patients, however revealing higher serum values for NPDR 
in comparison with PDR (Burgos et al., 1997; Hernandez et al., 2001; Krizova et al., 2015; 
Lee, Chae & Kim, 2005; Praidou et al., 2009; Simó et al., 2002). Nevertheless, Baharivand and 
colleagues (2012) demonstrated statistically significant differences between PDR and NPDR 
patients and contrarily to reports from other investigators, serum PDR levels were higher than 
NPDR. However, while Lee, Chae and Kim (2005) attributed the progression of DR not only to 
identified factors, cells and modulators but also to the circulating systemic VEGF-A, Burgos et 
al. (1997) considered intravitreous levels of VEGF-A in PDR patients to be due to intraocular 
synthesis, excluding the mechanisms of serum diffusion. 
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There is a hypothesis that the high serum concentration levels in the NPDR are due to 
unknown concurrent systemic diseases. It is known that several concurrent diseases besides 
cancer may alter serum VEGF-A and VEGF-B values, especially in the analyzed aged 
population (Ferrara, Gerber & LeCouter, 2003). Another hypothesis is due to diabetic 
therapy, the stage of DR or simply due to the fact that systemic levels of VEGF-A or VEGF-B 
were not related to the production of those vitreous cytokines by the retina. Baharivand and 
co-workers (2012) showed that serum VEGF-A levels are lower in diabetic patients with oral 
therapy, well-controlled diabetes, and early stages of DR, which in another case may partially 
explain these results. Moreover, Burgos et al. (1997) and Funatsu et al. (2002) suggested that 
the intraocular synthesis of VEGF, and not serum diffusion, was the principal contributing 
factor for the high VEGF-A levels observed in the vitreous humor of PDR patients. 
Most of the research reports from several investigators demonstrated increased levels 
of vitreous VEGF-A in PDR in comparison with a control group. However, the serum levels 
results were described by some investigators with no serum differences among distinctive 
groups of diabetic patients (Aiello et al., 1994; Burgos et al., 1997; Hernandez et al., 2001, 
2002; Krizova et al., 2015; Praidou et al., 2009; Simó et al., 2002). 
There is evidence that intravitreal levels of VEGF-B are increased in diabetic patients 
and vary dependently with disease severity from NPDR to PDR (Mesquita et al., 2017b). In the 
present study, higher vitreous VEGF-A and VEGF-B were associated with an increase in 
severity of DR. 
The analysis performed in the neovascular group showed that non-naïve patients had 
higher levels of vitreous VEGF-A and VEGF-B. This may be because there are more PDR 
patients in the non-naïve group, confirming our supposition that vitreous levels of the studied 
growth factors are related with disease severity, being higher in more developed stages. 
The comparison of vitreous VEGF-A and vitreous VEGF-B (in non-naïve patients) with 
the 5 treatment groups in the neovascular population suggested the existence of treatment 
recurrence. Anti-VEGFs are the standard gold treatment for neovascular and potentially 
blinding diseases, although there are limitations in the use of such therapies. One limitation 
is the unknown duration of anti-neovascular effects. Anti-angiogenics reduce regression of 
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neovascularization after treatment, but the duration of the effect is limited to a short period 
of time. In addition, the patients require several intravitreal injections to achieve successful 
treatment and stabilization of the disease. Moreover, some patients respond insufficiently 
even with several angiogenic treatments (Singer et al., 2016). Another limitation is the 
detectable levels of antiangiogenic drugs in the systemic circulation that may cause an 
increase in thromboembolic and cardiovascular events. Although the death rates did not seem 
to be increased due to the use of angiogenic drugs, the long-term consequences of its use are 
still unknown (Singer et al., 2016). Lastly, VEGF-A, as well as VEGF-B, plays an important role 
in neuroprotection, including the retina neurons, and promotion of cell survival. Therefore, 
VEGF-A and VEGF-B blockage may cause significant adverse events (Singer et al., 2016). 
An interesting finding was the positive and robust correlation between VEGF-A and 
VEGF-B either in serum or in vitreous demonstrating that those cytokines might increase 
simultaneously. This may support the statement that VEGF-B, besides VEGF-A, is another 
contributor to the pathogenesis of neovascular diseases.  
We tried to determine a correlation between serum VEGF-A vs. vitreous VEGF-A or 
between serum VEGF-B vs. vitreous VEGF-B. However, no correlation coefficient was found 
for VEGF-A or VEGF-B. Other researchers measured the levels of VEGF-A in vitreous and serum 
of patients and tried to correlate those growth factors (Abdel, Fahmy & Elsergani, 2008; 
Aiello et al., 1994; Ambati, Chalam & Chawla, 1997; Baharivand et al., 2012; Burgos et al., 
1997; Celik et al., 2005; Deng, Wu & Gao, 1999; Funatsu et al., 2002; Gao et al., 2016; 
Hernandez et al., 2001, 2002; Hogeboom et al., 2002; Krizova et al., 2015; Lee, Chae and 
Kim, 2005; Malik et al., 2005; Ozturk et al., 2009; Praidou et al., 2009; Simó et al., 2002; 
Watanabe et al., 2005; Zhou & Zhang, 1997). While most of the researchers did not found a 
correlation, Baharivand and colleagues (2012) found a positive correlation between serum and 
vitreous VEGF-A. 
The lack of correlation between the vitreous and serum may suggest that there is 
dissociation between the eye and other organs. It also suggests that vitreous VEGF-A and 
VEGF-B are synthetized intraoculary. 
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A statistically significant and positive correlation was found between vitreous VEGF-A 
vs. MV or between vitreous VEGF-B vs. MV in the diabetic population, demonstrating the 
effect that those two molecules may have in the establishment of edema. 
Overall, all results suggest an overexpression of vitreous VEGF-A and VEGF-B as well a 
strong correlation between these two growth factors, confirming the interesting finding that 
they simultaneously increase in neovascular eye pathologies. It was also confirmed the 
increase of vitreous VEGF-A and VEGF-B with stage of DR with higher levels in PDR.  
There are several pharmaceutical agents and non-drug procedures available to battle 
these multifactorial neovascular diseases. Despite laser and anti-angiogenics being the 
leading treatments for neovascular diseases, it is known that about 50% of patients have an 
insufficient response to angiogenic therapy and some would benefit from an early therapy 
switch as shown in the EARLY study (Gonzalez et al., 2016). Corticosteroids demonstrated 
their capability to lower inflammation and decrease VEGF levels (Gonzalez et al., 2016). 
Nevertheless, the combination therapy may be the rational approach to fight neovascular 
diseases by targeting VEGF factors while combating multiple and complex factors in the 
inflammatory and angiogenic cascade.  
Only with a profound knowledge of pathophysiology, vascular, inflammatory and 
biochemical mechanisms as well targeted molecules, it will be possible to develop a new 
treatment approach. Thus, targeting VEGF-A or and VEGF-B as additional treatment options 
for neovascular ocular diseases might provide better outcomes, sustained duration of action, 
and an increased efficiency. 
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General Discussion 
 
In this dissertation, VEGF-A, VEGF-B, and PIGF were quantified in the serum and vitreous of 
patients with neovascular diseases and compared with a group of patients with non-
neovascular diseases. This was done to clarify the role of these three growth factors involved 
in the pathogenesis of DR, RVO and AMD. The effects of the overexpression of VEGF-A, VEGF-
B, and PIGF were evaluated by the correlation: 
1. Between the three growth factors, 
2. Between serum and vitreous measurements within the same growth factor; 
3. Between growth factors and structural parameters measured by the OCT (central retinal 
thickness and macular volume); 
4. Between growth factors and functional parameters, such as visual acuity. 
 
For DR patients and to determine if the levels of growth factors increase with disease 
progression, its concentrations were related and compared with the stages of DR. 
Finally, the growth factors, VEGF-A, VEGF-B and PIGF levels were evaluated and compared 
with therapies performed by the patients to treat their eye condition before vitrectomy. 
 
The results showed an increase in the vitreous concentration of VEGF-A, VEGF-B, and PIGF in 
patients with neovascular diseases in comparison with patients with non-neovascular diseases. 
The concentration of these cytokines in the serum did not show significant differences 
between patients. However, there was a correlation between VEGF-A and VEGF-B, in vitreous 
and in serum of patients with neovascular pathology, which means a coordinated increase, 
i.e., when vitreous VEGF-A increases, vitreous VEGF-B also increases; the same is also true for 
serum samples. 
Moreover, between diabetic patients, a vitreous increase in VEGF-A, VEGF-B and PIGF was 
observed in patients with PDR in comparison with NPDR. Our research showed that the 
intravitreal levels of VEGF-A, VEGF-B and PIGF were increased in diabetic patients and were 
dependent on disease severity from NPDR to PDR. As expected, the levels of those growth 
factors were higher in the more severe stages of the DR, since they increase angiogenesis and 
consequently neovascularization and vascular permeability, thus, leading to macular edema 
and inflammation. This fact was supported by the finding that there was a positive 
correlation between vitreous VEGF-A or vitreous VEGF-B and MV, demonstrating the effect of 
those molecules in the establishment of edema. In the case of PIGF, the correlation was weak 
probably due to the patient population included in this study; however, a tendency of a 
positive correlation was observed between PIGF and MV. 
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Contrarily and unexpectedly, an increase in the studied VEGFs was detected in the serum of 
NPDR patients in comparison with PDR patients. There are several hypotheses why this may 
happen: 
1. Concurrent systemic diseases, i.e., not only cancer but also several other diseases that are 
influenced by growth factors levels.  
2. Concurrent diseases that may not be diagnosed or reported to the physicians by the 
patients. The difficulty in finding patients free of systemic health issues among this patient 
population is a reality and a limitation of this research. 
3. Intravitreal concomitant medications and non-drug therapies administered to the patients 
are other limitations of the study, even though the interval between intravitreal injections 
and vitrectomy was greater than 3 months. 
4. Diabetic therapy and stage of DR. Baharivand and co-workers showed that serum VEGF-A 
levels were lower in diabetic patients with oral therapy, well-controlled diabetes, and early 
stages of DR. Likely, lower serum results were also obtained in our research study (Baharivand 
et al., 2012). 
5. Systemic levels of VEGF-A or VEGF-B may not be related to the production of vitreous 
cytokines by the retina. Some researchers advocate that intraocular synthesis of VEGF-A (and 
not diffusion) is the responsible mechanism for the high VEGF-A levels observed in the 
vitreous humor of PDR patients. Other investigators attributed the progression of DR to the 
circulating systemic VEGF-A to the high levels of VEGF-A (Abdel et al., 2008; Burgos et al., 
1997; Funatsu et al., 2002; Lee et al., 2005) 
 
Also, there was no correlation between vitreous and serum samples for VEGF-A, VEGF-B and 
PIGF, indicating dissociation between the eye and some organs. This suggests that the 
application of specific drugs to the eye could be relatively safe. 
 
Furthermore, in our study, higher levels in the vitreous VEGF-A were constantly observed in 
comparison to vitreous VEGF-B and vitreous PIGF. This shows that despite additional and 
needed investigations to suppress other growth factors than VEGF-A and other pathways, the 
current pathway inhibiting VEGF-A is appropriate. 
 
The treatment of ocular neovascular diseases is challenging but improved dramatically in the 
last years. However, currently, there is no cure but only therapies that slow down the 
progression of the disease.  
 
One of the first therapies that appeared for the treatment of neovascular diseases was 
verteporfin (Visudyne®), an angio-occlusive that changed the course of AMD. The aim of 
Visudyne® therapy was to occlude vessels within the choroidal neovasculature while 
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preserving the overlying retinal tissue. Anti-angiogenic agents were discovered, and clinical 
trials showed powered outcomes of VEGF inhibition. VEGFs are angiogenic regulators of 
neovascularization and promoters of vascular permeability and are, thus, the key targets for 
treating neovascular diseases. 
 
Currently, there are five therapies involving VEGF inhibition for the treatment of retinal 
diseases. Pegaptanib sodium intravitreal injections, (Macugen®), it is a pegylated VEGF 
aptamer, a single strand of nucleic acid that binds with specificity to the 165 isoform of 
VEGF-A, approved in 2004 by the U.S. Food and Drug Administration (FDA) being the first 
therapy available for the treatment of neovascular AMD. However, it is currently not in the 
market, being succeeded by more innovative molecules, such as ranibizumab and aflibercept. 
Bevacizumab (Avastin®), is humanized anti-VEGF-A monoclonal IgG antibody developed as an 
anti-angiogenic agent for colon-rectal cancer, lung cancer, glioblastoma, and renal-cell 
carcinoma that was approved for medical use in the United States in 2004. However, it has 
been used by ophthalmologists (off-label) intravitreally for the treatment of proliferative eye 
diseases.  
Nevertheless, the drug that becomes the gold standard of treatment in these diseases it was 
ranibizumab. Ranibizumab (Lucentis®) is a fully humanized monoclonal antibody fragment 
targeted against human VEGF-A, with high affinity for all isoforms of VEGF-A. Until the 
appearance of ranibizumab, all medications used for treating AMD had the endpoint of 
maintaining vision or determine the percentage of patients who did not lose 15 or more 
letters. Ranibizumab changed the landmark of treatment being the first drug that recovered 
vision lost, with a turnover of the endpoint of the clinical trials to the percentage of patients 
who gained 15 or more letters. The binding of ranibizumab to VEGF-A at the receptor-binding 
site prevents the interaction of VEGF-A with its receptors VEGFR-1 and VEGFR-2 on the 
surface of the endothelial cells. This inhibits the cascade of events that leads to increased 
vascular permeability, increased activity, and proliferation of endothelial cells and 
inflammation. It is currently approved for the treatment of neovascular (wet) AMD, visual 
impairment due to choroidal neovascularization, visual impairment due to DME, and visual 
impairment due to macular edema secondary to RVO (BRVO or CRVO). 
Recently a new therapy emerged as a new light for the treatment of retinal diseases, 
aflibercept. Aflibercept (Eylea®) is a recombinant fusion protein consisting of VEGF binding 
portions from the extracellular domains of human VEGFR-1 and VEGFR-2 fused to the Fc 
portion of the human IgG1 immunoglobulin. It binds to all isoforms of VEGF-A, VEGF-B, and 
PIGF. It was approved in the United States and Europe for the treatment of neovascular (wet) 
AMD, visual impairment due to macular edema secondary to RVO (BRVO or CRVO), visual 
impairment due to DME, and visual impairment due to myopic choroidal neovascularization 
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(myopic CNV); and for metastatic colorectal cancer (Zaltrap). For ocular use, the first 
approved indication (wet AMD) was granted in 2011 by the FDA and in 2012 by EMA. 
Ultimately a new therapy it was developed being only available in some parts of Asia. 
Conbercept (Lumitin®) is an anti-VEGF approved drug for the treatment of wet AMD in China 
by the China State Food and Drug Administration in December 2013. It has a higher binding 
affinity, lower VEGF dissociation rate, and a longer clearance time. It is a recombinant fusion 
protein that binds to all VEGF-A isoforms, VEGF-B, VEGF-C and PIGF. The structural 
differences between this drug and other anti-VEGFs may pose a longer effect in vitreous. 
Conbercept has a therapeutically satisfactory effect even with a quarterly regimen. 
 
VEGF inhibitors are promising drugs for the treatment of neovascular eye diseases; however, 
it should be of note that there are some limitations of its usage: 
1. The unknown duration of anti-neovascular effects: Anti-angiogenics reduce regression of 
neovascularization after treatment and improve structural and functional parameters, but the 
duration of the effect is limited to a short period of time. 
2. The mode of drug delivery: there are complications after intravitreal injections, such as 
endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, acute 
intraocular pressure elevation and ocular hemorrhage. 
3. Anti-VEGF therapy currently requires frequent injections and assessments to determine if a 
patient is responsive to a treatment. This circumstance leads to a significant burden of 
injections and visits for all involved in the treatment of those patients, namely, patients, 
physicians, caregivers, and other health providers. The solution for this problem would be the 
administration of a medication that would improve visual and structural outcomes and 
simultaneously increase drug effectiveness and lengthen the durability of the treatment. 
4. Another issue is the systemic safety. Several serious and non-serious adverse events have 
been reported with the systemic administration of anti-VEGFs: thromboembolic events, 
myocardial infarction, stroke, hypertension, gastrointestinal perforations, and kidney disease, 
which lead to the inclusion of a black box in the summary of product characteristics of 
bevacizumab, ranibizumab, and aflibercept. Moreover, intravitreal antiangiogenic drugs were 
associated with detectable levels in the systemic circulation that may significantly suppress 
systemic VEGF levels, suggesting a rationale for the occurrence of potential cardiovascular 
adverse events. Although death rates observed in clinical trials did not seem to be increased 
due to the use of angiogenic drugs, the long-term consequences are still unknown. 
Furthermore, VEGF-A, VEGF-B, and PIGF have an important role in neuroprotection and 
cardioprotection. Therefore, the blockage may also have consequences in the long run.  
5. Nevertheless, not all patients respond sufficiently to anti-VEGF intravitreal injections 
despite frequent treatments. Descriptive and exploratory subanalyses conducted in our study 
by group therapies suggest an insufficient response of neovascular patients treated previously 
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with one or more of the following: laser, bevacizumab, ranibizumab, aflibercept or 
triamcinolone. Laser and anti-angiogenics are the standard gold treatment for neovascular 
diseases. However, it is known that about 40-50% of patients have an insufficient response to 
angiogenic therapy and that a significant percentage of patients would benefit from an early 
therapy switch as shown in the EARLY study. 
 
Corticosteroids are used alone or in conjunction with other pharmacologic or surgical 
treatments. Steroid treatments are invaluable in ophthalmology and one of the oldest 
treatments available for the treatment of persistent or recurrent diseases. Steroids have 
proven to be powerful and effective in suppressing inflammation and also playing a significant 
role in the inhibition of several cytokines inclusively antagonizing the action of VEGF-A. The 
best-studied steroids are triamcinolone acetonide, dexamethasone, and fluocinolone 
acetonide. 
 
Notwithstanding the well-known side effects caused by corticosteroids, such as the cataract 
formation and the increase in intraocular pressure, the efficacy already demonstrated that 
the benefits outweighed the risks. Moreover, there is an enormous advantage of the usage of 
intravitreal corticosteroids since the systemic side effects of locally administered steroids 
occur rarely. 
 
In table 4, the anti-angiogenic drugs currently available are summarized. Clinical trials and 
other studies should focus on other possible drugs that have not been studied in 
ophthalmology for their consideration as future targeted molecules. 
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Table 4 – Summary of anti-angiogenic agents (DRUGS 2017; Steeghs et al., 2007; U.S. National Library of Medicine 2017) 
 
Generic drug 
name 
Trade name 
Type of 
molecule 
Target 
Clinical stage in 
ophthalmology 
Therapeutic 
Indications 
Route of 
administration 
Commercialized by 
Pegaptanib Macugen® RNA aptamer VEGF-A 165 Commercialized Wet AMD 
Intravitreal 
injection 
OSI 
Pharmaceuticals/Pfizer 
/ Bausch & Lomb 
Bevacizumab Avastin® 
Recombinant 
humanized 
full 
monoclonal 
antibody 
All VEGF-A 
isoforms 
Not commercialized 
for ocular use 
Off-label usage 
Intravitreal 
injection 
Genentech in U.S. and 
Roche in Europe 
Ranibizumab Lucentis® 
Recombinant 
humanized 
monoclonal 
antibody 
fragment 
All VEGF-A 
isoforms 
Commercialized 
Wet AMD, macular 
edema following 
RVO, DME, DR with 
DME, and myopic 
choroidal 
neovascularization 
 
Intravitreal 
injection 
Genentech in U.S. and 
Novartis in Europe 
Aflibercept Eylea® Fusion protein 
All VEGF-A & 
VEGF-B isoforms 
and PIGF 
Commercialized 
Wet AMD; ME 
following RVO, DME 
and DR in Patients 
with DME 
Intravitreal 
injection 
Regeneron in U.S. and 
Bayer in Europe 
Conbercept Lumitin® Fusion protein 
All VEGF-A 
isoforms, VEGF-B, 
VEGF-C and PIGF 
Commercialized in 
China; Not 
commercialized in 
US or EU 
Wet AMD 
Intravitreal 
injection 
Kanghong Biotech 
AGN-150998; 
Abicipar Pegol 
Not 
available 
DARPin VEGF-A Phase III Wet AMD, DME 
Intravitreal 
injection 
Allergan 
Multi VEGF-
PDGF DARPin 
Not 
available 
Multi-DARPin VEGF-A Pre-clinical Wet AMD Not available Allergan 
Bevasiranib 
Not 
available 
siRNA VEGF-A mRNA 
Phase III, 
Discontinued 
Wet AMD 
Intravitreal 
injection 
Opko Health 
AGN211745, 
formerly SIRNA-
027 
Not 
available 
siRNA VEGFR-1 mRNA 
Phase I, 
Discontinued 
Wet AMD 
Intravitreal 
injection 
Allergan 
PF-04523655 
Not 
available 
siRNA DDIT4 mRNA 
Phase II, 
Terminated 
Wet AMD and DME 
Intravitreal 
injection 
Quark Pharmaceuticals 
/Pfizer 
ALN-VSP02 
Not 
available 
Dual siRNA 
VEGF-A and KSP 
mRNAs 
Phase I − − Alnylam 
E10030; 
Pegplenarib 
Fovista® DNA aptamer PDGF-BB 
Phase III 
Discontinued 
Wet AMD 
Intravitreal 
injection 
Ophthotech/ Novartis 
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Note: DARPin - Designed Ankyrin Repeat Proteins, DDIT4 mRNA- DNA-damage-inducible transcript 4 mRNA, DME – diabetic macular edema, DR – diabetic retinopathy, KSP mRNAs 
- Kinesin spindle protein mRNAs, PDGF - Platelet-derived growth factor, PIGF - placental growth factor, RVO – retinal vein occlusion, siRNA– Small interfering RNA, VEGF - 
vascular endothelial growth factor, VEGFR-1 - vascular endothelial growth factor receptor 1, Wet AMD – Wet age related macular degeneration. TKI- tyrosine kinase inhibitors 
** Sunitinib licensed for Pfizer is marketed for gastrointestinal stromal tumors; pancreatic cancer; renal cell carcinoma. 
 
ARC1905; 
Avacincaptad 
pegol 
Not 
available 
RNA aptamer C5 complement  
 
Phase I Dry AMD, Wet AMD Intravitreal 
injection 
Ophthotech 
ESBA-1008; 
RTH258 
(brolucizumab) 
Not 
available 
Humanized 
single chain 
anti-body 
fragment 
VEGF-A Phase III Wet AMD, DME 
Intravitreal 
injection 
Alcon Research 
TB-403; THR 
317 
Not 
available 
Monoclonal 
antibody 
PIGF 
Phase II – DME 
Pre-clinical - DR 
DME, DR − ThromboGenics /Roche 
5D11D4 
Not 
available 
Monoclonal 
antibody 
PIGF Pre-clinical _ Systemic ThromboGenics 
Lapatinib Tyverb® TKI Small molecules _ Breast Cancer Oral GlaxoSmithKline 
Sunitinib 
maleate- 
Sutent® 
(oral) 
TKI Small molecules 
Phase I/II AMD 
Preclinical DME, 
RVO 
** Intravitreal GrayBug Inc. 
Sorafenib Nexavar® TKI Small molecules Phase I Acute 
Hepatocellular 
carcinoma; Renal 
cell carcinoma; 
Thyroid cancer 
Oral Bayer 
Axitinib/ 
Axitinib 
ophthalmic 
Inlyta® Oral 
formulation 
/Pfizer) 
TKI, PDGF, 
VEGF-A 
Small molecules 
Preclinical Age-
related macular 
degeneration 
Renal cell 
carcinoma 
_ Clearside Biomedical 
Pazopanib Votrient® TKI Small molecules Discontinued AMD 
Renal cell 
carcinoma; 
Sarcoma 
 
Oral GlaxoSmithKline 
Regorafenib/ 
BAY 73-4506 
Stivarga TKI Small molecule  
Colorectal cancer; 
advanced 
gastrointestinal 
stromal tumors 
Oral Bayer 
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Although laser, anti-VEGFs and steroids were established as successful target treatments, 
many other new therapies and approaches are arising in the pipeline, holding promises in the 
improvement of eye pathologies. Regardless of the future discoveries, significant progress has 
been made in understanding the molecular pathogenesis of retinal neovascular disorders and 
investigating new targets for therapeutic interventions. 
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Concluding remarks and future trends 
 
Overall from our research: 
1. We have proven and measured for the first time vitreous VEGF-B levels and reported also 
for the first time their overexpression in ocular neovascular diseases. Also, vitreous PIGF 
levels were not much studied until date. Contrarily, vitreous and systemic VEGF-A have 
widely been the subject of research. VEGF-A facilitated the beginning of our investigation as 
a “control,” becoming more important as a comparator and as a correlation factor for other 
growth factors. Moreover, it showed to be the growth factor that has higher concentration 
levels in retinal diseases, demonstrating the accurate direction of current drugs targeting 
VEGF-A for the treatment of neovascular diseases. 
2. The VEGF-B overexpression confirms the possibility as a target. VEGF-B is a strong 
apoptotic molecule that can offer an alternative and challenging therapeutic target in the 
treatment of neovascular conditions. However, clinical trials are needed to confirm the 
efficacy of anti-VEGF-B therapy as well safety due to its neuroprotective and cardioprotective 
effects. 
3. PlGF may be a favorite target for the inhibition of angiogenesis in relation to VEGF-A. The 
safety profile of anti-PlGF needs also preclinical studies and human clinical trials to confirm 
the possibility of systemic delivery of anti-PlGF monoclonal antibodies and also its 
effectiveness and safety, in combination with an anti-VEGF therapy or as a partial 
replacement of anti-VEGF. 
Contrary to VEGF-A, the VEGF-B is inert under normal conditions and PIGF are restricted to 
pathological conditions, making those molecules high targets for therapy. 
4. We tried to identify serum VEGF-A, VEGF-B, and PIGF as markers in the early detection of 
neovascular disease and we also tried to find a correlation between serum and vitreous VEGF-
A or between serum and vitreous VEGF-B, or between serum and vitreous PIGF. However, no 
correlation coefficient was found between serum and vitreous VEGF-A, VEGF-B or PIGF, which 
can be a sign of the dissociation between eye and other organs. 
 
Future research should continue focusing on new anti-VEGF strategies in the treatment of 
ocular diseases linked to abnormal vascularization. The discovery of new isoforms of the VEGF 
family revealed an increased biology complexity and faced many obstacles that must be 
overcome while exploring new targets. The blockage selectivity is as far one of the most 
important factors to be considered when testing new anti-VEGF molecules. 
 
A better and deep understanding of all mechanisms, interactions and specific functions 
between the members of the VEGF family and its receptors in both normal states and diseases 
is crucial for the development of new drugs. Also, new experimental and clinical trials 
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targeting therapies for the newly discovered and innovative molecules will allow the 
development of more specific, precise, safe and effective therapies, resulting in better 
outcomes for patients with pathological ocular angiogenesis. 
 
Finally, new serum and vitreous studies measuring VEGF family growth factors with a high 
number of patients should be continued in order to find out a correlation between disease 
characteristics and vitreous or serum levels of growth factors.  
Only the early intervention in disease through an adequate screening of patients and the 
treatment with the specific drugs at the right time will lead to considerably vision 
improvements and a decrease in worldwide blindness. 
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